Patent Application
20150133469
The present invention relates in general to the field of Mycobacterium tuberculosis infection, and more particularly, to methods for monitoring treatment response and determining treatment effectiveness.
None.
Without limiting the scope of the invention, its background is described in connection with the treatment of Mycobacterium tuberculosis infection.
United States Patent Application Publication No. 2009/0104602, entitled “Diagnosis of Tuberculosis,” filed by Fernandez-Reyes et al. describes methods of diagnosing tuberculosis comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp6671032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than tuberculosis (TB), thereby determining whether or not said test subject has TB.
United States Patent Application Publication No. 2003/0138813, entitled “Method of diagnosis and disease risk assessment,” filed by Engstrand et al., relates to methods of determining information about the likely clinical outcome of a microbiological infection in a patient and also to methods of selecting a suitable therapeutic regimen for a patient with a microbiological infection. The application describes analyzing the virulence gene of Mycobacterium tuberculosis to determine the likely clinical outcome.
Nahid et al., CDC/NIH Workshop Report, “Tuberculosis biomarker and surrogate endpoint research roadmap,” Am J Respir Crit Care Med. 2011 Oct. 15; 184(8):972-9, states that Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. It is said that, at a minimum, a biomarker of treatment response most useful for drug development would need to: 1) correspond closely with treatment outcomes; 2) have a wide dynamic range that would allow analysis as a continuous variable; and 3) provide this information from a limited number of early time points.
Wallis et al., “Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice,” Lancet 2010 May 29; 375(9729):1920-37. Epub 2010 May 18, states that host or pathogen-specific tuberculosis biomarkers provide prognostic information, either for individual patients or study cohorts. It is said that detection of volatile organic compounds in the breath of patients with pulmonary tuberculosis has been reported, but no study has reported changes during treatment. It is stated that studies have examined levels of M. tuberculosis antigen 85 and 85B RNA in sputum during treatment, and the magnitude and duration of increases in this protein during the first week of treatment predicted relapse or failure in four of 42 patients.
Berry et al., “An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis,” Nature 2010 Aug. 19; 466(7309):973-7, reports identification of a whole-blood 393 transcript signature for active tuberculosis in intermediate and high-burden settings, which is missing in the majority of individuals with latent tuberculosis, and missing from healthy controls. The signature correlated with radiological extent of disease and diminished after two months of treatment and reverted to that of healthy controls after completion of treatment. An 86-transcript signature discriminated between active TB and other inflammatory and infectious diseases, and this signature was also diminished after two months of treatment. The tuberculosis signature was dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, consisting of both IFN-gamma and type I IFN-alpha beta signaling.
Marchant et al., “Serological markers of disease activity in tuberculosis and HIV infection,” Clin Exp Immunol. 2000 October; 122(1):10-2, states that markers of disease activity are needed to evaluate disease progression and to monitor response to therapy. It is suggested that e.g., soluble tumour necrosis factor receptor type 1 (sTNF-RI) and beta 2-macroglobulin, could be used as independent markers of disease activity in TB and HIV infection, respectively.
Frahm et al., “Discriminating between latent and active tuberculosis with multiple biomarker responses,” Tuberculosis (Edinb). 2011 May; 91(3):250-6. Epub 2011 Mar. 10, states that twenty-five biomarkers were evaluated and it was found that IL-15 and MCP-1 identified 83% of active and 88% of latent infections. The combination of IL-15 and MCP-1 responses was accurate in distinguishing persons with active tuberculosis from persons with latent tuberculosis in this study.
Part of the inventive subject matter that the present invention provides includes methods for early detection of a treatment response in a patient suspected of being infected with Mycobacterium tuberculosis. In some embodiments, changes in the blood transcriptome are detectable within two weeks or less of the initiation of antituberculosis therapy.
In one aspect, a method is provided for evaluating tuberculosis treatment response in a patient, the method comprising: measuring expression levels of genes in a biological sample from the patient to generate a first gene expression profile, wherein the biological sample is obtained at a first time point that is before or concurrent with commencement of tuberculosis treatment; measuring expression levels of genes in a second biological sample from the patient to generate a second gene expression profile, wherein the second biological sample is obtained after commencement of the treatment but at two weeks or less after commencement; and calculating a temporal molecular response value by comparing the first and second gene expression profiles. In a related aspect, a method is provided for evaluating effectiveness of tuberculosis treatment, the method comprising: measuring expression levels of genes in a biological sample from a tuberculosis patient to generate a first gene expression profile, wherein the biological sample is obtained at a first time point that is before or concurrent with commencement of tuberculosis treatment; administering the treatment to the patient; measuring expression levels of genes in a second biological sample from the patient to generate a second gene expression profile, wherein the second biological sample is obtained after commencement of the treatment but at two weeks or less after commencement; and calculating a temporal molecular response value by comparing the first and second gene expression profiles. In some embodiments, a significant temporal molecular response value is a biomarker for an effective treatment.
In a further related aspect, a method is provided for treating a patient with Mycobacterium tuberculosis infection, the method comprising: measuring expression levels of genes in a biological sample from the patient to generate a first gene expression profile, wherein the biological sample is obtained at a first time point that is before or concurrent with commencement of treatment for the infection; administering a treatment for the infection to the patient; measuring expression levels of genes in a second biological sample from the patient to generate a second gene expression profile, wherein the second biological sample is obtained after commencement of the treatment but at two weeks or less after commencement; and calculating a temporal molecular response value by comparing the first and second gene expression profiles. In an associated method, the treatment is continued if the temporal molecular response value is significant. In a further associated method, the treatment is discontinued if the temporal molecular response value is not significant.
In some embodiments, the biological sample is blood. In addition, a gene expression profile may comprise RNA transcriptome expression data. Genes of a gene expression profile may comprise 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes, between 11 and 20 genes, between 21 and 30 genes, between 31 and 50 genes, between 51 and 75 genes, between 76 and 100 genes, between 101 and 200 genes, between 201 and 300 genes, between 301 and 500 genes, between 501 and 750 genes, or more than 751 genes. In addition, genes of a gene expression profile may comprise genes selected from Table 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 disclosed herein.
In related embodiments of these methods, the second time point is 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days or less, or 1 day or less, after commencement of treatment. In other related embodiments, genes of the gene expression profile comprise 1, 2, 3, 4, 5, 6 or more different genes selected from the group consisting of IF135, IFIT1, IFIT3, IFITM1, IRF1, JAK2, SOCS1, STAT1, TAP1, CD40LG, CD79A, CD79B, FAS, FCER1G, IL15, IL1B, IL1RN, SLAMF1, TLR2, TLR5, TNFSF13B, C2, C1QB, C1QC, C4BPA, CD59, CR1, SERPING1, C5, CASP1, IFIH1, IL1B, IRF7, NLRC4, NOD2, MAPK14, OSM, SOCS3, CD86, CXCL10, FCER1G, TLR8, CD86, CREB5, FCGR1A, FCGR1B, IL15, IL23A, STAT2, CASP5, ITGAX, PLCG1, F2RL1, IL18R1, IL18RAP, IRAK3, NFAT5, PDGFA, PLCG1, TRAF5, CD3E, FCGR1C, FCGR2C, FCGR3B, and LCK.
In one embodiment, the present invention includes a method to determine effectiveness of a treatment for tuberculosis in a patient suspected of being infected with Mycobacterium tuberculosis, the method comprising: obtaining a first gene expression dataset from a sample of the patient at a first time point, wherein the first time point is before or simultaneous with a commencement of the treatment for tuberculosis; obtaining a second gene expression dataset from the sample of the patient at a second time point, wherein the second time point is less than 2 months after the commencement of the treatment for tuberculosis, wherein the first gene expression dataset and the second gene expression dataset comprises one or more genes; comparing the first gene expression dataset with the second gene expression dataset; determining that treatment is effective if a significant change between the first gene expression dataset and the second gene expression dataset is detected; or determining that treatment is ineffective if no change or less than a significant change between the first gene expression dataset and the second gene expression dataset is detected. In one aspect, the gene expression data set comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes, between 10 and 19 genes, between 20 and 99 genes or 100 or more genes of genes listed in table 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to IFN Signaling selected from the group consisting of IF135, IFIT1, IFIT3, IFITM1, OAS1, IRF1, JAK2, SOCS1, STAT1, STAT2, and TAP1, significantly changed upon two weeks after initiation of anti-TB drug treatment. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to T and B cell signaling selected from the group consisting of CD40LG, CD79A, CD79A, CD79B, FAS, FCER1G, IL15, IL23A, IL1B, IL1RN, SLAMF1, TLR2, TLR5, TLR8, TNFSF13B, TNFRSF13B, and CD86. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to a complement system selected from the group consisting of C2, C1QB, C1QC, C4BPA, CD59, CR1, and SERPING1. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes having a role in pattern recognition selected from the group consisting of C5, C1QB, C1QC, CASP1, IFIH1, IL1B, IRF7, NLRC4, OAS1, OAS2, OAS3, NOD2, TLR2, TLR5, TLR8, and C3AR1. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to JAK family kinases in IL-6 type cytokine signaling selected from the group consisting of MAPK14, OSM, SOCS1, SOCS3, and STAT1. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes having a role in communication between innate and adaptive immune cells selected from the group consisting of CD86, CD40LG, CXCL10, FCER1G, IL15, IL1B, IL1RN, TLR2, TLR5, TLR8, TNFRSF13B, and TNFSF13B. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to dendritic cell maturation selected from the group consisting of CD86, CD40LG, CREB5, FCER1G, FCGR1A, FCGR1B, IL15, IL1B, IL1RN, IL23A, JAK2, MAPK14, STAT1, STAT2, and TLR2. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to TREM signaling selected from the group consisting of CASP1, CASP5, IL1B, ITGAX, JAK2, NOD2, PLCG1, TLR2, and TLR5. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to a role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis selected from the group consisting of C5, CREB5, F2RL1, FCGR1A, IL15, IL18R1, IL18RAP, IL1B, IL1RN, IRAK3, JAK2, MAPK14, NFAT5, OSM, PDGFA, PLCG1, SOCS1, SOCS3, TLR2, TLR5, TNFSF13B, and TRAF5. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of genes related to systemic lupus erythematous signaling selected from the group consisting of C5, CD3E, CD40LG, CD79A, CD79B, FCER1G, FCGR1A, FCGR1B, FCGR1C, FCGR2C, FCGR3B, IL1B, IL1RN, LCK, NFAT5, PLCG1, and TNFSF13B. In another aspect, the gene expression data set comprises one or more genes selected from the group consisting of IFI35, IFIT1, IFIT3, IFITM1, OAS1, IRF1, JAK2, SOCS1, STAT1, STAT2, TAP1, CD40LG, CD79A, CD79A, CD79B, FAS, FCER1G, IL15, IL23A, IL1B, IL1RN, SLAMF1, TLR2, TLR5, TLR8, TNFSF13B, TNFRSF13B, CD86, C2, C1QB, C1QC, C4BPA, CD59, CR1, SERPING1, C5, CASP1, IFIH1, IRF7, NLRC4, OAS2, OAS3, NOD2, TLR2, TLR5, TLR8, C3AR1, MAPK14, OSM, SOCS3, STAT1, CD86, CD40LG, CXCL10, FCER1G, IL15, IL1RN, TLR2, TLR5, TLR8, TNFRSF13B, TNFSF13B, CD86, CD40LG, CREB5, FCER1G, FCGR1A, FCGR1B, IL15, IL1RN, IL23A, JAK2, MAPK14, CASP5, ITGAX, JAK2, NOD2, PLCG1, TLR2, TLR5, CREB5, F2RL1, FCGR1A, IL15, IL18R1, IL18RAP, IL1RN, IRAK3, JAK2, MAPK14, NFAT5, OSM, PDGFA, PLCG1, SOCS3, TLR2, TLR5, TNFSF13B, TRAF5, CD3E, CD40LG, CD79A, FCER1G, FCGR1A, FCGR1B, FCGR1C, FCGR2C, FCGR3B, IL1RN, LCK, NFAT5, PLCG1, TNFSF13B.
In another aspect, the second time point is between the start of treatment and two weeks after commencement of treatment. In another aspect, the significant change between the first gene expression dataset and the second gene expression dataset comprises the sum of transcripts that are greater than 2-fold different between the first and second time points, expressed as a percentage of the total number of transcripts in each of the gene signatures (Temporal Molecular Response Algorithm derived for this study). In another aspect the second time point is between 2 weeks and 2 months, showing a significant change after the commencement of treatment. In another aspect, 2 months and 6 months after the commencement of treatment. In another aspect, the change between the first gene expression dataset and the second gene expression dataset comprises is at least twofold change of expression most significant as described by the Temporal Molecular Response from initiation of treatment to after 2 weeks. In another aspect, the change between the first gene expression dataset and the second gene expression is observed in between 10 and 100 percent of genes. In another aspect, the treatment comprises treatment with rifampin, pyrazinamide, isoniazid ethambutol, or combinations thereof. In certain aspects, the treatment comprises treatment with anti-mycobacterial drugs against drug-sensitive Mtb, including the addition or substitution of other anti-mycobacterial agents such as levofloxacin, moxifloxacin, prothioniamide, ethionamide, cycloserine, amikacin, streptomycin, kanamycin, para-amino salicylic acid, capreomycin, linezolid, TMC-205, or other similar drugs. In addition it could be applied to the monitoring of new drugs being tested for greater efficacy, and also new drugs tested against MDR- and XDR-TB.
Another embodiment is a method of performing a clinical trial to evaluate the effectiveness of a candidate drug believed to be useful in treating Mycobacterium tuberculosis, the method comprising: (a) obtaining a biological sample from a patient with a Mycobacterium tuberculosis infection; (b) from the patient sample determining a first gene expression dataset from the sample of the patient at a first time point, wherein the first time point is before or simultaneous with a commencement of the treatment for Mycobacterium tuberculosis in one or more biological sample of the patient; (b) administering a candidate drug to the patient, and obtaining a second gene expression dataset from a second sample obtained from the patient at a second time point, wherein the second time point is less than 2 months after commencement of the treatment for Mycobacterium tuberculosis, wherein the first gene expression dataset and the second gene expression comprises one or more genes; comparing the first gene expression dataset with the second gene expression dataset following the treatment with the candidate drug; and determining that treatment is effective if a significant change between the first gene expression dataset and the second gene expression dataset is detected or determining that treatment is ineffective if less than a significant change between the first gene expression dataset and the second gene expression dataset is detected.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures and in which:
Table 1 lists genes present in the top significantly represented canonical pathways of Ingenuity Pathway Analysis in the 664 transcript list from an Untreated South Africa 2011 Cohort.
Summaries of demographics and clinical data are provided in Table 2A, a South African 2011 cohort, and Table 2B, a UK 2011 cohort.
Table 3 lists genes present in the top significantly represented canonical pathways of Ingenuity Pathway Analysis in active TB transcriptional signatures of 2009 UK and South Africa cohorts.
Tables 4 through 12 provide gene transcript lists for 224, 86, 393, 565, 664, 391, 1129, 711, and 320 genes, respectively.
Related summaries of demographics and clinical data are provided in Table 13A, a South African 2011 cohort, and Table 13B, a UK 2011 cohort.
While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.
To facilitate understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an,” and “the” are not intended to refer to only a singular entity but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.
Globally there are approximately nine million new active tuberculosis (TB) cases and 1.7 million deaths annually. Effective anti-TB treatment monitoring is difficult as determining a treatment response by currently used methods takes at least two months. Inadequate treatment leads to worsening disease, disease transmission, and drug resistance. Currently, the best accepted method to predict treatment success in pulmonary tuberculosis is the two-month sputum culture conversion. However, this method is of low sensitivity for prediction of individual treatment response and is difficult to implement since many patients cannot produce sputum. In the United States 30% of TB patients are treated empirically and in South Africa 50% are treated with confirmation of diagnosis by culture. Currently, no recognized biomarkers of poor adherence or inadequate treatment earlier than two months exist.
The present inventors determined if blood transcriptional signatures change in response to anti-TB treatment and could act as biomarkers of a successful response.
Surprisingly, transcriptional blood gene signatures {e.g.: a 664—(Table 8) (
As demonstrated herein, a change in whole blood host transcriptional signatures is significantly detectable as early as two weeks or sooner after commencement of treatment for tuberculosis; this provides early biomarkers for treatment monitoring.
In short, blood transcriptional profiles of untreated active and latent TB patients in South Africa were analyzed, before, during (at two weeks and at two months), at the end of (six months) and after (12 months) anti-TB treatment. The signature in active TB patients as compared to latent individuals (664 transcripts) was significantly diminished by two weeks after initiation of treatment and this significant response was measured using a novel algorithm (termed “Temporal Molecular Responses”) developed for this study. A specific treatment response-transcriptional signature (391 transcripts) was derived and validated in two independent cohorts, to which two quantitative scoring algorithms were applied to score the changes in the transcriptional response. The most significantly represented pathways were determined using Ingenuity Pathway Analysis. The South African active TB-transcriptional signature revealed more differentially expressed genes than previously reported in UK cohorts. Interferon inducible genes were highly significantly elevated in all cohorts. The active TB-transcriptional signatures and the treatment specific transcriptional-signature significantly diminished after two weeks of treatment and continued to diminish significantly until six months. Significant changes in the transcriptional signatures measured by blood tests were readily detectable just two weeks after treatment initiation. Therefore transcriptional responses provide a clinical tool for monitoring an individual TB patient's response to treatment.
As used herein, a “significant change” between gene expression datasets is indicative that treatment is effective; in contrast, treatment is ineffective if less than a significant change between the first gene expression dataset and the second gene expression dataset is detected. A significant change can be determined by a person of ordinary skill in the art upon viewing a clearly visible change in transcriptional response using a heatmap or time-scaled profile plot of normalized intensity values or a simple time-scaled line graph of the transcriptional signature between the first and second time point. In some embodiments, the significant change can be determined upon generating a simple time-scaled line graph (also called a profile plot) of normalized signal intensity values. See, for example,
As used herein, the term “array” refers to a solid support or substrate with one or more peptides or nucleic acid probes attached to the support. Arrays typically have one or more different nucleic acid or peptide probes that are coupled to a surface of a substrate in different, known locations. These arrays, also described as “microarrays” or “gene-chips” that may have 10,000; 20,000, 30,000; or 40,000 different identifiable genes based on the known genome, e.g., the human genome. These pan-arrays are used to detect the entire “transcriptome” or transcriptional pool of genes that are expressed or found in a sample, e.g., nucleic acids that are expressed as RNA, mRNA and the like that may be subjected to RT and/or RT-PCR to made a complementary set of DNA replicons. Arrays may be produced using mechanical synthesis methods, light directed synthesis methods and the like that incorporate a combination of non-lithographic and/or photolithographic methods and solid phase synthesis methods.
Various techniques for the synthesis of these nucleic acid arrays have been described, e.g., fabricated on a surface of virtually any shape or even a multiplicity of surfaces. Arrays may be peptides or nucleic acids on beads, gels, polymeric surfaces, fibers such as fiber optics, glass or any other appropriate substrate. Arrays may be packaged in such a manner as to allow for diagnostics or other manipulation of an all-inclusive device, see for example, U.S. Pat. No. 6,955,788, which is incorporated herein by reference in its entirety.
As used herein, the term “disease” refers to a physiological state of an organism with any abnormal biological state of a cell. Disease includes, but is not limited to, an interruption, cessation or disorder of cells, tissues, body functions, systems or organs that may be inherent, inherited, caused by an infection, caused by abnormal cell function, abnormal cell division and the like. A disease that leads to a “disease state” is generally detrimental to the biological system, that is, the host of the disease. With respect to the present invention, any biological state, such as an infection (e.g., viral, bacterial, fungal, helminthic, etc.), inflammation, autoinflammation, autoimmunity, anaphylaxis, allergies, premalignancy, malignancy, surgical, transplantation, physiological, and the like that is associated with a disease or disorder is considered to be a disease state. A pathological state is generally the equivalent of a disease state.
Disease states may also be categorized into different levels of disease state. As used herein, the level of a disease or disease state is a measure reflecting the progression of a disease or disease state as well as the physiological response upon, during and after treatment. Generally, a disease or disease state will progress through levels or stages, wherein the effects of the disease become increasingly severe. The level of a disease state may be impacted by the physiological state of cells in the sample.
As used herein, the terms “therapy” or “therapeutic regimen” refer to those medical steps taken to alleviate or alter a disease state, e.g., a course of treatment intended to reduce or eliminate the affects or symptoms of a disease using pharmacological, surgical, dietary and/or other techniques. A therapeutic regimen may include a prescribed dosage of one or more drugs or surgery. Therapies will most often be beneficial and reduce the disease state but in many instances the effect of a therapy will have non-desirable or side-effects. The effect of therapy will also be impacted by the physiological state of the host, e.g., age, gender, genetics, weight, other disease conditions, etc.
As used herein, the term “pharmacological state” or “pharmacological status” refers to those samples from diseased individuals that will be, are and/or were treated with one or more drugs, surgery and the like that may affect the pharmacological state of one or more nucleic acids in a sample, e.g., newly transcribed, stabilized and/or destabilized as a result of the pharmacological intervention. The pharmacological state of a sample relates to changes in the biological status before, during and/or after drug treatment and may serve as a diagnostic or prognostic function, as taught herein. Some changes following drug treatment or surgery may be relevant to the disease state and/or may be unrelated side-effects of the therapy. Changes in the pharmacological state are the likely results of the duration of therapy, types and doses of drugs prescribed, degree of compliance with a given course of therapy, and/or un-prescribed drugs ingested.
As used herein, the term “biological state” refers to the state of the transcriptome (that is the entire collection of RNA transcripts) of the cellular sample isolated and purified for the analysis of changes in expression. The biological state reflects the physiological state of the cells in the blood sample by measuring the abundance and/or activity of cellular constituents, characterizing according to morphological phenotype or a combination of the methods for the detection of transcripts.
As used herein, the term “expression profile” refers to the relative abundance of RNA, DNA abundances or activity levels. The expression profile can be a measurement for example of the transcriptional state or the translational state by any number of methods and using any of a number of gene-chips, gene arrays, beads, multiplex PCR, quantitative PCR, run-on assays, Northern blot analysis, or using RNA-seq, nanostring, nanopore RNA sequencing etc. Apparatus and system for the determination and/or analysis of gene expression that are readily commercially available.
As used herein, the term “transcriptional state” of a sample includes the identities and relative abundances of the RNA species, especially mRNAs present in the sample. The entire transcriptional state of a sample, that is the combination of identity and abundance of RNA, is also referred to herein as the transcriptome. Generally, a substantial fraction of all the relative constituents of the entire set of RNA species in the sample are measured.
Regarding the “expression level,” the group comparison for a given disease provides the list of differentially expressed transcripts. It was found that different diseases yield different subsets of gene transcripts.
Using the present invention it is possible to determine the effectiveness of a treatment for tuberculosis at the gene-level; i.e., two diseases can have the same vector (identical proportion of differentially expressed transcripts, identical “polarity”), but the gene composition of the vector can still be disease-specific. Gene-level expression provides the distinct advantage of greatly increasing the resolution of the analysis. Furthermore, the present invention takes advantage of composite transcriptional markers.
As used herein, the term “composite transcriptional markers” refers to the average expression values of multiple genes (composite of transcripts) as compared to using individual genes as markers (and the composition of these markers can be disease-specific). The composite transcriptional markers approach is unique because the user can develop multivariate microarray scores to assess disease severity in patients with, e.g., tuberculosis (TB) or systemic lupus erythematosus (SLE), or to derive expression vectors disclosed herein. It has been found that using the composite transcriptional markers of the present invention the results found herein are reproducible across microarray platform, thereby providing greater reliability for regulatory approval.
Gene expression monitoring systems for use with the present invention may include customized gene arrays with a limited and/or basic number of genes that are specific and/or customized for the one or more target diseases. Unlike the general, pan-genome arrays that are in customary use, the present invention provides for not only the use of these general pan-arrays for retrospective gene and genome analysis without the need to use a specific platform, but more importantly, it provides for the development of customized arrays that provide an optimal gene set for analysis without the need for the thousands of other, non-relevant genes. One distinct advantage of the optimized arrays and gene sets of the present invention over the existing art is a reduction in the financial costs (e.g., cost per assay, materials, equipment, time, personnel, training, etc.), and more importantly, the environmental cost of manufacturing pan-arrays where the vast majority of the data is irrelevant. By reducing the total number of genes for analysis, or eliminating genes for analysis, it is possible to, e.g., eliminate the need to manufacture thousands of expensive platinum masks for photolithography during the manufacture of pan-genetic chips that provide vast amounts of irrelevant data. Using the present invention it is possible to completely avoid the need for microarrays if the limited probe set(s) of the present invention are used with, e.g., digital optical chemistry arrays, ball bead arrays, multiplex PCR, quantitative PCR, “RNA-seq” for measuring mRNA levels using next-generation sequencing technologies, nanostring-type technologies or any other method, apparatus and system for the determination and/or analysis of gene expression that are readily commercially available.
The “molecular fingerprinting system” of the present invention may be used to facilitate and conduct a comparative analysis of expression in different cells or tissues, different subpopulations of the same cells or tissues, different physiological states of the same cells or tissue, different developmental stages of the same cells or tissue, or different cell populations of the same tissue against other diseases and/or normal cell controls. In some cases, the normal or wild-type expression data may be from samples analyzed at or about the same time or it may be expression data obtained or culled from existing gene array expression databases, e.g., public databases such as the NCBI Gene Expression Omnibus database.
As used herein, the term “differentially expressed” refers to the measurement of a cellular constituent (e.g., nucleic acid, protein, enzymatic activity and the like) that varies in two or more samples, e.g., between a disease sample and a normal sample. The cellular constituent may be on or off (present or absent), upregulated relative to a reference or downregulated relative to the reference. For use with gene-chips or gene-arrays, differential gene expression of nucleic acids, e.g., mRNA or other RNAs (miRNA, siRNA, hnRNA, rRNA, tRNA, etc.) may be used to distinguish between cell types or nucleic acids. Most commonly, the measurement of the transcriptional state of a cell is accomplished by quantitative reverse transcriptase (RT) and/or quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), genomic expression analysis, post-translational analysis, modifications to genomic DNA, translocations, in situ hybridization and the like.
The skilled artisan will appreciate readily that samples may be obtained from a variety of sources including, e.g., single cells, a collection of cells, tissue, cell culture and the like. In certain cases, it may even be possible to isolate sufficient RNA from cells found in, e.g., urine, blood, saliva, tissue or biopsy samples and the like. In certain circumstances, enough cells and/or RNA may be obtained from: mucosal secretion, feces, tears, blood plasma, peritoneal fluid, interstitial fluid, intradural, cerebrospinal fluid, sweat or other bodily fluids. The nucleic acid source, e.g., from tissue or cell sources, may include a tissue biopsy sample, one or more sorted cell populations, cell culture, cell clones, transformed cells, biopsies or a single cell. The tissue source may include, e.g., brain, liver, heart, kidney, lung, spleen, retina, bone, neural, lymph node, endocrine gland, reproductive organ, blood, nerve, vascular tissue, and olfactory epithelium.
The present invention includes the following basic components, which may be used alone or in combination, namely, one or more data mining algorithms, one a novel algorithm specifically developed for this TB treatment monitoring, the Temporal Molecular Response; the characterization of blood leukocyte transcriptional gene sets; the use of aggregated gene transcripts in multivariate analyses for the molecular diagnostic/prognostic of human diseases; and/or visualization of transcriptional gene set-level data and results. Using the present invention it is also possible to develop and analyze composite transcriptional markers. The composite transcriptional markers for individual patients in the absence of control sample analysis may be further aggregated into a reduced multivariate score.
An explosion in data acquisition rates has spurred the development of mining tools and algorithms for the exploitation of microarray data and biomedical knowledge. Approaches aimed at uncovering the function of transcriptional systems constitute promising methods for the identification of robust molecular signatures of disease. Indeed, such analyses can transform the perception of large-scale transcriptional studies by taking the conceptualization of microarray data past the level of individual genes or lists of genes.
The present inventors have recognized that current microarray-based research is facing significant challenges with the analysis of data that are notoriously “noisy,” that is, data that are difficult to interpret and do not compare well across laboratories and platforms. A widely accepted approach for the analysis of microarray data begins with the identification of subsets of genes differentially expressed between study groups. Users may try subsequently to “make sense” out of resulting gene lists using standard algorithms and existing scientific knowledge and by validating in independent sample sets and in different microarray analyses.
Pulmonary tuberculosis (PTB) is a major and increasing cause of morbidity and mortality worldwide caused by Mycobacterium tuberculosis (M. tuberculosis). However, the majority of individuals infected with M. tuberculosis remain asymptomatic, retaining the infection in a latent form, and it is thought that this latent state is maintained by an active immune response. Blood is the pipeline of the immune system, and as such it is the ideal biologic material from which the health and immune status of an individual can be established.
Blood represents a reservoir and a migration compartment for cells of the innate and the adaptive immune systems, including either neutrophils, dendritic cells and monocytes, or B and T lymphocytes, respectively, which during infection will have been exposed to infectious agents in the tissue. For this reason whole blood from infected individuals provides an accessible source of clinically relevant material where an unbiased molecular phenotype can be obtained using gene expression microarrays as previously described for the study of cancer in tissues (Alizadeh A A., 2000; Golub, T R., 1999; Bittner, 2000), and autoimmunity (Bennet, 2003; Baechler, E C, 2003; Burczynski, M E, 2005; Chaussabel, D., 2005; Cobb, J P., 2005; Kaizer, E C., 2007; Allantaz, 2005; Allantaz, 2007), and inflammation (Thach, D C., 2005) and infectious disease (Ramillo, Blood, 2007) in blood or tissue (Bleharski, J R et al., 2003). Microarray analyses of gene expression in blood leucocytes have identified diagnostic and prognostic gene expression signatures, which have led to a better understanding of mechanisms of disease onset and responses to treatment (Bennet, L 2003; Rubins, K H., 2004; Baechler, E C, 2003; Pascual, V., 2005; Allantaz, F., 2007; Allantaz, F., 2007). These microarray approaches have been attempted for the study of active and latent TB but as yet have yielded small numbers of differentially expressed genes only (Jacobsen, M., Kaufmann, S H., 2006; Mistry, R, Lukey, P T, 2007), and in relatively small numbers of patients (Mistry, R., 2007), which may not be robust enough to distinguish between other inflammatory and infectious diseases. The present inventors recognize that a neutrophil driven blood transcriptional signature in active TB patients was missing in the majority of latent TB individuals and in healthy controls. See, also (9). This signature of active TB was reflective of lung radiographic disease and was diminished after two months of treatment. The signature was dominated by interferon-inducible genes, and at a modular level the active TB signature was distinct from other infectious or autoimmune diseases.
To define an immune signature in TB, the blood of TB patients before and after commencement of treatment and controls were analyzed; patients were selected using very stringent clinical criteria.
Approximately one third of the world is infected with the pathogen Mycobacterium tuberculosis (Mtb), the cause of TB. While most remain asymptomatic, termed latent, approximately 10% develop active TB during their lifetime (1). Over nine million new cases of active TB and 1.7 million deaths annually have been reported (2). Improved diagnostics, more effective and shorter treatments than the current minimum of six months, and improvements in treatment monitoring are badly needed.
Active pulmonary TB diagnosis requires culture of Mtb, which may take up to six weeks (3). Conventional determination of antibiotic sensitivities demands several more weeks of culture. Mtb is isolated from sputum, which is often difficult to obtain, or from lung washings using invasive and expensive methods, which are prohibitive in developing countries. Due to insufficient samples and poor availability of culture, approximately 30% of patients in the USA and 50% of South African patients are treated empirically (2, 4). Although the World Health Organization (WHO) endorsed Xpert MTB/RIF automated molecular test for Mtb results in rapid diagnosis, this test still requires sputum (5). After diagnosis there are no available early biomarkers correlating with treatment success, resulting in significant delay in assessing treatment response. In poor responders this delay can result in worsening disease and spread of drug resistant bacteria. Currently sputum conversion to negative culture after two months of treatment is the only accepted biomarker (6). However a systematic review and meta-analysis to assess its accuracy to predict an individual's treatment failure revealed low sensitivity and modest specificity (7). Chest X-rays are commonly used to assess response but are not universally available and assessment is difficult to standardize (8). Lack of practicable treatment monitoring is concerning due to the development of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, mainly caused by non-adherence or inappropriate drug regimens, resulting in a detrimental impact on global TB treatment programs.
A whole blood transcriptional signature can distinguish active TB from latent TB and other diseases, and be correlated with radiographic extent of disease (9). This active TB blood signature diminished after two months of successful treatment and reverted to that of healthy individuals after completing treatment (9). Early blood biomarkers correlating with treatment response will allow monitoring of patients without sputum, expedite knowledge of an individual's treatment response and may permit stratification of patients requiring differing treatment regimens. Furthermore early biomarkers can be instrumental in drug development.
Certain embodiments of the present invention are designed to establish that early changes in a blood transcriptional response can be observed during anti-TB treatment. Furthermore, it adds to previous results by examining the transcriptional treatment response directly in a larger cohort from a high-burden TB country, South Africa (2).
METHODS: Study Population: Blood was collected between May 2008-November 2011 in Ubuntu TB/HIV clinic, South Africa and Royal Free Hospital NHS Trust, London from patients (age>17 years) with Mtb culture positive active pulmonary TB (
Expression Profiling: The following were performed according to the manufacturer's instructions. Blood was collected into Tempus tubes (Applied Biosystems/Ambion). 2011 sample's RNA was isolated using MagMAX-96 Blood RNA Isolation Kit (Applied Biosystems/Ambion), globin reduced using GLOBINclear 96-well format kit (Applied Biosystems/Ambion), biotinylated, amplified antisense complementary RNA (cRNA) targets were prepared using Illumina CustomPrep RNA amplification kit (Applied Biosystems/Ambion). RNA integrity and yield were assessed using Agilent 2100 Bioanalyzer (Agilent Technologies) and NanoDrop 800 spectrophotometer (NanoDrop Products, Thermo Fisher Scientific), respectively. Labeled cRNA was hybridized to Illumina Human HT-12 V4 BeadChip arrays (Illumina) and scanned on an Illumina iScan. GenomeStudio (Illumina) was used for quality control and to generate signal intensity values. 2009 sample's RNA was processed as previously described (9). Using GeneSpring GX version 11.5 (Agilent Technologies) raw data were analyzed by the following: background subtraction, filtering by detection significance (p<0.01), threshold set, log 2 transformed, per-chip normalised (75th percentile shift algorithm) and per-gene normalised to median of latent TB samples.
Statistical Analysis: GeneSpring 11.5 was used to select transcripts with an expression fold change (active TB-signature: twofold expression from latent TB samples; treatment specific signature: threefold expression in 8/11 training set matched untreated and six-month treated samples). Statistical filtering was then applied using non-parametric tests and multiple testing corrections (Benjamini Hochberg or Bonferroni) (10, 11). The Treated South Africa 2011 cohort was randomised into a training and test set (12). Derived signatures were then applied to the: Treated South Africa 2011 cohort, Treated UK 2011 Cohort, and cohorts from the earlier Berry et al. (2010) study. Data was displayed in heatmaps generated by hierarchical clustering (distance metric: Pearson's uncentered with average linkage (13)) showing either clustering of transcripts and samples, or just clustering of transcripts.
Molecular distance to health (MDTH) was determined as previously described (14). In one embodiment, the Temporal Molecular Response was calculated from the sum of transcripts that were greater than twofold different between one time point and the baseline values, then expressed as a percentage of the total number of transcripts in that signature. MDTH and temporal molecular response were calculated in Microsoft Excel 2010. Graphs, p-values and linear regression were generated in GraphPad Prism version 5 for Windows except linear mixed models was performed in SASTM software (SAS Institute Inc., USA). Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood, Calif.), identified significant canonical pathways (Fisher's exact Benjamini Hochberg p<0.05).
Study Population and Inclusion Criteria: All participants in South Africa were recruited from the Ubuntu TB/HIV clinic in Khayelitsha, a large peri-urban African township in Cape Town which has over 1000 TB notifications annually. During the period May 2008-August 2010 whole blood was collected from adult patients (age>17 years) with drug sensitive Mtb culture proven active pulmonary TB (
All participants in the 2009 UK Training and Test cohorts were selected as previously described (9). The UK 2011 Active TB Validation Cohort were all Mtb culture proven adults (>17 years) recruited between August 2009-November 2011 from the Royal Free Hospital, London (
Follow Up Period: All 20 Treated 2011 South Africa active TB patients completed a full six months of treatment. Each patient was sampled for venous blood at every time point: two weeks, two months, six months and 12 months after initiation of treatment (FIG. 1A). Patient's response to anti-TB treatment was assessed clinically during the 12-month period. All patients were discharged from the program as cured.
Eight Treated 2011 UK Active TB patients completed a full six months of treatment, one patient completed nine months of treatment due to radiographic uncertainty of treatment success. Each patient was sampled for venous blood at two weeks, two months, four months and six months after initiation of treatment (
IFNγ Release Assay Testing: The QFT Assay (Cellestis) was performed according to the manufacturer's instructions.
Gene Expression Profiling: 3 ml of whole blood were collected into Tempus tubes (Applied Biosystems/Ambion) by standard phlebotomy, vigorously mixed immediately after collection, and stored between −20 and −80° C. before RNA extraction. South Africa and UK 2011 sample's RNA was isolated using 1.5 ml whole blood and the MagMAX-96 Blood RNA Isolation Kit (Applied Biosystems/Ambion) according to the manufacturer's instructions. 250 μg of isolated total RNA was globin reduced using the GLOBINclear 96-well format kit (Applied Biosystems/Ambion) according to the manufacturer's instructions. Total and globin-reduced RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA yield was assessed using a NanoDrop 800 spectrophotometer (NanoDrop Products, Thermo Fisher Scientific). Biotinylated, amplified antisense complementary RNA (cRNA) targets were then prepared from 200-250 ng of the globin-reduced RNA using the Illumina CustomPrep RNA amplification kit (Applied Biosystems/Ambion). 750 ng of labeled cRNA was hybridized overnight to Illumina Human HT-12 V4 BeadChip arrays (Illumina), which contained more than 47,000 probes. The arrays were washed, blocked, stained and scanned on an Illumina iScan, as per manufacturer's instructions. GenomeStudio (Illumina) was then used to perform quality control and generate signal intensity values.
South African and UK 2009 sample's RNA was isolated as previously described and hybridized to Illumina Human HT-12 V3 BeadChip arrays (Illumina) (9). Probes were translated from the HT-12 V3 BeadChip arrays to HT-12 V4 BeadChip arrays using GeneSpring GX version 11.5 (Agilent Technologies) and translated to slightly fewer probes in V4.
Raw data were processed using GeneSpring GX version 11.5 (Agilent Technologies), and the following was applied to all analysis. After background subtraction each probe was attributed a flag to denote its signal intensity detection p-value. Flags were used to filter out probe sets that did not result in a ‘present’ call in at least 10% of the samples, where the ‘present’ lower cut off=0.99. Signal values were then set to a threshold level of 1, log 2 transformed, and per-chip normalised using 75th percentile shift algorithm. Next per-gene normalisation was applied by dividing each messenger RNA transcript by the median intensity of the latent TB samples. All statistical analysis was performed after this stage.
All data collected and analyzed in the experiments adhere to the Minimal Information About a Microarray Experiment (MIAME) guidelines.
Statistical Analysis: GeneSpring 11.5 was used to select transcripts that displayed a degree of expression variability. A filter was set to include only transcripts that had at least twofold changes from the median intensity of all latent TB samples and present in at least 10% of the samples. This approach was used to determine all the ‘active TB-transcriptional signatures’. To divide the South Africa 2011 cohort into a training and test set, a computer algorithm was used for randomization (12). For the specific treatment response signature transcripts had to satisfy a threefold expression filter in eight of the 11 training set matched untreated and six month treated samples. Selected transcripts were then filtered by different levels of statistical stringency in GeneSpring 11.5. Non-parametric tests with multiple testing corrections were applied to all analyses (10, 11). The active TB-transcriptional signatures were generated by Mann Whitney unpaired Benjamini Hochberg p<0.01 or Bonferroni p<0.01 (
Molecular distance to health (MDTH) was determined for each time point, as previously described (14). Temporal Molecular Response was determined per individual, for each transcriptional signature, by calculating the sum of the transcripts that were greater than twofold up or down at a specific time point, e.g. two weeks, compared to the raw pre-treatment intensity values. For intensity values of zero a value of 10 to the power of −20 (10−20) was introduced. The calculated number of altered transcripts was then expressed as a percentage of the total number of transcripts in the transcriptional signature. This calculation was then repeated for the rest of the time points. MDTH and temporal molecular response were calculated in Microsoft Excel 2010. GraphPad Prism version 5 for Windows was used to generate graphs, determine linear regression, and determine associated p-values using either Friedman and Dunn's multiple comparison test for MDTH data or ANOVA repeated measures and Tukey's multiple comparison test for temporal molecular response data. Linear mixed models, fixed effects, was performed in SAS/STAT® software (SAS Institute Inc., USA). Statistical tests applied were dependent on the distribution of the data as determined by D'Agostino and Pearson omnibus normality test. Pathway analyses were performed using Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood, Calif.). Canonical pathways analysis identified the most significantly represented pathways in the datasets (Fisher's exact Benjamini Hochberg p<0.05).
Results: Participants Demographics and Characteristics: Participant numbers in the South Africa 2011 cohort are described in
A Change in Transcriptional Response is Readily Detectable after Two Weeks of Treatment: To determine whether an active TB transcriptional signature in the blood of the 2011 South Africa cohort was perturbed upon treatment, gene expression profiles of only significantly detectable genes without further filtering (detected p<0.01 from background, 16,856 transcripts), were examined in the 20 active TB patients before, during (two weeks and two months), at the end (six months), and after treatment (12 months). By plotting the expression profiles of the 16856 transcripts along a time scaled x-axis, a marked change was readily observed after two weeks of anti-TB treatment (
An active TB 664-transcript signature was derived from differentially expressed genes in the active TB patients compared to the latent TB patients in the Untreated South Africa 2011 cohort (
The Transcriptional Response Changes Significantly at Two Weeks, Two Months & Six Months after Treatment Initiation: Since the South Africa untreated active TB signatures diminished in response to treatment, the present inventors determined that there was a significant change in the transcriptional signature during treatment. For this determination, the molecular distance to health (MDTH) algorithm was determined as this generates a quantitative score for the degree of transcriptional perturbation in a disease cohort relative to the controls (14). The present inventors recognized that MDTH positively correlates with the severity of active pulmonary TB, as defined by the radiological extent of disease (9). The present inventors found that the median MDTH associated with the 664 South African untreated active TB-transcriptional signature altered significantly at two, six, and twelve months, compared to the median pre-treatment MDTH (
To expand on the treatment induced transcriptional response, a metric was developed that allowed us to evaluate each individual's change in gene expression relative to their own expression profile, rather than relative to a control group. This ‘temporal molecular response’ offers a potential advantage in the clinical setting to allow separate assessment of each patient's outcome. For a given signature, the temporal molecular response was determined by measuring the transcriptional perturbation between two time points, and expressing this value as a percentage of the total number of transcripts constituting the signature. The mean temporal molecular response associated with the South Africa untreated active TB 664 transcript signature altered rapidly and significantly as early as two weeks, and continued to alter significantly at two months and six months (
The changing transcriptional response is independent of the magnitude of the untreated transcriptional signature: It may be predicted that individuals with more extensive disease would respond to treatment differently from those with minimal disease. However the magnitude of the patient's temporal molecular response during treatment, at both two weeks and two months, did not correlate with the magnitude of their pre-treatment transcriptional signature, as evidenced by MDTH (r2<0.1, non-significant) (
A specific ‘TB treatment response signature’ significantly diminishes at two weeks, two months and after completion of treatment: The 664-transcript active TB signature significantly and rapidly changed in response to treatment (
In addition, a transcriptional signature that specifically reflected the response of patients to clinically successful anti-TB treatment (comparing time points 0 and 6 months) was determined. To determine the treatment specific signature, a computer algorithm was used to randomize the South Africa 2011 cohort into two groups of patients (12) (
Measuring an individual patient's transcriptional response to anti-TB treatment: Each patient's discrete treatment response is shown in the heatmaps and by graphical form using the temporal molecular response in
By both the MDTH and temporal molecular response, it was observed that none of the transcriptional signatures revealed significant differences between two months and six months post treatment initiation (
Validation of early anti-TB treatment blood transcriptional response: To determine whether the significant change in the 391-transcript treatment specific signature that had been demonstrated in a South Africa cohort was also generalizable to patients in an intermediate burden setting, the signature was tested in UK. As observed in the South Africa cohort the signature was rapidly and significantly diminished at two weeks onwards post commencing treatment (
The significant change in transcriptional response at two weeks occurs when applying active TB signatures derived from other cohorts: thus far it was demonstrated that the 664-transcript active TB signature (
The established 393- and 86-transcript active TB signatures from the earlier Berry et al. (2010) study (9) obtained by comparing active TB patients to latent TB patients and healthy controls were applied first. The present inventors demonstrate that the 393 and 86-transcript active TB signatures significantly and rapidly diminished in the South Africa 2011 cohort, and this occurred as early again as two weeks (
A core set of genes (344 transcripts) were found to be overlapping between these 2009 derived active TB transcriptional signatures (
The whole blood active TB-transcriptional signatures derived from a South African cohort, dominated by IFN signaling and innate immune response genes, showed a readily detectable change in response to clinically successful anti-TB treatment. Importantly the treatment-associated changes in the active TB-transcriptional signature and a specific TB treatment response-transcriptional signature were rapid and highly significant as early as two weeks after the initiation of therapy. The transcriptional response to treatment could be individually measured in each patient and was independent of the magnitude of their pre-treatment transcriptional signature. The significant and early change in the treatment specific transcriptional signature was then validated in a UK cohort. These findings demonstrate that blood transcriptional signatures can be pragmatic as early surrogate markers of a successful treatment response, and can be used as biomarkers in both the clinical setting and in drug development. In certain embodiments, the method is useful for improving stratification and monitoring of clinical treatment of active TB patients, testing novel therapies in to enhance efficacy in treatment of drug-sensitive Mtb infection in clinical trials, and in the testing of novel drugs for use in the potential treatment of MDR- and XDR-TB.
An active TB transcriptional signature, originally derived from a UK cohort, which distinguished active TB patients from patients with other inflammatory and infectious diseases and which correlated with the radiographic extent of disease, was demonstrated (9). The transcriptional response in the high-burden TB country of South Africa was evaluated before, during, and after anti-TB treatment. The study of TB patients in both the UK and South Africa provided gene expression profiles across diverse host populations, exposed to different local environments and likely different Mtb strains. The South African cohort contained participants from Khayelitsha, a large peri-urban African township in Cape Town, where 1.5% of the population develops active TB annually. It was found that South Africa active TB patients (all HIV uninfected) had more differentially expressed genes that those from the UK. This may be explained by a higher incidence of co-infection with other micro-organisms and viruses, besides HIV, or a higher burden of Mtb infection due to delayed diagnosis relative to countries like the UK, present in South Africa. For example, although the exact helminth prevalence in adults is unknown, data from surveys suggest between 70-100% of children are infected (15). Although the number of genes differed between the South Africa and UK cohorts, the most significantly represented pathways, IFN signaling and innate immune response pathways, were the same. Notably many of the genes contained within the innate immune response pathways in all the cohorts, were also interferon inducible genes (Table 1), including the complement genes, Toll-like receptor genes, and familiar IFN inducible genes such as CXCL10 and OAS genes (16-20).
Studies in TB. Maertzdorf et al examined whole blood gene expression of active TB and latent TB patients in cohorts from both South Africa and The Gambia (21, 22). Although some IFN inducible and innate response genes were significantly over expressed in the active TB patients, different microarray chips and analysis strategy were employed.
While it is widely appreciated that the diagnosis of TB has many difficulties, the present inventors recognize that TB treatment monitoring is a difficult challenge in trying to eradicate Mtb infection. So much so that in April 2010 the Centers for Disease Control and National Institutes of Health brought together experts in the field and research scientists with the sole purpose of addressing this problem (23). The consequences of poor treatment monitoring, and therefore impending inadequate treatment, includes worsening of a patient's disease, increasing potential for disease spread and most worryingly an escalation in drug resistant mycobacteria. Currently the two-month sputum culture conversion rate, used to measure anti-TB treatment response, is the only biomarker of successful TB treatment (6). However sputum culture conversion is a time consuming test, since it takes several weeks to grow the bacilli and results can be compromised by contamination. In fact, often the patients who have improved are unable to expectorate sputum at two months but then are wrongly labeled as having a negative result (24). Furthermore although sputum conversion has efficacy as a surrogate end point of treatment response in clinical trials evaluating new drugs, a systematic review and meta-analysis to assess its accuracy to predict an individual's treatment failure revealed low sensitivity and modest specificity (7, 25). While other biomarkers have also been trialed, including C-reactive protein, IFN-γ and neopterin, all have shown poor sensitivity and specificity (26). Chest X-rays are commonly used in the clinical setting as a marker of treatment response but they generally improve more slowly than the clinical response and lack specificity as interpretation can be confounded by previous lung damage (24). Moreover, interpretation of chest X-ray changes in response to treatment has not yet been standardised, and the facilities are not always available in developing countries (8). Therefore there is clearly a need for early and easily detectable biomarkers for treatment monitoring, capable of detecting drug resistance or poor treatment adherence and available for patients unable to produce sputum. In addition, such blood biomarkers of early anti-TB treatment response would be vital in clinical trials to aid the evaluation and development of more effective new and shorter treatment regimens.
In UK patients, active TB signatures, 393 and 86 transcripts, diminished at two months of treatment (9). The present inventors now show a significant blood transcriptional response to treatment occurs rapidly and as early as two weeks (
Although no other studies have looked directly at the transcriptional response to TB treatment, two other studies have observed some transcriptional changes, but only measured at two months or after treatment completion. Mistry et al. studied whole blood gene expression in patients from South Africa, comparing patients with active TB, recurrent reactivation of TB, cured TB and latent TB (28). These study methods were different from the methods employed herein because Mistry et al. did not measure the transcriptional profile during treatment but only after completion of treatment. Mistry et al. showed that those who were cured from TB displayed similar expression profiles to those with latent infection. There was a small but non-significant increase in gene expression six months after stopping the anti-TB treatment in a small number of active TB patients (e.g.,
A further problem in the management of TB is the extended length of treatment, requiring a minimum of six months, which has a negative impact on patient adherence and treatment completion. Therefore the ability to stratify patients into groups that may require shorter lengths of treatment, particularly in resource limited settings, could be of value in improving patient compliance and reducing treatment related side effects. It is shown herein that transcriptional response of some patients appeared to plateau before six months (
This example provides further advances by the present inventors in methods for monitoring changes in blood transcriptional signatures in response to antituberculosis treatment and details use of these changes as early biomarkers of a successful response. In particular, significant changes in the transcriptional signatures measured by blood tests were readily detectable just two weeks after treatment initiation, and transcriptional response to treatment is shown as being readily measured in individual patients. These findings further support that blood transcriptional signatures are useful as early surrogate biomarkers of successful treatment response. Unlike Example 1, use of a 320 gene (Table 12) transcriptional signature is prominently disclosed in Example 2.
More specifically, blood transcriptional profiles of untreated active tuberculosis patients in South Africa were analysed before, during (two weeks and two months), at the end of (six months) and after (12 months) antituberculosis treatment, and compared to individuals with latent tuberculosis. An active-tuberculosis transcriptional signature and a specific treatment-response transcriptional signature were derived. The specific treatment response transcriptional signature was tested in two independent cohorts. Two quantitative scoring algorithms were applied to measure the changes in the transcriptional response. The most significantly represented pathways were again determined using Ingenuity Pathway Analysis. An active tuberculosis 664-transcript signature and a treatment specific 320-transcript signature significantly diminished after two weeks of treatment in all cohorts, and these continued to diminish until six months. The transcriptional response to treatment could be individually measured in each patient.
Active pulmonary TB diagnosis requires culture of Mtb, which may take up to six weeks [3]. Although the World Health Organization (WHO) endorsed GeneXpert MTB/RIF automated molecular test for Mtb results in rapid diagnosis [4], this test still requires sputum which may be difficult to obtain. Difficulties in obtaining sputum lead to approximately 30% of patients in the USA and 50% of South African patients to be treated empirically [2], [5]. After diagnosis there are no available early biomarkers correlating with treatment success, resulting in significant delay in assessing treatment response. Currently conversion to negative culture after two months of treatment is the only accepted biomarker [6]. However a systematic review and meta-analysis of sputum conversion revealed low sensitivity and modest specificity for the prediction of treatment failure [7]. Chest X-rays are commonly used to assess response but are not universally available and assessment is difficult to standardise [8]. This lack of effective treatment monitoring can lead to the development and spread of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which are mainly caused by non-adherence or inappropriate drug regimens, with a detrimental impact on global TB control.
To date transcriptional profiling has been used successfully in cancer classification, to identify prognostic biomarkers [9], and to distinguish between inflammatory and infectious diseases [10]. Moreover, a whole blood transcriptional signature may be used to distinguish active TB from latent TB and other diseases, and it is correlated with radiographic extent of disease [11]. This active TB blood signature diminished in seven patients after two months of successful treatment and reverted to that of healthy individuals after completing treatment [11]. Earlier blood biomarkers correlating with treatment response would improve monitoring of individual patient treatment responses without the need for sputum production, which may permit stratification of patients requiring differing treatment regimens. Additionally, early biomarkers may aid in anti-TB drug development.
The study detailed in this example was designed to establish if early changes in blood transcriptional responses can be observed during standard anti-TB treatment. It adds to previous studies in part by examining the transcriptional treatment response directly in a larger cohort from a high-burden TB country, South Africa [2].
Materials and Methods. All participants in South Africa were recruited from the Ubuntu TB/HIV clinic in Khayelitsha, a large peri-urban African township in Cape Town which has over 1000 TB notifications annually. During the period May 2008-August 2010 whole blood was collected from adult patients (age>17 years) with drug sensitive Mtb culture proven active pulmonary TB (
The UK 2011 Active TB Validation Cohort were all Mtb culture proven adults (>17 years) recruited between August 2009-November 2011 from the Royal Free Hospital, London (
Ethics Statement. This study was approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, Cape Town, South Africa (FHS HREC 012/2007), and the Central London 3 Research Ethics Committee (09/H0716/41). All participants gave informed written consent.
Follow Up Period. All 29 treated 2011 South Africa active TB patients completed a full 6 months of treatment. Patients were sampled for venous blood at time points: pre-treatment (29/29 patients), 2 weeks (25/29 patients), 2 months (24/29 patients), 6 months (25/29 patients) and 12 months (29/29 patients) after initiation of treatment (
Eight treated 2011 UK Active TB patients completed a full six months of treatment, one patient completed nine months of treatment due to radiographic uncertainty of treatment success. Each patient was sampled for venous blood at two weeks, two months, four months and six months after initiation of treatment (
IFNγ, Release Assay Testing. The QFT Assay (Cellestis) was performed according to the manufacturer's instructions.
Gene Expression Profiling. 3 ml of whole blood were collected into Tempus tubes (Applied Biosystems/Ambion) by standard phlebotomy, vigorously mixed immediately after collection, and stored between −20 and −80° C. before RNA extraction. South Africa and UK 2011 sample's RNA was isolated using 1.5 ml whole blood and the MagMAX-96 Blood RNA Isolation Kit (Applied Biosystems/Ambion) according to the manufacturer's instructions. 250 μg of isolated total RNA was globin reduced using the GLOBINclear 96-well format kit (Applied Biosystems/Ambion) according to the manufacturer's instructions. Total and globin-reduced RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA yield was assessed using a NanoDrop800 spectrophotometer (NanoDrop Products, Thermo Fisher Scientific). Biotinylated, amplified antisense complementary RNA (cRNA) targets were then prepared from 200-250 ng of the globin-reduced RNA using the Illumina CustomPrep RNA amplification kit (Applied Biosystems/Ambion). 750 ng of labeled cRNA was hybridized overnight to Illumina Human HT-12 V4 BeadChip arrays (Illumina), which contained more than 47,000 probes. The arrays were washed, blocked, stained and scanned on an Illumina iScan, as per manufacturer's instructions. GenomeStudio (Illumina) was then used to perform quality control and generate signal intensity values.
The 393- and 86-transcript signatures were translated from the HT-12 V3 BeadChip arrays to HT-12 V4 BeadChip arrays using GeneSpring GX version 11.5 (Agilent Technologies) and translated to slightly fewer probes in V4 (
Raw data were processed using GeneSpring GX version 11.5 (Agilent Technologies) and the following was applied to all analyses. After background subtraction each probe was attributed a flag to denote its signal intensity detection p-value. Flags were used to filter out probe sets that did not result in a ‘present’ call in at least 10% of the samples, where the ‘present’ lower cut off=0.99. Signal values were then set to a threshold level of 1, log 2 transformed, and per-chip normalised using 75th percentile shift algorithm. Next per-gene normalisation was applied by dividing each messenger RNA transcript by the median intensity of the latent TB samples. All statistical analysis was performed after this stage.
The raw and normalised microarray data has been deposited with the GEO (GSE40553). All data collected and analysed in the experiments adhere to the Minimal Information About a Microarray Experiment (MIAME) guidelines.
Data Analysis. GeneSpring 11.5 was used to select transcripts that displayed a degree of expression variability. A filter was set to include only transcripts that had at least twofold changes from the median and present in at least 10% of the samples. To divide the South Africa 2011 cohort into a training and test set, a computer algorithm was used for randomisation [12]. For the specific treatment response signature transcripts had to satisfy a threefold expression filter in 12 of the 15 training set matched untreated and six month treated samples.
Selected transcripts were then filtered by different levels of statistical stringency in GeneSpring 11.5. Non-parametric tests with multiple testing corrections were applied to all analyses [13], [14]. The active TB-transcriptional signatures was generated by Mann Whitney unpaired Bonferroni p<0.01.
Molecular distance to health (MDTH) was determined for each time point, as previously described [16]. The temporal molecular response was calculated for a particular gene list for each individual patient. The raw intensity transcript values in the gene list were consecutively compared at each time point to the baseline (pre-treatment). The numbers of transcripts that were at least two-fold up or two-fold down from the baseline were added together for each time point. This sum was then divided by the total number of transcripts in the gene list to calculate a percentage score for each time point. This generated a percentage score of change at each time point compared to the baseline, where the baseline always remains zero (no change from itself). To allow for two-fold changes from zero any baseline raw transcript intensity values of zero were converted to 10−20 (ten raised to the power of minus twenty). MDTH and temporal molecular response were calculated in Microsoft Excel 2010. GraphPad Prism version 5 for Windows was used to generate graphs and determine simple linear regression. Linear mixed models, fixed effects, were used to determine p-values associated with MDTH and temporal molecular response graphs, using SAS/STAT® software (SAS Institute Inc., USA). Pathway analyses were performed using Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood, Calif.). Canonical pathways analysis identified the most significantly represented pathways in the datasets (Fisher's exact Benjamini Hochberg p<0.05).
Results. Participants Demographics and Characteristics. Participant numbers in the 2011 cohorts are described in
A Change in Transcriptional Response is Readily Detectable after Two Weeks of Treatment. To determine whether an active TB blood transcriptional signature was perturbed upon treatment, gene expression profiles of significantly detectable genes without further filtering (detected p<0.01 from background, 15,837 transcripts) were examined in the 29 active TB patients before, during (two weeks and two months), at the end of (six months), and after treatment (12 months). By plotting the expression profiles of the 15,837 transcripts along a time scaled x-axis, a marked change was readily observed after two weeks of anti-TB treatment (
Next an active TB 664-transcript signature (as in Table 8; see also Table S2 at at doi:10.1371/journal.pone.0046191.g001 by Bloom et al. 2012) was derived from differentially expressed genes in the pre-treatment active TB patients compared to the latent TB patients in the South Africa 2011 cohort. First, all transcripts were normalised to the median of the latent TB patients, then only transcripts with ≧twofold change from the median were selected, before applying a statistical filter. When this signature was applied to the South Africa 2011 Cohort, during and after treatment, a marked and rapid change in the transcriptional response was observed as early as two weeks, which then continued through two and six months, after treatment initiation (
The Transcriptional Response Changes Significantly at Two Weeks after Treatment Initiation. Since it was observed that the South Africa active TB 664-transcript signature diminished in response to treatment, determining if this was a statistically significant change was desirable. To assess this, the previously described weighted molecular distance to health (MDTH) algorithm was employed as this generates a quantitative score for the degree of transcriptional perturbation in a disease cohort relative to the controls [16]. Moreover, as already has been demonstrated, MDTH positively correlates with the severity of active pulmonary TB, as defined by the radiological extent of disease [11]. The median MDTH of the South African untreated active TB 664-transcript signature was found to have decreased significantly at two weeks onwards, compared to the median pre-treatment MDTH (
The present inventors then developed a novel metric that provides a quantitative measure of an individual's temporal change in gene expression. This ‘temporal molecular response’ offers a potential advantage in the clinical setting, allowing assessment of each patient's expression change without reference to a control group. For a given signature the temporal molecular response was determined by measuring the transcriptional perturbation between two time points, and expressing this value as a percentage of the total number of transcripts constituting the signature. The mean temporal molecular response calculated for the active TB 664-transcript signature revealed a statistically significant change in the transcriptional response at two weeks after treatment initiation (
As a result, this active TB 664-transcript signature (derived from untreated active and latent TB patients) significantly and rapidly changed after two weeks of initiating treatment (
A Specific TB Treatment Response Signature Also Significantly Diminishes at Two Weeks Post Treatment. Defining transcriptional signature that specifically reflected the patients' response to clinically successful anti-TB treatment (comparing time points zero and six months) was next sought. To determine this treatment specific signature, a computer algorithm was first used to randomise the South Africa 2011 cohort into two groups of patients [12] (
Although by applying the temporal molecular response it was observed that the treatment specific 320-transcript signature changed significantly between two weeks and six months post treatment initiation, this was no longer apparent between two months and six months post treatment initiation (
Measuring an Individual Patient's Transcriptional Response to Anti-TB Treatment. Each patient's discrete treatment specific response (320 transcripts) is shown in the heatmaps of
To determine whether the significant change in the treatment specific 320-transcript signature that had been demonstrated in a South African cohort was also applicable to patients in an intermediate burden setting, the 320-transcript signature was tested in a UK cohort. As observed in the South African cohort, the signature was rapidly and significantly diminished from two weeks post-treatment initiation (
For additional validation that active-TB transcriptional signatures show significant changes as early as two weeks after treatment initiation, it was demonstrated that the active TB signatures (393- and 86-transcript signatures) from an earlier study [11], also significantly diminished after two weeks treatment, in the South Africa 2011 treated cohort (
Discussion. As disclosed herein, a whole blood active-TB transcriptional signature was derived consisting of 664 transcripts capable of distinguishing untreated South African active TB patients from South African latent TB patients. It was demonstrated that this active-TB transcriptional signature significantly diminishes in active TB patients after just two weeks of initiation of clinically successful anti-TB treatment. In addition, it was demonstrated that a treatment-specific transcriptional signature, consisting of 320 transcripts, derived from comparing a cohort of South African untreated active TB samples to their paired six-month end-of-treatment samples, also significantly diminishes after just two weeks of anti-TB treatment. Furthermore the significant change in the treatment-specific signature was validated in two more clinically successfully treated cohorts, from the high TB-burden setting of South Africa and from the intermediate TB-burden setting of London, UK. Both the active-TB and treatment-specific transcriptional signatures were dominated by IFN signaling and innate immune response genes. The transcriptional response to anti-TB treatment could also be individually quantified for each patient. Together, these findings suggest that blood transcriptional signatures could be used as early surrogate biomarkers of a successful treatment response, in both the clinical setting and in drug development.
TB treatment monitoring is a major challenge for attempts to eradicate Mtb infection. In April 2010 the Centers for Disease Control and National Institutes of Health brought together experts in the field and research scientists with the sole purpose of addressing this problem [17]. Poor treatment monitoring, and hence inadequate treatment, leads to worsening of a patient's disease, increasing the potential for disease spread and the risk of developing drug resistant mycobacteria. Currently the two-month sputum culture conversion is the only biomarker of successful TB treatment [6]. However it is time consuming, taking several weeks to grow the bacilli and results can be compromised by contamination. Moreover patients who have clinically improved may be unable to expectorate sputum at two months and potentially incorrectly labeled as having a negative culture [18]. Furthermore, although sputum conversion is commonly used as a surrogate end point for treatment response in clinical trials evaluating new drugs, a systematic review and meta-analysis to assess its accuracy in predicting an individual's treatment failure revealed low sensitivity and only modest specificity [7], [19]. While other biomarkers have also been trialed, including C-reactive protein, IFN-γ and neopterin, all have similarly shown poor sensitivity and specificity [20]. Chest X-rays are commonly used in the clinical setting as a marker of treatment response but they generally improve slower than the clinical response and lack specificity as interpretation can be confounded by previous lung damage [18]. Moreover interpretation of radiographic changes in response to treatment has not yet been standardised, and the facilities are not always available in developing countries [8]. Therefore there is clearly a need for early and easily detectable biomarkers for treatment monitoring, capable of potentially identifying poor responses due to drug resistance or lack of treatment adherence, and available for patients unable to produce sputum.
In an earlier study, it was demonstrated in a small number of patients that blood transcriptional signatures in UK active TB patients diminished after two months of anti-TB treatment [11]. In study disclosed herein, a significant blood transcriptional response to anti-TB treatment has been shown to occur rapidly, as early as two weeks (
With the disclosure of this Example, it is shown that the whole blood active-TB transcriptional signature is dominated by IFN signaling and innate immune response genes. These findings are in agreement with previous work [11], and with other gene expression studies in TB [25], [26]. This robust correlation occurring between different host populations, likely different Mtb strains, diverse environments and microarray analysis strategies indicates that blood transcriptomics may be developed into robust novel diagnostic tools. Furthermore, as demonstrated herein, the derived treatment specific 320-transcript signature also had many genes in common with the active TB 664-transcript signature (
Due to the ethical design of this study, active TB patients who did not respond to TB treatment are not presented. But this study has demonstrated a very important proof-of-principle that active TB patients who are successfully treated have a dramatic measurable change in their blood gene expression profiles as early as two weeks. The use of a commercially available whole genome microarray platform together with broadly available bioinformatics analyses programmes should easily allow rapid validation in subsequent TB treatment studies, including a comparison with patients with MDR-TB and HIV/TB co-infected cohorts. This study focused on TB patients who are not co-infected with HIV, as they represent the majority of patients infected with Mtb. WHO 2010 reports that of the 1.4 million deaths, three-quarters were not known to be co-infected with HIV [2].
No other studies appear to have specifically derived transcriptional signatures of response to TB treatment. However, two other studies have described relevant treatment related transcriptional differences. Mistry et al. found that patients who had completed a course of anti-TB treatment displayed similar expression profiles to a latent TB group, but Mistry et al. did not examine any patients during their anti-TB treatment course, and Mistry et al. used custom arrays [27], making it therefore more difficult for others to validate. Joosten et al. showed in a small number of samples that their active TB gene set diminished after two months of anti-TB treatment; however they did not examine any patients at earlier timepoints [28]. The early TB treatment blood transcriptional signature disclosed herein has great potential for development in blood biomarkers for clinical use and could be measured in the field using a polymerase chain reaction assay, similar to the WHO endorsed GeneXpert MTB/RIF test already in use for TB diagnostics in both developing and developed countries. However a blood host biomarker, based on the transcriptional signature of the study disclosed herein, would have advantages over the GeneXpert test since it would not require sputum.
A further problem in the management of TB is the extended length of treatment, requiring a minimum duration of six months. However the treatment duration required for maximum efficacy and preventing resistance, has not been fully established. The ability therefore to stratify patients into groups requiring shorter or longer treatment durations, particularly in resource limited settings, could be of value in improving patient compliance and reducing treatment related side effects. We demonstrate here that some patient's transcriptional response appeared to plateau before six months (
Use of a 320 gene transcriptional signature, as prominently disclosed in Example 2, was also prominently used for tests disclosed in this Example 3. In particular, data from preliminary studies demonstrate that blood-derived transcriptional signatures are diminished between three to six days after initiation of anti-TB treatment.
Materials and Methods. Recruitment methodology (i.e., inclusion and exclusion criteria) as detailed in the above Examples was not changed. For a small sample of six patients having symptoms of TB, blood was sampled every day for the first two weeks (depending on patient availability; i.e., missing data points for various days are due to patient unavailability). Three of these patients were later confirmed as having TB and as unambiguously meeting the previously-noted inclusion and exclusion criteria: Patient ID 2208; Patient ID 2220; and Patient ID 2232.
For RNA isolation and analysis, a few small methodology modifications were made to the methodologies of Example 2. First, sample RNA was isolated using 1 ml whole blood and the PerfectPure RNA Blood Kit (Invitrogen/Applied Biosystems/Ambion) according to the manufacturer's instructions. Second, 0.7-2.2 μg isolated total RNA was globin reduced using the GLOBINclear Human Kit (Invitrogen/Applied Biosystems/Ambion) according to the manufacturer's instructions. Third, raw data were processed using GeneSpring GX version 12 (Agilent Technologies).
In addition to generating heatmaps and temporal molecular response data from 320-transcript signatures for Patient ID 2208, Patient ID 2220, and Patient ID 2232, heatmaps and temporal molecular response data were generated for 393- and 86-transcript signatures for each of these patients using the methodologies of Example 2. In detail, 393- and 86-transcript signatures were translated from the HT-12 V3 BeadChip arrays to HT-12 V4 BeadChip arrays using GeneSpring GX version 11.5 (Agilent Technologies) and translated to slightly fewer probes in V4′ due to slight differences in probe sets between Illumina Human HT-12 V3 and V4 BeadChip versions. That is, data were also obtained for 380 list (i.e., Illumina Human HT-12 V4 BeadChip translation of Illumina Human HT-12 V3 BeadChip 393 list) and 83 list (i.e., Illumina Human HT-12 V4 BeadChip translation of Illumina Human HT-12 V3 BeadChip 86 list) treatment response profiles.
Results. Heatmaps and corresponding temporal molecular response data for Patient ID 2208, Patient ID 2220, and Patient 2232 are provided in
In summary, transcriptional signatures, measured in easily accessible whole blood, showed a detectable response to anti-TB treatment, and this response was rapid and could be measured as early as two weeks (or, as preliminary data from Example 3 show, very much sooner) after initiation of treatment—far more quickly, and more consistently, than in currently available tests. In addition, this early response to anti-TB treatment was demonstrated in both high- and intermediate-burden settings. Transcriptional response could be measured for each individual TB patient, thus providing a potential clinical tool for single patient treatment monitoring. Furthermore, this monitoring promises to aid in patient stratification for treatment(s) with differing regimen lengths. These findings provide compelling evidence for a biomarker successful in assessing early anti-TB treatment response. This biomarker of early treatment response would allow rapid detection of both inadequate treatment regimens and poor treatment compliance, and therefore shows particular usefulness for reducing the spread of TB as brought about through the generation and spread of drug resistant Mtb.
It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.
It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims.
All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference in the entirety of each to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Throughout this application, the teem “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. As used herein, the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. As used herein, the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim except for, e.g., impurities ordinarily associated with the element or limitation.
The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof” is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
As used herein, words of approximation such as, without limitation, “about”, “substantial” or “substantially” refers to a condition that when so modified is understood to not necessarily be absolute or perfect but would be considered close enough to those of ordinary skill in the art to warrant designating the condition as being present. The extent to which the description may vary will depend on how great a change can be instituted and still have one of ordinary skilled in the art recognize the modified feature as still having the required characteristics and capabilities of the unmodified feature. In general, but subject to the preceding discussion, a numerical value herein that is modified by a word of approximation such as “about” may vary from the stated value by at least ±1, 2, 3, 4, 5, 6, 7, 10, 12 or 15%.
All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
TABLES
sapiens cDNA clone IMAGp998A124183;
Homo sapiens glutamate-ammonia ligase (glutamine
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens pregnancy specific beta-1-glycoprotein 9
Homo sapiens epithelial stromal interaction 1 (breast)
Homo sapiens complement component 2 (C2), mRNA.
Homo sapiens G protein-coupled receptor 84 (GPR84),
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens cathelicidin antimicrobial peptide
Homo sapiens proline-serine-threonine phosphatase
Homo sapiens cytidine monophosphate (UMP-CMP)
Homo sapiens vesicle-associated membrane protein 5
Homo sapiens coiled-coil domain containing 65
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens Fc fragment of IgG binding protein
Homo sapiens guanylate binding protein 5 (GBP5),
Homo sapiens ets variant 7 (ETV7), mRNA.
Homo sapiens pregnancy specific beta-1-glycoprotein 3
Homo sapiens Fc fragment of IgG, low affinity IIIa,
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens interleukin 15 (IL15), transcript variant
Homo sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo sapiens SLAM family member 8 (SLAMF8),
Homo sapiens CD38 molecule (CD38), mRNA.
Homo sapiens gamma-glutamyltransferase-like 3
Homo sapiens serpin peptidase inhibitor, clade G (C1
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens zinc finger protein 540 (ZNF540),
Homo sapiens granulysin (GNLY), transcript variant
Homo sapiens hypothetical protein FLJ40504
Homo sapiens centrosomal protein 68 kDa (CEP68),
Homo sapiens cDNA FLJ20012 fis, clone ADKA03438
Homo sapiens megakaryocyte-associated tyrosine
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens ankyrin repeat domain 36 (ANKRD36),
Homo sapiens GTP cyclohydrolase 1 (GCH1),
Homo sapiens F-box protein 6 (FBXO6), mRNA.
Homo sapiens AF4/FMR2 family, member 3 (AFF3),
Homo sapiens solute carrier family 6 (neurotransmitter
Homo sapiens lymphocyte antigen 6 complex, locus E
Homo sapiens cDNA FLJ46319 fis, clone
Homo sapiens interleukin 15 receptor, alpha (IL15RA),
Homo sapiens BCR downstream signaling 1 (BRDG1),
Homo sapiens basic leucine zipper transcription factor,
Homo sapiens eukaryotic translation initiation factor 2-
Homo sapiens C-type lectin domain family 4, member
Homo sapiens calcium channel, voltage-dependent, R
Homo sapiens non-SMC condensin II complex, subunit
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens lemur tyrosine kinase 2 (LMTK2),
Homo sapiens transglutaminase 2 (C polypeptide,
Homo sapiens lamin B1 (LMNB1), mRNA.
Homo sapiens activating transcription factor 3 (ATF3),
Homo sapiens haptoglobin (HP), mRNA.
Homo sapiens B lymphoid tyrosine kinase (BLK),
Homo sapiens ceroid-lipofuscinosis, neuronal 8
Homo sapiens microsomal glutathione S-transferase 1
Homo sapiens KIAA1632 (KIAA1632), mRNA.
Homo sapiens tripartite motif-containing 6 (TRIM6),
Homo sapiens olfactory receptor, family 2, subfamily
Homo sapiens phosphatase, orphan 2 (PHOSPHO2),
Homo sapiens lymphocyte-specific protein tyrosine
Homo sapiens ankyrin repeat and death domain
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens DKFZP564O0823 protein
Homo sapiens similar to Interferon-induced guanylate-
Homo sapiens early B-cell factor 1 (EBF1), mRNA.
Homo sapiens macrophage receptor with collagenous
Homo sapiens chemokine (C-C motif) ligand 4-like 1
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens nuclear receptor subfamily 4, group A,
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens matrix metallopeptidase 28 (MMP28),
Homo sapiens DNA segment on chromosome 4
Homo sapiens G patch domain containing 4
Homo sapiens GTP cyclohydrolase 1 (GCH1),
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens hippocalcin like 4 (HPCAL4), mRNA.
Homo sapiens complement component 1, q
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens granzyme K (granzyme 3; tryptase II)
Homo sapiens inhibitory caspase recruitment domain
Homo sapiens G protein-coupled estrogen receptor 1
Homo sapiens lipoma HMGIC fusion partner-like 2
Homo sapiens family with sequence similarity 102,
Homo sapiens Meis homeobox 3 pseudogene 1
Homo sapiens espin (ESPN), mRNA.
Homo sapiens zinc finger protein 74 (ZNF74),
Homo sapiens TRAF-interacting protein with forkhead-
Homo sapiens chromosome 19 open reading frame 59
Homo sapiens phospholipid scramblase 1 (PLSCR1),
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens synaptotagmin-like 2 (SYTL2),
Homo sapiens potassium voltage-gated channel, Isk-
Homo sapiens 2′-5′-oligoadenylate synthetase 3,
Homo sapiens 2′-5′-oligoadenylate synthetase 3,
Homo sapiens membrane-spanning 4-domains,
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens zinc finger protein 831 (ZNF831),
Homo sapiens IKAROS family zinc finger 3 (Aiolos)
Homo sapiens DENN/MADD domain containing 1A
Homo sapiens translocase of inner mitochondrial
Homo sapiens small nucleolar RNA, C/D box 21
Homo sapiens deleted in lung and esophageal cancer 1
Homo sapiens apolipoprotein B mRNA editing enzyme,
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens myosin, light chain 9, regulatory
Homo sapiens integrin, alpha 2b (platelet glycoprotein
Homo sapiens killer cell lectin-like receptor subfamily
Homo sapiens interferon, alpha-inducible protein 6
Homo sapiens 2′,5′-oligoadenylate synthetase 1,
Homo sapiens 2′,5′-oligoadenylate synthetase 1,
Homo sapiens guanylate cyclase 1, soluble, alpha 3
Homo sapiens SWI/SNF related, matrix associated,
Homo sapiens pleiomorphic adenoma gene 1 (PLAG1),
Homo sapiens zinc finger protein 365 (ZNF365),
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens RAB20, member RAS oncogene family
Homo sapiens suppressor of cytokine signaling 1
Homo sapiens ADAM metallopeptidase domain 28
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens glycosyltransferase 25 domain
Homo sapiens transmembrane protein 158
Homo sapiens GTP binding protein 3 (mitochondrial)
Homo sapiens leucine aminopeptidase 3 (LAP3),
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens zinc finger protein 181 (ZNF181),
Homo sapiens interferon-induced protein with
Homo sapiens interferon-induced protein with
Homo sapiens resistance to inhibitors of cholinesterase
Homo sapiens killer cell lectin-like receptor subfamily
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens protein S (alpha) (PROS1), mRNA.
Homo sapiens T cell receptor alpha locus, mRNA
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens chromosome X open reading frame 57
Homo sapiens tumor necrosis factor receptor
Homo sapiens defensin, alpha 1 (DEFA1), mRNA.
Homo sapiens deoxyribonuclease I-like 3
Homo sapiens dual specificity phosphatase 2 (DUSP2),
sapiens cDNA 3, mRNA sequence
Homo sapiens centromere protein K (CENPK), mRNA.
Homo sapiens family with sequence similarity 26,
Homo sapiens Fc receptor-like A (FCRLA), mRNA.
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens chromosome 6 open reading frame 150
Homo sapiens CD274 molecule (CD274), mRNA.
Homo sapiens interferon induced transmembrane
Homo sapiens signal transducer and activator of
Homo sapiens MYST histone acetyltransferase
Homo sapiens solute carrier family 25, member 26
Homo sapiens interferon-induced protein 44-like
Homo sapiens aquaporin 10 (AQP10), mRNA.
Homo sapiens mixed lineage kinase 4 (KIAA1804),
Homo sapiens SCO cytochrome oxidase deficient
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens defensin, alpha 3, neutrophil-specific
Homo sapiens oxysterol binding protein-like 10
Homo sapiens BMX non-receptor tyrosine kinase
Homo sapiens Fc fragment of IgG, high affinity Ia,
Homo sapiens interferon-induced protein 44 (IFI44),
Homo sapiens 2′-5′-oligoadenylate synthetase-like
Homo sapiens sialic acid binding Ig-like lectin 16
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens matrix metallopeptidase 9 (gelatinase B,
Homo sapiens SWI/SNF related, matrix associated,
Homo sapiens homeobox C4 (HOXC4), transcript
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens GM2 ganglioside activator (GM2A),
Homo sapiens guanylate binding protein 4 (GBP4),
Homo sapiens BTB and CNC homology 1, basic
Homo sapiens Fas apoptotic inhibitory molecule
Homo sapiens harakiri, BCL2 interacting protein
Homo sapiens transcobalamin II; macrocytic anemia
Homo sapiens complement component 1, q
Homo sapiens solute carrier family 26, member 8
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens dysferlin, limb girdle muscular
Homo sapiens solute carrier family 22 (organic cation
Homo sapiens interferon-induced protein with
Homo sapiens myeloperoxidase (MPO), nuclear gene
Homo sapiens chromosome 8 open reading frame 13
Homo sapiens S100 calcium binding protein A12
Homo sapiens chemokine (C-X-C motif) ligand 10
Homo sapiens coagulation factor C homolog, cochlin
Homo sapiens synaptotagmin XVII (SYT17), mRNA.
Homo sapiens transmembrane protein 107
Homo sapiens RAR-related orphan receptor A (RORA),
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens receptor (chemosensory) transporter
Homo sapiens ATP-binding cassette, sub-family B
Homo sapiens guanylate binding protein family,
Homo sapiens guanylate binding protein family,
Homo sapiens chromosome 11 open reading frame 80
sapiens cDNA clone DKFZp686H1820 5, mRNA
Homo sapiens calcium/calmodulin-dependent protein
Homo sapiens CD1e molecule (CD1E), transcript
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens TWIST neighbor (TWISTNB), mRNA.
Homo sapiens inositol 1,4,5-triphosphate receptor
Homo sapiens tumor necrosis factor, alpha-induced
Homo sapiens RanBP-type and C3HC4-type zinc finger
Homo sapiens thioesterase superfamily member 2 (THEM2),
Homo sapiens WD repeat domain 33 (WDR33), transcript
Homo sapiens transmembrane protein 51 (TMEM51), mRNA.
Homo sapiens Dmx-like 2 (DMXL2), mRNA.
Homo sapiens polymerase (DNA directed), beta (POLB),
Homo sapiens fer-1-like 3, myoferlin (C. elegans) (FER1L3),
Homo sapiens chitinase 3-like 2 (CHI3L2), transcript variant
Homo sapiens valosin containing protein (p97)/p47 complex
Homo sapiens cDNA FLJ20012 fis, clone ADKA03438
Homo sapiens solute carrier family 16, member 6
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens calcyphosine (CAPS), transcript variant 2,
Homo sapiens glutathione S-transferase kappa 1 (GSTK1),
Homo sapiens myeloid cell leukemia sequence 1 (BCL2-
Homo sapiens nuclear factor of kappa light polypeptide gene
Homo sapiens erythrocyte membrane protein band 4.1-like 3
Homo sapiens cDNA FLJ34585 fis, clone KIDNE2008758
Homo sapiens major histocompatibility complex, class I, F
Homo sapiens tribbles homolog 2 (Drosophila) (TRIB2),
Homo sapiens WD repeat and SOCS box-containing 2
Homo sapiens mitochondrial ribosomal protein L44
Homo sapiens transmembrane channel-like 6 (TMC6),
Homo sapiens protein tyrosine phosphatase, receptor type, E
Homo sapiens membrane-spanning 4-domains, subfamily A,
Homo sapiens EFR3 homolog A (S. cerevisiae) (EFR3A),
Homo sapiens glutaredoxin (thioltransferase) (GLRX),
Homo sapiens KIAA1632 (KIAA1632), mRNA.
Homo sapiens phosphodiesterase 7A (PDE7A), transcript
Homo sapiens ATPase, H+ transporting, lysosomal 9 kDa, V0
Homo sapiens ATPase, H+ transporting, lysosomal 9 kDa, V0
Homo sapiens caspase 4, apoptosis-related cysteine peptidase
Homo sapiens prolylcarboxypeptidase (angiotensinase C)
Homo sapiens ribonuclease L (2′,5′-oligoisoadenylate
Homo sapiens chemokine (C-C motif) receptor 2 (CCR2),
Homo sapiens toll-like receptor 7 (TLR7), mRNA.
Homo sapiens RNA binding motif, single stranded interacting
Homo sapiens proteasome (prosome, macropain) subunit, beta
Homo sapiens LysM, putative peptidoglycan-binding, domain
Homo sapiens zinc finger, MYND-type containing 15
Homo sapiens similar to nuclear pore complex interacting
Homo sapiens proteasome (prosome, macropain) subunit,
Homo sapiens proteasome (prosome, macropain) subunit,
Homo sapiens proteasome (prosome, macropain) subunit, beta
Homo sapiens phosphatidylinositol glycan anchor
Homo sapiens leucine rich repeat containing 37, member A4
Homo sapiens ras-related C3 botulinum toxin substrate 1 (rho
Homo sapiens proteasome maturation protein (POMP),
Homo sapiens TYRO protein tyrosine kinase binding protein
Homo sapiens karyopherin (importin) beta 1 (KPNB1),
Homo sapiens ubiquitin specific peptidase 47 (USP47),
Homo sapiens diazepam binding inhibitor (GABA receptor
Homo sapiens chromosome 20 open reading frame 24
Homo sapiens ATG3 autophagy related 3 homolog
Homo sapiens agmatine ureohydrolase (agmatinase)
Homo sapiens chemokine (C-C motif) receptor 7 (CCR7),
Homo sapiens ankyrin repeat domain 13A (ANKRD13A),
Homo sapiens eukaryotic translation initiation factor 4E
Homo sapiens solute carrier family 7 (cationic amino acid
Homo sapiens ubiquitin specific peptidase 15 (USP15),
Homo sapiens chromosome 20 open reading frame 24
Homo sapiens Niemann-Pick disease, type C2 (NPC2),
Homo sapiens BR serine/threonine kinase 1 (BRSK1),
Homo sapiens chromosome 9 open reading frame 127
Homo sapiens DEP domain containing 5 (DEPDC5),
Homo sapiens CD74 molecule, major histocompatibility
Homo sapiens methylenetetrahydrofolate dehydrogenase
Homo sapiens clone 23700 mRNA sequence
Homo sapiens calcium binding and coiled-coil domain 2
Homo sapiens protein phosphatase 1, regulatory (inhibitor)
Homo sapiens chromosome 4 open reading frame 34
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens Fc receptor-like 3 (FCRL3), transcript variant
Homo sapiens C-type lectin domain family 1, member A
Homo sapiens Sec23 homolog B (S. cerevisiae) (SEC23B),
Homo sapiens purinergic receptor P2Y, G-protein coupled, 5
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens glutaminyl-peptide cyclotransferase (QPCT),
Homo sapiens epithelial stromal interaction 1 (breast)
Homo sapiens WD repeat and FYVE domain containing 3
Homo sapiens G protein-coupled receptor 84 (GPR84),
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens Fc fragment of IgE, high affinity I, receptor
Homo sapiens ankyrin repeat
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens tropomyosin 2 (beta) (TPM2), transcript
Homo sapiens proline-serine-threonine phosphatase
Homo sapiens cytidine monophosphate (UMP-CMP) kinase
Homo sapiens vesicle-associated membrane protein 5
Homo sapiens Fc fragment of IgG, high affinity Ib, receptor
Homo sapiens Fc fragment of IgG binding protein (FCGBP),
Homo sapiens small nucleolar RNA, C/D box 13
Homo sapiens histone cluster 2, H2bf (HIST2H2BF),
Homo sapiens guanylate binding protein 5 (GBP5), mRNA.
Homo sapiens complement component 5 (C5), mRNA.
Homo sapiens SEC14 and spectrin domains 1 (SESTD1),
Homo sapiens ets variant 7 (ETV7), mRNA.
Homo sapiens thioredoxin domain containing 12
Homo sapiens selenoprotein M (SELM), mRNA.
Homo sapiens ecotropic viral integration site 2A (EVI2A),
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens interleukin 15 (IL15), transcript variant 1,
Homo sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens G protein-coupled receptor 109B
Homo sapiens dual specificity phosphatase 3 (vaccinia virus
Homo sapiens transmembrane protein 51 (TMEM51),
Homo sapiens CD38 molecule (CD38), mRNA.
Homo sapiens inhibitor of DNA binding 3, dominant
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens T cell receptor beta variable 21-1, mRNA
Homo sapiens serpin peptidase inhibitor, clade G (C1
Homo sapiens sulfide quinone reductase-like (yeast)
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens KIAA1618 (KIAA1618), mRNA.
Homo sapiens 5′-3′ exoribonuclease 1 (XRN1), transcript
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens RRN3 RNA polymerase I transcription factor
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens cDNA FLJ41813 fis, clone NT2RI2011450
Homo sapiens cDNA FLJ20012 fis, clone ADKA03438
Homo sapiens interferon induced transmembrane protein 1
Homo sapiens G protein-coupled receptor 109A
Homo sapiens interferon-induced protein 35 (IFI35),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens actin binding LIM protein 1 (ABLIM1),
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens interferon, gamma-inducible protein 16
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens interleukin 7 receptor (IL7R), mRNA.
Homo sapiens ADAM metallopeptidase domain 7
Homo sapiens F-box protein 6 (FBXO6), mRNA.
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens ectonucleoside triphosphate
Homo sapiens Kruppel-like factor 12 (KLF12), mRNA.
Homo sapiens Kruppel-like factor 12 (KLF12), mRNA.
Homo sapiens TRAF-type zinc finger domain containing 1
Homo sapiens cAMP responsive element binding protein 5
Homo sapiens basic leucine zipper transcription factor,
Homo sapiens erythrocyte membrane protein band 4.1-like 3
Homo sapiens C-type lectin domain family 4, member D
Homo sapiens calcium channel, voltage-dependent, R type,
Homo sapiens tribbles homolog 2 (Drosophila) (TRIB2),
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens phosphoinositide-3-kinase, class 2, beta
Homo sapiens transporter 2, ATP-binding cassette, sub-
Homo sapiens signal-induced proliferation-associated 1 like
Homo sapiens feline leukemia virus subgroup C cellular
Homo sapiens lamin B1 (LMNB1), mRNA.
Homo sapiens proteasome (prosome, macropain) subunit,
Homo sapiens activating transcription factor 3 (ATF3),
Homo sapiens CD5 molecule (CD5), mRNA.
Homo sapiens sortilin 1 (SORT1), mRNA.
Homo sapiens v-maf musculoaponeurotic fibrosarcoma
Homo sapiens chromosome 11 open reading frame 82
Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA.
Homo sapiens phosphoinositide-3-kinase interacting protein
Homo sapiens zinc finger protein 438 (ZNF438), mRNA.
Homo sapiens cathepsin L1 (CTSL1), transcript variant 2,
Homo sapiens actin, alpha 2, smooth muscle, aorta
Homo sapiens SATB homeobox 1 (SATB1), mRNA.
Homo sapiens caspase 4, apoptosis-related cysteine
Homo sapiens solute carrier family 22 (organic
Homo sapiens toll-like receptor 2 (TLR2), mRNA.
Homo sapiens melanoma antigen family E, 1 (MAGEE1),
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens ATP-binding cassette, sub-family G
Homo sapiens S1 RNA binding domain 1 (SRBD1), mRNA.
Homo sapiens chromosome 12 open reading frame 57
Homo sapiens N-acetyltransferase 6 (GCN5-related)
Homo sapiens lin-7 homolog A (C. elegans) (LIN7A),
Homo sapiens sterile alpha motif and leucine zipper
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens serpin peptidase inhibitor, clade A (alpha-1
Homo sapiens similar to Interferon-induced guanylate-
Homo sapiens succinate receptor 1 (SUCNR1), mRNA.
Homo sapiens chromosome 16 open reading frame 30
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens heterogeneous nuclear ribonucleoprotein A1
Homo sapiens WD repeat and FYVE domain containing 1
Homo sapiens tumor protein D52 (TPD52), transcript
Homo sapiens kinesin family member 1B (KIF1B),
Homo sapiens caspase 5, apoptosis-related cysteine
Homo sapiens chromosome 16 open reading frame 7
Homo sapiens v-ets erythroblastosis virus E26 oncogene
Homo sapiens CD28 molecule (CD28), mRNA.
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens dedicator of cytokinesis 9 (DOCK9), mRNA.
Homo sapiens ArfGAP with dual PH domains 2 (ADAP2),
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA.
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens Z-DNA binding protein 1 (ZBP1), mRNA.
Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase
Homo sapiens syntaxin 11 (STX11), mRNA.
Homo sapiens complement component 1, q subcomponent,
Homo sapiens Fc fragment of IgG, high affinity Ib, receptor
Homo sapiens nuclear receptor subfamily 3, group C,
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens toll-like receptor 5 (TLR5), mRNA.
Homo sapiens sparc/osteonectin, cwcv and kazal-like
Homo sapiens granzyme K (granzyme 3; tryptase II)
Homo sapiens inhibitory caspase recruitment domain
Homo sapiens PR domain containing 1, with ZNF domain
Homo sapiens SFRS protein kinase 1 (SRPK1), mRNA.
Homo sapiens polymerase (RNA) I polypeptide E, 53 kDa
Homo sapiens lipoma HMGIC fusion partner-like 2
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens kazrin (KIAA1026), transcript variant B,
Homo sapiens kazrin (KIAA1026), transcript variant B,
Homo sapiens family with sequence similarity 102, member
Homo sapiens family with sequence similarity 102, member
Homo sapiens bridging integrator 1 (BIN1), transcript
Homo sapiens chromatin modifying protein 5 (CHMP5),
Homo sapiens TRAF-interacting protein with forkhead-
Homo sapiens CDK5 regulatory subunit associated protein 2
Homo sapiens GRB2-related adaptor protein (GRAP),
Homo sapiens EPH receptor A4 (EPHA4), mRNA.
Homo sapiens chromosome 19 open reading frame 59
Homo sapiens CDK5 regulatory subunit associated protein 2
Homo sapiens phospholipid scramblase 1 (PLSCR1),
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens DKFZp761E198 protein (DKFZp761E198),
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens CD151 molecule (Raph blood group)
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens interleukin 1 receptor antagonist (IL1RN),
Homo sapiens 2′-5′-oligoadenylate synthetase 3, 100 kDa
Homo sapiens putative homeodomain transcription factor 1
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens XIAP associated factor 1 (XAF1), transcript
Homo sapiens XIAP associated factor 1 (XAF1), transcript
Homo sapiens interferon-induced protein with
Homo sapiens IKAROS family zinc finger 3 (Aiolos)
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens MORC family CW-type zinc finger 2
Homo sapiens breast carcinoma amplified sequence 4
Homo sapiens translocase of inner mitochondrial membrane
Homo sapiens transporter 1, ATP-binding cassette, sub-
Homo sapiens calpain 12 (CAPN12), mRNA.
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens PAS domain containing serine/threonine
Homo sapiens PAS domain containing serine/threonine
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens Kruppel-like factor 12 (KLF12), transcript
Homo sapiens interleukin 15 (IL15), transcript variant 3,
Homo sapiens cAMP responsive element binding protein 5
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens interferon, alpha-inducible protein 6 (IFI6),
Homo sapiens 2′,5′-oligoadenylate synthetase 1, 40/46 kDa
Homo sapiens 2′,5′-oligoadenylate synthetase 1, 40/46 kDa
Homo sapiens hexokinase 2 (HK2), mRNA.
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens SRY (sex determining region Y)-box 8
Homo sapiens T cell receptor alpha locus, mRNA (cDNA
Homo sapiens sterile alpha motif domain containing 9-like
Homo sapiens up-regulated gene 4 (URG4), nuclear gene
Homo sapiens chromosome 11 open reading frame 75
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens signal transducer and activator of
Homo sapiens RAB20, member RAS oncogene family
Homo sapiens suppressor of cytokine signaling 1 (SOCS1),
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens proteasome (prosome, macropain) activator
Homo sapiens agmatine ureohydrolase (agmatinase)
Homo sapiens ISG15 ubiquitin-like modifier (ISG15),
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA.
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens sestrin 1 (SESN1), mRNA.
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens interferon-induced protein with
Homo sapiens interferon-induced protein with
Homo sapiens zinc finger protein 429 (ZNF429), mRNA.
Homo sapiens G protein-coupled receptor 141 (GPR141),
Homo sapiens solute carrier family 30 (zinc transporter),
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens CD40 ligand (CD40LG), mRNA.
Homo sapiens AF4/FMR2 family, member 1 (AFF1),
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens deltex 3-like (Drosophila) (DTX3L), mRNA.
Homo sapiens adrenomedullin (ADM), mRNA.
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens glycogenin 1 (GYG1), mRNA.
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens UDP-GlcNAc: betaGal beta-1,3-N-
Homo sapiens limb bud and heart development homolog
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens NDRG family member 2 (NDRG2), transcript
Homo sapiens family with sequence similarity 26, member F
Homo sapiens Fc receptor-like A (FCRLA), mRNA.
Homo sapiens aldehyde dehydrogenase 1 family, member
Homo sapiens zinc finger, DHHC-type containing 19
Homo sapiens myocyte enhancer factor 2D (MEF2D),
Homo sapiens CD59 molecule, complement regulatory
Homo sapiens major histocompatibility complex, class II,
Homo sapiens clusterin associated protein 1 (CLUAP1),
Homo sapiens CD274 molecule (CD274), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 2,
Homo sapiens Janus kinase 2 (a protein tyrosine kinase)
Homo sapiens cyclin-dependent kinase 5, regulatory subunit
Homo sapiens interferon induced transmembrane protein 3
Homo sapiens citrate lyase beta like (CLYBL), mRNA.
Homo sapiens signal transducer and activator of
Homo sapiens signal transducer and activator of
Homo sapiens cathepsin L1 (CTSL1), transcript variant 1,
Homo sapiens cDNA: FLJ21199 fis, clone COL00235
Homo sapiens peptidoglycan recognition protein 1
Homo sapiens interferon-induced protein 44-like (IFI44L),
Homo sapiens transcription factor 7 (T-cell specific, HMG-
Homo sapiens chromosome 11 open reading frame 1
Homo sapiens CD27 molecule (CD27), mRNA.
Homo sapiens histone cluster 2, H2ac (HIST2H2AC),
Homo sapiens Fas apoptotic inhibitory molecule 3 (FAIM3),
Homo sapiens SCO cytochrome oxidase deficient homolog
Homo sapiens chemokine (C-X-C motif) ligand 6
Homo sapiens interleukin 18 receptor accessory protein
Homo sapiens BR serine/threonine kinase 1 (BRSK1),
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens hect domain and RLD 5 (HERC5), mRNA.
Homo sapiens signal transducer and activator of
Homo sapiens Fc fragment of IgG, high affinity Ia, receptor
Homo sapiens interferon-induced protein 44 (IFI44),
Homo sapiens 2′-5′-oligoadenylate synthetase-like (OASL),
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens methylenetetrahydrofolate dehydrogenase
Homo sapiens apolipoprotein L, 1 (APOL1), transcript
Homo sapiens stomatin (STOM), transcript variant 1,
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens ATPase, class I, type 8B, member 2
Homo sapiens caspase-1 dominant-negative inhibitor
Homo sapiens SP140 nuclear body protein (SP140),
Homo sapiens teashirt zinc finger homeobox 2 (TSHZ2),
Homo sapiens sialic acid binding Ig-like lectin 16
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens matrix metallopeptidase 9 (gelatinase B,
Homo sapiens transporter 2, ATP-binding cassette, sub-
Homo sapiens damage-regulated autophagy modulator
Homo sapiens cat eye syndrome chromosome region,
Homo sapiens leucine rich repeat and fibronectin type III
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens interferon-induced protein with
Homo sapiens guanylate binding protein 4 (GBP4), mRNA.
Homo sapiens thioredoxin domain containing 3
Homo sapiens interferon induced with helicase C domain 1
Homo sapiens proline rich Gla (G-carboxyglutamic acid) 4
Homo sapiens calcium channel, voltage-dependent, T type,
Homo sapiens chemokine (C-C motif) receptor 6 (CCR6),
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens transcobalamin II; macrocytic anemia
Homo sapiens ATPase, H+ transporting V0 subunit e2
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens nephroblastoma overexpressed gene (NOV),
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
Homo sapiens tripartite motif-containing 22 (TRIM22),
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens guanylate binding protein 2, interferon-
Homo sapiens insulin-like growth factor 2 mRNA binding
Homo sapiens 2′-5′-oligoadenylate synthetase-like (OASL),
Homo sapiens dysferlin, limb girdle muscular dystrophy 2B
Homo sapiens family with sequence similarity 159, member
Homo sapiens hypothetical protein LOC552891
Homo sapiens apolipoprotein L, 6 (APOL6), mRNA.
Homo sapiens interferon-induced protein with
Homo sapiens lysophosphatidylcholine acyltransferase 2
Homo sapiens CD3d molecule, delta (CD3-TCR complex)
Homo sapiens acyl-CoA thioesterase 9 (ACOT9), transcript
Homo sapiens chemokine (C-X-C motif) ligand 10
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens endothelial cell growth factor 1 (platelet-
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein
Homo sapiens glycerol kinase (GK), transcript variant 1,
Homo sapiens leukotriene B4 receptor (LTB4R), mRNA.
Homo sapiens similar to 2010300C02Rik protein
Homo sapiens dynein, light chain, Tctex-type 1 (DYNLT1),
Homo sapiens keratin 72 (KRT72), mRNA.
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens annexin A3 (ANXA3), mRNA.
Homo sapiens free fatty acid receptor 2 (FFAR2), mRNA.
Homo sapiens receptor (chemosensory) transporter protein 4
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens nibrin (NBN), mRNA.
Homo sapiens poliovirus receptor related immunoglobulin
Homo sapiens cDNA clone IMAGE: 5277162
Homo sapiens oncostatin M (OSM), mRNA.
Homo sapiens chromosome 9 open reading frame 66
Homo sapiens chromosome 9 open reading frame 72
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens FERM domain containing 3 (FRMD3),
Homo sapiens v-myc myelocytomatosis viral oncogene
Homo sapiens guanylate binding protein family, member 6
Homo sapiens guanylate binding protein family, member 6
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens suppressor of cytokine signaling 3 (SOCS3),
Homo sapiens proteasome (prosome, macropain) activator
Homo sapiens 2′-5′-oligoadenylate synthetase 2, 69/71 kDa
Homo sapiens abhydrolase domain containing 14A
Homo sapiens aspartate beta-hydroxylase domain containing
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens tumor necrosis factor, alpha-induced protein 6
sapiens cDNA clone IMAGp998A124183;
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens glutaminyl-peptide cyclotransferase
Homo sapiens epithelial stromal interaction 1
Homo sapiens complement component 2 (C2), mRNA.
Homo sapiens WD repeat and FYVE domain containing 3
Homo sapiens G protein-coupled receptor 84 (GPR84),
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens Fc fragment of IgE, high affinity I, receptor
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens cathelicidin antimicrobial peptide (CAMP),
Homo sapiens calpain, small subunit 2 (CAPNS2),
Homo sapiens proline-serine-threonine phosphatase
Homo sapiens calmodulin binding transcription activator 1
Homo sapiens cytidine monophosphate (UMP-CMP)
Homo sapiens vaccinia related kinase 2 (VRK2), mRNA.
Homo sapiens lymphocyte antigen 96 (LY96), mRNA.
Homo sapiens vesicle-associated membrane protein 5
Homo sapiens coiled-coil domain containing 65
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens FK506 binding protein 9-like (FKBP9L),
Homo sapiens piwi-like 4 (Drosophila) (PIWIL4), mRNA.
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens Fc fragment of IgG binding protein
Homo sapiens histone cluster 2, H2bf (HIST2H2BF),
Homo sapiens guanylate binding protein 5 (GBP5),
Homo sapiens SEC14 and spectrin domains 1 (SESTD1),
Homo sapiens ets variant 7 (ETV7), mRNA.
Homo sapiens pregnancy specific beta-1-glycoprotein 3
Homo sapiens cadherin-like 23 (CDH23), transcript
Homo sapiens selenoprotein M (SELM), mRNA.
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens interleukin 15 (IL15), transcript variant 1,
Homo sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens G protein-coupled receptor 109B
Homo sapiens aspartic peptidase, retroviral-like 1
Homo sapiens abhydrolase domain containing 2
Homo sapiens SLIT and NTRK-like family, member 4
Homo sapiens claudin 23 (CLDN23), mRNA.
Homo sapiens dual specificity phosphatase 3 (vaccinia
Homo sapiens transmembrane protein 51 (TMEM51),
Homo sapiens progestin and adipoQ receptor family
Homo sapiens SLAM family member 8 (SLAMF8),
Homo sapiens CD38 molecule (CD38), mRNA.
Homo sapiens tripartite motif-containing 21 (TRIM21),
Homo sapiens inhibitor of DNA binding 3, dominant
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens serpin peptidase inhibitor, clade G (C1
Homo sapiens sulfide quinone reductase-like (yeast)
Homo sapiens Dmx-like 2 (DMXL2), mRNA.
Homo sapiens polymerase (DNA directed), beta (POLB),
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens zinc finger protein 540 (ZNF540), mRNA.
Homo sapiens KIAA1618 (KIAA1618), mRNA.
Homo sapiens 5′-3′ exoribonuclease 1 (XRN1), transcript
sapiens cDNA clone IMAGE: 5849985 3, mRNA
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens multiple C2 domains, transmembrane 1
Homo sapiens kinesin family member 1B (KIF1B),
Homo sapiens lysosomal-associated membrane protein 3
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens cDNA FLJ41813 fis, clone NT2RI2011450
Homo sapiens chemokine (C—X—C motif) receptor 7
Homo sapiens cDNA FLJ20012 fis, clone ADKA03438
Homo sapiens interferon induced transmembrane protein 1
Homo sapiens G protein-coupled receptor 109A
Homo sapiens interferon-induced protein 35 (IFI35),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens vanin 1 (VNN1), mRNA.
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens ubiquitin-conjugating enzyme E2C
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens interleukin 7 receptor (IL7R), mRNA.
Homo sapiens germinal center expressed transcript 2
Homo sapiens ADAM metallopeptidase domain 7
Homo sapiens F-box protein 6 (FBXO6), mRNA.
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens dpy-19-like 3 (C. elegans) (DPY19L3),
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens solute carrier family 6 (neurotransmitter
Homo sapiens lymphocyte antigen 6 complex, locus E
Homo sapiens Sp4 transcription factor (SP4), mRNA.
Homo sapiens T cell receptor alpha variable 20, mRNA
Homo sapiens TRAF-type zinc finger domain containing
Homo sapiens C-type lectin domain family 5, member A
Homo sapiens interleukin 23, alpha subunit p19 (IL23A),
Homo sapiens cAMP responsive element binding protein
Homo sapiens basic leucine zipper transcription factor,
Homo sapiens complement component 3a receptor 1
Homo sapiens C-type lectin domain family 4, member D
Homo sapiens calcium channel, voltage-dependent, R
Homo sapiens NLR family, pyrin domain containing 2
Homo sapiens solute carrier family 41, member 1
Homo sapiens ATP binding domain 4 (ATPBD4), mRNA.
Homo sapiens cDNA, mRNA sequence
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens neutrophil cytosolic factor 1B pseudogene
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens transporter 2, ATP-binding cassette, sub-
Homo sapiens signal-induced proliferation-associated 1
Homo sapiens lemur tyrosine kinase 2 (LMTK2), mRNA.
Homo sapiens cytoplasmic FMR1 interacting protein 1
Homo sapiens testis specific, 14 (TSGA14), mRNA.
Homo sapiens contactin associated protein 1 (CNTNAP1),
Homo sapiens feline leukemia virus subgroup C cellular
Homo sapiens coiled-coil domain containing 149
Homo sapiens lamin B1 (LMNB1), mRNA.
Homo sapiens proteasome (prosome, macropain) subunit,
Homo sapiens activating transcription factor 3 (ATF3),
Homo sapiens CD5 molecule (CD5), mRNA.
Homo sapiens adenylate kinase 3-like 1 (AK3L1), nuclear
Homo sapiens haptoglobin (HP), mRNA.
Homo sapiens sortilin 1 (SORT1), mRNA.
Homo sapiens v-maf musculoaponeurotic fibrosarcoma
Homo sapiens chromosome 11 open reading frame 82
Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA.
Homo sapiens zinc finger protein 438 (ZNF438), mRNA.
Homo sapiens solute carrier family 22 (organic
Homo sapiens cathepsin L1 (CTSL1), transcript variant 2,
Homo sapiens actin, alpha 2, smooth muscle, aorta
Homo sapiens SATB homeobox 1 (SATB1), mRNA.
Homo sapiens tripartite motif-containing 6 (TRIM6),
Homo sapiens caspase 4, apoptosis-related cysteine
Homo sapiens solute carrier family 22 (organic
Homo sapiens zinc finger protein 485 (ZNF485), mRNA.
Homo sapiens toll-like receptor 2 (TLR2), mRNA.
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens WD repeat and FYVE domain containing 3
Homo sapiens ankyrin repeat and death domain containing
Homo sapiens multiple C2 domains, transmembrane 1
Homo sapiens STEAP family member 4 (STEAP4),
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens F-box and leucine-rich repeat protein 5
Homo sapiens S1 RNA binding domain 1 (SRBD1),
Homo sapiens keratin 73 (KRT73), mRNA.
Homo sapiens sterile alpha motif and leucine zipper
Homo sapiens (clone 5) macronuclear mRNA
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens CD86 antigen (CD28 antigen ligand 2, B7-
Homo sapiens 2′,5′-oligoadenylate synthetase 1, 40/46 kDa
Homo sapiens serpin peptidase inhibitor, clade A (alpha-1
Homo sapiens DKFZP564O0823 protein
Homo sapiens similar to Interferon-induced guanylate-
Homo sapiens caveolin 2 (CAV2), transcript variant 1,
Homo sapiens succinate receptor 1 (SUCNR1), mRNA.
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens ubiquitin specific peptidase 30 (USP30),
Homo sapiens signal-induced proliferation-associated 1
Homo sapiens kinesin family member 1B (KIF1B),
Homo sapiens interleukin-1 receptor-associated kinase 3
Homo sapiens NLR family, CARD domain containing 4
Homo sapiens caspase 5, apoptosis-related cysteine
Homo sapiens chromosome 16 open reading frame 7
Homo sapiens early B-cell factor 1 (EBF1), mRNA.
Homo sapiens RGD motif, leucine rich repeats,
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens lactotransferrin (LTF), mRNA.
Homo sapiens interleukin 1, beta (IL1B), mRNA.
Homo sapiens Mov10, Moloney leukemia virus 10,
Homo sapiens leucine zipper, down-regulated in cancer 1
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens GRAM domain containing 1C
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens dedicator of cytokinesis 9 (DOCK9),
Homo sapiens ArfGAP with dual PH domains 2
Homo sapiens matrix metallopeptidase 8 (neutrophil
Homo sapiens ribosomal protein S23 (RPS23), mRNA.
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA.
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens nibrin (NBN), transcript variant 2, mRNA.
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens platelet-derived growth factor alpha
Homo sapiens olfactomedin 1 (OLFM1), transcript variant
Homo sapiens Z-DNA binding protein 1 (ZBP1), mRNA.
Homo sapiens syntaxin 11 (STX11), mRNA.
Homo sapiens complement component 1, q
Homo sapiens poliovirus receptor-related 2 (herpesvirus
Homo sapiens zinc finger, MYND-type containing 15
Homo sapiens secreted and transmembrane 1 (SECTM1),
Homo sapiens chemokine (C—X—C motif) receptor 5
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens nuclear receptor subfamily 3, group C,
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens hypothetical protein LOC152195
Homo sapiens class II, major histocompatibility complex,
Homo sapiens toll-like receptor 5 (TLR5), mRNA.
Homo sapiens granzyme K (granzyme 3; tryptase II)
Homo sapiens inhibitory caspase recruitment domain
Homo sapiens thyroid hormone receptor, alpha
Homo sapiens SFRS protein kinase 1 (SRPK1), mRNA.
Homo sapiens lipoma HMGIC fusion partner-like 2
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens kazrin (KIAA1026), transcript variant B,
Homo sapiens kazrin (KIAA1026), transcript variant B,
Homo sapiens family with sequence similarity 102,
Homo sapiens family with sequence similarity 102,
Homo sapiens InaD-like (Drosophila) (INADL), transcript
Homo sapiens chromatin modifying protein 5 (CHMP5),
Homo sapiens TRAF-interacting protein with forkhead-
Homo sapiens ADP-ribosylation factor-like 4C (ARL4C),
Homo sapiens pecanex-like 2 (Drosophila) (PCNXL2),
Homo sapiens EPH receptor A4 (EPHA4), mRNA.
Homo sapiens T cell antigen receptor alpha chain
Homo sapiens chromosome 19 open reading frame 59
Homo sapiens CDK5 regulatory subunit associated protein
Homo sapiens phospholipid scramblase 1 (PLSCR1),
Homo sapiens hypothetical protein FLJ22795 (FLJ22795),
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens DKFZp761E198 protein
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens synaptotagmin-like 2 (SYTL2), transcript
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens potassium voltage-gated channel, Isk-
Homo sapiens tripartite motif-containing pseudogene 1
Homo sapiens hexokinase 3 (white cell) (HK3), nuclear
Homo sapiens coagulation factor II (thrombin) receptor-
Homo sapiens lysosomal trafficking regulator (LYST),
Homo sapiens interleukin 1 receptor antagonist (IL1RN),
Homo sapiens 2′-5′-oligoadenylate synthetase 3, 100 kDa
Homo sapiens putative homeodomain transcription factor
Homo sapiens methylenetetrahydrofolate dehydrogenase
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens XIAP associated factor 1 (XAF1),
Homo sapiens XIAP associated factor 1 (XAF1),
Homo sapiens inhibitor of growth family, member 5
Homo sapiens zinc finger protein 831 (ZNF831), mRNA.
Homo sapiens methionine sulfoxide reductase B2
Homo sapiens interferon-induced protein with
Homo sapiens cystatin A (stefin A) (CSTA), mRNA.
Homo sapiens IKAROS family zinc finger 3 (Aiolos)
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens apolipoprotein L, 1 (APOL1), transcript
Homo sapiens interferon, gamma-inducible protein 30
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens KIAA0082 (KIAA0082), mRNA.
Homo sapiens kinesin family member 5C (KIF5C),
Homo sapiens FYN binding protein (FYB-120/130)
Homo sapiens breast carcinoma amplified sequence 4
Homo sapiens DENN/MADD domain containing 1A
Homo sapiens toll-like receptor 8 (TLR8), transcript
Homo sapiens translocase of inner mitochondrial
Homo sapiens transporter 1, ATP-binding cassette, sub-
Homo sapiens HORMA domain containing 1
Homo sapiens viral DNA polymerase-transactivated
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens PAS domain containing serine/threonine
Homo sapiens PAS domain containing serine/threonine
Homo sapiens small nucleolar RNA, C/D box 21
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens interleukin 15 (IL15), transcript variant 3,
Homo sapiens heat shock 70 kDa protein 6 (HSP70B′)
Homo sapiens zinc finger, DHHC-type containing 11
Homo sapiens cAMP responsive element binding protein
Homo sapiens Fas (TNF receptor superfamily, member 6)
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens zinc finger protein 667 (ZNF667), mRNA.
Homo sapiens caspase 1, apoptosis-related cysteine
Homo sapiens caspase 1, apoptosis-related cysteine
Homo sapiens plasmalemma vesicle associated protein
Homo sapiens N-deacetylase/N-sulfotransferase (heparan
Homo sapiens interferon, alpha-inducible protein 6 (IFI6),
Homo sapiens 2′,5′-oligoadenylate synthetase 1, 40/46 kDa
Homo sapiens 2′,5′-oligoadenylate synthetase 1, 40/46 kDa
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens pleiomorphic adenoma gene 1 (PLAG1),
Homo sapiens troponin I type 2 (skeletal, fast) (TNNI2),
Homo sapiens sterile alpha motif domain containing 9-like
Homo sapiens 5-oxoprolinase (ATP-hydrolysing)
Homo sapiens CD63 molecule (CD63), transcript variant
Homo sapiens chromosome 11 open reading frame 75
Homo sapiens sushi domain containing 2 (SUSD2),
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens signal transducer and activator of
Homo sapiens syntaxin binding protein 4 (STXBP4),
Homo sapiens RAB20, member RAS oncogene family
Homo sapiens suppressor of cytokine signaling 1
Homo sapiens diacylglycerol kinase, alpha 80 kDa
Homo sapiens procollagen-lysine, 2-oxoglutarate 5-
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens proteasome (prosome, macropain) activator
Homo sapiens purinergic receptor P2X, ligand-gated ion
Homo sapiens ISG15 ubiquitin-like modifier (ISG15),
Homo sapiens C-type lectin domain family 12, member A
Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA.
Homo sapiens zinc finger protein 681 (ZNF681), mRNA.
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens interferon-induced protein with
Homo sapiens interferon-induced protein with
Homo sapiens ropporin 1-like (ROPN1L), mRNA.
Homo sapiens G protein-coupled receptor 141 (GPR141),
Homo sapiens G protein-coupled receptor 141 (GPR141),
Homo sapiens phosphatidylglycerophosphate synthase 1
Homo sapiens alpha-kinase 1 (ALPK1), mRNA.
Homo sapiens interleukin 1 receptor antagonist (IL1RN),
Homo sapiens KIAA1394 protein (KIAA1394), mRNA.
sapiens cDNA clone IMAGE: 1027283 3, mRNA
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens CD40 ligand (CD40LG), mRNA.
Homo sapiens AF4/FMR2 family, member 1 (AFF1),
Homo sapiens histone cluster 1, H3d (HIST1H3D),
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens deltex 3-like (Drosophila) (DTX3L),
Homo sapiens docking protein 3 (DOK3), mRNA.
Homo sapiens adrenomedullin (ADM), mRNA.
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens glycogenin 1 (GYG1), mRNA.
Homo sapiens zinc finger protein 91 (ZNF91), mRNA.
Homo sapiens cytokeratin associated protein
Homo sapiens sperm acrosome associated 4 (SPACA4),
Homo sapiens CD36 molecule (thrombospondin receptor)
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens limb bud and heart development homolog
Homo sapiens bactericidal/permeability-increasing protein
Homo sapiens ST3 beta-galactoside alpha-2,3-
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens family with sequence similarity 26,
Homo sapiens Fc receptor-like A (FCRLA), mRNA.
Homo sapiens aldehyde dehydrogenase 1 family, member
Homo sapiens zinc finger, DHHC-type containing 19
Homo sapiens chromosome 6 open reading frame 150
Homo sapiens CD59 molecule, complement regulatory
Homo sapiens CD274 molecule (CD274), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 2,
Homo sapiens membrane metallo-endopeptidase (MME),
Homo sapiens Janus kinase 2 (a protein tyrosine kinase)
Homo sapiens pleckstrin homology, Sec7 and coiled-coil
Homo sapiens interferon induced transmembrane protein 3
Homo sapiens signal transducer and activator of
Homo sapiens signal transducer and activator of
Homo sapiens von Willebrand factor A domain containing
Homo sapiens cathepsin L1 (CTSL1), transcript variant 1,
Homo sapiens cathepsin L1 (CTSL1), transcript variant 1,
Homo sapiens cDNA: FLJ21199 fis, clone COL00235
Homo sapiens peptidoglycan recognition protein 1
Homo sapiens protein phosphatase 1, regulatory
Homo sapiens interferon-induced protein 44-like (IFI44L),
Homo sapiens transcription factor 7 (T-cell specific,
Homo sapiens sidekick homolog 2 (chicken) (SDK2),
Homo sapiens leucine-rich alpha-2-glycoprotein 1
sapiens cDNA clone IMAGE: 2736025 3, mRNA
Homo sapiens RALBP1 associated Eps domain containing
Homo sapiens poliovirus receptor-related 3 (PVRL3),
Homo sapiens multiple C2 domains, transmembrane 2
Homo sapiens WD repeat and SOCS box-containing 1
Homo sapiens CD27 molecule (CD27), mRNA.
Homo sapiens histone cluster 2, H2ac (HIST2H2AC),
Homo sapiens Fas apoptotic inhibitory molecule 3
Homo sapiens SCO cytochrome oxidase deficient
Homo sapiens tudor domain containing 9 (TDRD9),
Homo sapiens chromosome 20 open reading frame 24
Homo sapiens neutrophil cytosolic factor 1 (NCF1),
Homo sapiens interleukin 18 receptor accessory protein
Homo sapiens hypothetical protein LOC285016
Homo sapiens BR serine/threonine kinase 1 (BRSK1),
Homo sapiens oxysterol binding protein-like 10
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens oxidized low density lipoprotein (lectin-
Homo sapiens hect domain and RLD 5 (HERC5), mRNA.
Homo sapiens signal transducer and activator of
Homo sapiens TIMP metallopeptidase inhibitor 2
Homo sapiens Fc fragment of IgG, high affinity Ia,
Homo sapiens interferon-induced protein 44 (IFI44),
Homo sapiens polymerase (RNA) II (DNA directed)
Homo sapiens 2′-5′-oligoadenylate synthetase-like
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens methylenetetrahydrofolate dehydrogenase
Homo sapiens glutathione S-transferase M2 (muscle)
Homo sapiens apolipoprotein L, 1 (APOL1), transcript
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens ATPase, class I, type 8B, member 2
Homo sapiens caspase-1 dominant-negative inhibitor
Homo sapiens caspase-1 dominant-negative inhibitor
Homo sapiens F-box and leucine-rich repeat protein 16
Homo sapiens teashirt zinc finger homeobox 2 (TSHZ2),
Homo sapiens sialic acid binding Ig-like lectin 16
Homo sapiens scavenger receptor class F, member 1
Homo sapiens chromosome 1 open reading frame 165
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens septin 4 (SEPT4), transcript variant 3,
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens matrix metallopeptidase 9 (gelatinase B,
Homo sapiens transporter 2, ATP-binding cassette, sub-
Homo sapiens damage-regulated autophagy modulator
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens cat eye syndrome chromosome region,
Homo sapiens leucine rich repeat and fibronectin type III
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens interferon-induced protein with
Homo sapiens lectin, galactoside-binding, soluble, 3
Homo sapiens guanylate binding protein 4 (GBP4),
Homo sapiens thioredoxin domain containing 3
Homo sapiens interferon induced with helicase C domain
Homo sapiens proline rich Gla (G-carboxyglutamic acid)
Homo sapiens neuroblastoma, suppression of
Homo sapiens calcium channel, voltage-dependent, T
Homo sapiens pyruvate dehydrogenase kinase, isozyme 3
Homo sapiens harakiri, BCL2 interacting protein (contains
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens aldehyde dehydrogenase 1 family, member
Homo sapiens transcobalamin II; macrocytic anemia
Homo sapiens interferon-induced protein with
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
Homo sapiens homeobox A9 (HOXA9), mRNA.
Homo sapiens tripartite motif-containing 22 (TRIM22),
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens guanylate binding protein 2, interferon-
Homo sapiens insulin-like growth factor 2 mRNA binding
Homo sapiens 2′-5′-oligoadenylate synthetase-like
Homo sapiens dysferlin, limb girdle muscular dystrophy
Homo sapiens hypothetical protein LOC552891
Homo sapiens mucin 1, cell surface associated (MUC1),
Homo sapiens solute carrier family 22 (organic cation
Homo sapiens apolipoprotein L, 6 (APOL6), mRNA.
Homo sapiens interferon-induced protein with
Homo sapiens lysophosphatidylcholine acyltransferase 2
Homo sapiens interleukin 28 receptor, alpha (interferon,
Homo sapiens acyl-CoA thioesterase 9 (ACOT9),
Homo sapiens S100 calcium binding protein A12
Homo sapiens chemokine (C—X—C motif) ligand 10
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens endothelial cell growth factor 1 (platelet-
Homo sapiens endothelial cell growth factor 1 (platelet-
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger
Homo sapiens glycerol kinase (GK), transcript variant 1,
Homo sapiens arylsulfatase B (ARSB), transcript variant
Homo sapiens 2′-5′-oligoadenylate synthetase 2, 69/71 kDa
Homo sapiens leukotriene B4 receptor (LTB4R), mRNA.
Homo sapiens dynein, light chain, Tctex-type 1
Homo sapiens RAR-related orphan receptor A (RORA),
Homo sapiens maltase-glucoamylase (alpha-glucosidase)
Homo sapiens keratin 72 (KRT72), mRNA.
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens annexin A3 (ANXA3), mRNA.
Homo sapiens phosphatidylinositol transfer protein,
Homo sapiens free fatty acid receptor 2 (FFAR2), mRNA.
Homo sapiens RCAN family member 3 (RCAN3),
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens leucine rich repeat containing 25
Homo sapiens CD79a molecule, immunoglobulin-
Homo sapiens chromosome 9 open reading frame 84
Homo sapiens receptor (chemosensory) transporter protein
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens cDNA clone IMAGE: 5277162
Homo sapiens acidic (leucine-rich) nuclear
Homo sapiens oncostatin M (OSM), mRNA.
Homo sapiens chromosome 9 open reading frame 72
Homo sapiens sterile alpha motif domain containing 4A
Homo sapiens DIP2 disco-interacting protein 2 homolog
Homo sapiens transmembrane protein 207 (TMEM207),
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens FERM domain containing 3 (FRMD3),
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens histone cluster 1, H4h (HIST1H4H),
Homo sapiens guanylate binding protein family, member
Homo sapiens guanylate binding protein family, member
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens suppressor of cytokine signaling 3
Homo sapiens hypothetical protein LOC153561
Homo sapiens proteasome (prosome, macropain) activator
Homo sapiens KIAA0367 (KIAA0367), mRNA.
Homo sapiens 2′-5′-oligoadenylate synthetase 2, 69/71 kDa
Homo sapiens abhydrolase domain containing 14A
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens aspartate beta-hydroxylase domain
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens granulin (GRN), mRNA.
Homo sapiens ephrin-A1 (EFNA1), transcript variant 1,
Homo sapiens tumor necrosis factor, alpha-induced
Homo sapiens mitochondrial ribosomal protein L38
Homo sapiens collagen, type IX, alpha 2 (COL9A2),
Homo sapiens seryl-tRNA synthetase 2, mitochondrial
Homo sapiens ectonucleoside triphosphate
Homo sapiens exoribonuclease 1 (ERI1), mRNA.
Homo sapiens ketch domain containing 8B (KLHDC8B),
Homo sapiens monoglyceride lipase (MGLL), transcript
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens cDNA: FLJ22140 fis, clone HEP20977
Homo sapiens glucuronidase, beta pseudogene
Homo sapiens epithelial stromal interaction 1 (breast)
Homo sapiens alkaline phosphatase, liver/bone/kidney
Homo sapiens WD repeat and FYVE domain containing 3
Homo sapiens tissue factor pathway inhibitor (lipoprotein-
Homo sapiens tissue factor pathway inhibitor (lipoprotein-
Homo sapiens G protein-coupled receptor 84 (GPR84),
Homo sapiens tRNA methyltransferase 11 homolog (S. cerevisiae)
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens Fc fragment of IgE, high affinity I, receptor
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens proline-serine-threonine phosphatase
Homo sapiens vesicle-associated membrane protein 5
Homo sapiens Fc fragment of IgG, high affinity Ic,
Homo sapiens CD79b molecule, immunoglobulin-
Homo sapiens coiled-coil domain containing 65
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens MOB1, Mps One Binder kinase activator-
Homo sapiens nucleolar complex associated 3 homolog (S. cerevisiae)
Homo sapiens Fc fragment of IgG binding protein
Homo sapiens melanoma antigen family D, 1 (MAGED1),
Homo sapiens guanylate binding protein 5 (GBP5),
Homo sapiens complement component 5 (C5), mRNA.
Homo sapiens SEC14 and spectrin domains 1 (SESTD1),
Homo sapiens ets variant 7 (ETV7), mRNA.
Homo sapiens pregnancy specific beta-1-glycoprotein 3
Homo sapiens ilvB (bacterial acetolactate synthase)-like
Homo sapiens granulysin (GNLY), transcript variant
Homo sapiens interferon regulatory factor 1 (IRF1),
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens dual adaptor of phosphotyrosine and 3-
Homo sapiens cell division cycle associated 7-like
Homo sapiens interleukin 15 (IL15), transcript variant 1,
Homo sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo sapiens immediate early response 3 (IER3), mRNA.
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens colony stimulating factor 2 receptor, beta,
Homo sapiens G protein-coupled receptor 109B
Homo sapiens histone cluster 2, H4b (HIST2H4B),
Homo sapiens DnaJ (Hsp40) homolog, subfamily C,
Homo sapiens abhydrolase domain containing 2 (ABHD2),
Homo sapiens dual specificity phosphatase 3 (vaccinia
virus phosphatase VH1-related) (DUSP3), mRNA.
Homo sapiens endothelin converting enzyme 1 (ECE1),
Homo sapiens inhibitor of DNA binding 3, dominant
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens TAP binding protein (tapasin) (TAPBP),
Homo sapiens serpin peptidase inhibitor, clade G (C1
Homo sapiens hypothetical LOC100129637
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens tetraspanin 9 (TSPAN9), mRNA.
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens paroxysmal nonkinesiogenic dyskinesia
Homo sapiens zinc finger protein 540 (ZNF540), mRNA.
Homo sapiens granulysin (GNLY), transcript variant 519,
Homo sapiens WD repeat domain 36 (WDR36), mRNA.
Homo sapiens selectin P (granule membrane protein
Homo sapiens chitinase 3-like 2 (CHI3L2), transcript
Homo sapiens chromodomain helicase DNA binding
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens ankyrin repeat domain 9 (ANKRD9),
Homo sapiens nucleotide-binding oligomerization domain
Homo sapiens multiple C2 domains, transmembrane 1
Homo sapiens B-cell scaffold protein with ankyrin repeats
Homo sapiens acetyl-Coenzyme A carboxylase beta
Homo sapiens sterile alpha motif domain containing 3
Homo sapiens sterile alpha motif domain containing 3
Homo sapiens myoferlin (MYOF), transcript variant 1,
Homo sapiens nuclear factor of activated T-cells 5,
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens Fc fragment of IgG, low affinity IIIb,
Homo sapiens zinc finger protein 329 (ZNF329), mRNA.
Homo sapiens calcium/calmodulin-dependent protein
Homo sapiens cholesteryl ester transfer protein, plasma
Homo sapiens ubiquitin associated and SH3 domain
Homo sapiens tropomyosin 1 (alpha) (TPM1), transcript
Homo sapiens interferon induced transmembrane protein 1
Homo sapiens G protein-coupled receptor 109A
Homo sapiens interferon-induced protein 35 (IFI35),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens formyl peptide receptor 2 (FPR2), transcript
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens kringle containing transmembrane protein 1
Homo sapiens vanin 1 (VNN1), mRNA.
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens hypothetical LOC644873 (FLJ33630), non-
Homo sapiens F-box protein 6 (FBXO6), mRNA.
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens interleukin 18 receptor 1 (IL18R1), mRNA.
sapiens cDNA clone IMAGE: 2726592 3, mRNA sequence
Homo sapiens zinc finger protein 337 (ZNF337), mRNA.
Homo sapiens AF4/FMR2 family, member 3 (AFF3),
Homo sapiens Kruppel-like factor 12 (KLF12), mRNA.
Homo sapiens cDNA FLJ31407 fis, clone NT2NE2000137
Homo sapiens neurocalcin delta (NCALD), transcript
Homo sapiens Src-like-adaptor (SLA), transcript variant 1,
Homo sapiens dedicator of cytokinesis 5 (DOCK5),
Homo sapiens TRAF-type zinc finger domain containing 1
Homo sapiens polycomb group ring finger 5 (PCGF5),
Homo sapiens cAMP responsive element binding protein 5
Homo sapiens basic leucine zipper transcription factor,
Homo sapiens solute carrier family 2 (facilitated glucose
Homo sapiens C-type lectin domain family 4, member D
Homo sapiens calcium channel, voltage-dependent, R type,
Homo sapiens tribbles homolog 2 (Drosophila) (TRIB2),
Homo sapiens pre-B lymphocyte gene 3 (VPREB3),
Homo sapiens septin 1 (SEPT1), mRNA. XM_944608
Homo sapiens phosphoribosylformylglycinamidine
Homo sapiens CD320 molecule (CD320), mRNA.
Homo sapiens axin 2 (conductin, axil) (AXIN2), mRNA.
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens secreted protein, acidic, cysteine-rich
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens seven in absentia homolog 2 (Drosophila)
Homo sapiens peroxisomal proliferator-activated receptor
Homo sapiens protein phosphatase 2 (formerly 2A),
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens lipocalin 2 (LCN2), mRNA.
Homo sapiens bromodomain adjacent to zinc finger
Homo sapiens nuclear receptor subfamily 1, group I,
Homo sapiens up-regulated gene 4 (URG4), nuclear gene
Homo sapiens methionyl-tRNA synthetase 2,
Homo sapiens (human)
Homo sapiens signal-induced proliferation-associated 1
Homo sapiens protein tyrosine phosphatase, receptor type,
Homo sapiens cathepsin A (CTSA), transcript variant 1,
Homo sapiens transglutaminase 2 (C polypeptide, protein-
Homo sapiens chemokine (C-C motif) ligand 4-like 2
Homo sapiens feline leukemia virus subgroup C cellular
Homo sapiens lamin B1 (LMNB1), mRNA.
Homo sapiens mitogen-activated protein kinase kinase
Homo sapiens proteasome (prosome, macropain) subunit,
Homo sapiens activating transcription factor 3 (ATF3),
Homo sapiens CD5 molecule (CD5), mRNA.
Homo sapiens H2A histone family, member J (H2AFJ),
Homo sapiens haptoglobin (HP), mRNA.
Homo sapiens protein phosphatase 1, regulatory (inhibitor)
Homo sapiens histone cluster 1, H2bk (HIST1H2BK),
Homo sapiens histone cluster 1, H2bk (HIST1H2BK),
Homo sapiens transmembrane protein 140 (TMEM140),
Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA.
Homo sapiens CD160 molecule (CD160), mRNA.
Homo sapiens CD19 molecule (CD19), mRNA.
Homo sapiens zinc finger protein 438 (ZNF438), mRNA.
Homo sapiens chromosome 6 open reading frame 25
Homo sapiens solute carrier family 22 (organic
Homo sapiens actin, alpha 2, smooth muscle, aorta
Homo sapiens KIAA1632 (KIAA1632), mRNA.
Homo sapiens caspase 4, apoptosis-related cysteine
Homo sapiens solute carrier family 22 (organic
Homo sapiens glyoxalase domain containing 4 (GLOD4),
Homo sapiens POU class 2 associating factor 1
Homo sapiens toll-like receptor 2 (TLR2), mRNA.
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens melanoma antigen family E, 1 (MAGEE1),
Homo sapiens STEAP family member 4 (STEAP4),
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger
Homo sapiens myeloproliferative leukemia virus oncogene
Homo sapiens coiled-coil domain containing 102A
Homo sapiens platelet factor 4 variant 1 (PF4V1), mRNA.
Homo sapiens killer cell lectin-like receptor subfamily F,
Homo sapiens phosphorylated adaptor for RNA export
Homo sapiens lin-7 homolog A (C. elegans) (LIN7A),
Homo sapiens sterile alpha motif and leucine zipper
Homo sapiens hypothetical LOC283663 (LOC283663),
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens serpin peptidase inhibitor, clade A (alpha-1
Homo sapiens immunoglobulin superfamily, member 6
Homo sapiens similar to Interferon-induced guanylate-
Homo sapiens caveolin 2 (CAV2), transcript variant 1,
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens Fc fragment of IgG, low affinity IIc,
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens kinesin family member 1B (KIF1B),
Homo sapiens interleukin-1 receptor-associated kinase 3
Homo sapiens LIM domain and actin binding 1 (LIMA1),
Homo sapiens NLR family, CARD domain containing 4
Homo sapiens histone cluster 1, H2bc (HIST1H2BC),
Homo sapiens src kinase associated phosphoprotein 1
Homo sapiens caspase 5, apoptosis-related cysteine
Homo sapiens GAR1 ribonucleoprotein homolog (yeast)
Homo sapiens UDP-Gal:betaGlcNAc beta 1,4-
Homo sapiens chromosome 16 open reading frame 7
Homo sapiens aldehyde dehydrogenase 18 family, member
Homo sapiens cDNA FLJ20182 fis, clone COLF0190
Homo sapiens cortactin (CTTN), transcript variant 1,
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens potassium large conductance calcium-
Homo sapiens purinergic receptor P2X, ligand-gated ion
Homo sapiens interleukin 1, beta (IL1B), mRNA.
Homo sapiens cyclin B1 interacting protein 1
Homo sapiens IQ motif containing B1 (IQCB1), transcript
Homo sapiens histone cluster 2, H2be (HIST2H2BE),
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens guanylate cyclase 1, soluble, alpha 3
Homo sapiens C-type lectin domain family 2, member D
Homo sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA.
Homo sapiens signaling lymphocytic activation molecule
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens cut-like 1, CCAAT displacement protein
Homo sapiens B and T lymphocyte associated (BTLA),
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens platelet-derived growth factor alpha
Homo sapiens leucine rich repeat neuronal 3 (LRRN3),
Homo sapiens cDNA clone MGC: 13035
Homo sapiens netrin 3 (NTN3), mRNA.
Homo sapiens Z-DNA binding protein 1 (ZBP1), mRNA.
Homo sapiens syntaxin 11 (STX11), mRNA.
Homo sapiens complement component 1, q subcomponent,
Homo sapiens X-linked Kx blood group (McLeod
Homo sapiens zinc finger, MYND-type containing 15
Homo sapiens secreted and transmembrane 1 (SECTM1),
Homo sapiens chemokine (C—X—C motif) receptor 5
Homo sapiens chemokine (C—X—C motif) receptor 5
Homo sapiens Fas (TNF receptor superfamily, member 6)
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens adenylate cyclase 3 (ADCY3), mRNA.
Homo sapiens lanosterol synthase (2,3-oxidosqualene-
Homo sapiens toll-like receptor 5 (TLR5), mRNA.
Homo sapiens nicotinamide phosphoribosyltransferase
Homo sapiens granzyme K (granzyme 3; tryptase II)
Homo sapiens caspase recruitment domain family, member
Homo sapiens caspase recruitment domain family, member
Homo sapiens mitogen-activated protein kinase kinase
Homo sapiens family with sequence similarity 129,
Homo sapiens migration and invasion inhibitory protein
Homo sapiens polymerase (RNA) I polypeptide E, 53 kDa
Homo sapiens chromosome 17 open reading frame 60
Homo sapiens lipoma HMGIC fusion partner-like 2
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens family with sequence similarity 102,
Homo sapiens family with sequence similarity 102,
Homo sapiens calcium channel, voltage-dependent, alpha
Homo sapiens tyrosyl-DNA phosphodiesterase 1 (TDP1),
Homo sapiens chromatin modifying protein 5 (CHMP5),
Homo sapiens hippocampus abundant transcript-like 1
Homo sapiens TRAF-interacting protein with forkhead-
Homo sapiens ADP-ribosylation factor-like 4C (ARL4C),
Homo sapiens filamin B, beta (actin binding protein 278)
Homo sapiens EPH receptor A4 (EPHA4), mRNA.
Homo sapiens chromosome 19 open reading frame 59
Homo sapiens protein phosphatase 2 (formerly 2A),
Homo sapiens CDK5 regulatory subunit associated protein
Homo sapiens phospholipid scramblase 1 (PLSCR1),
Homo sapiens glycoprotein IX (platelet) (GP9), mRNA.
Homo sapiens ATPase, class II, type 9A (ATP9A),
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens DKFZp761E198 protein (DKFZp761E198),
Homo sapiens sterile alpha motif domain containing 14
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens OCIA domain containing 2 (OCIAD2),
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens CD151 molecule (Raph blood group)
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens prostaglandin D2 receptor (DP) (PTGDR),
Homo sapiens acyl-CoA synthetase long-chain family
Homo sapiens sorting nexin 20 (SNX20), mRNA.
Homo sapiens coagulation factor II (thrombin) receptor-
Homo sapiens coagulation factor II (thrombin) receptor-
Homo sapiens milk fat globule-EGF factor 8 protein
Homo sapiens interleukin 1 receptor antagonist (IL1RN),
Homo sapiens putative homeodomain transcription factor
Homo sapiens membrane-spanning 4-domains, subfamily
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens amyloid beta (A4) precursor protein (APP),
Homo sapiens amyloid beta (A4) precursor protein (APP),
Homo sapiens XIAP associated factor 1 (XAF1), transcript
Homo sapiens XIAP associated factor 1 (XAF1), transcript
Homo sapiens zinc finger protein 831 (ZNF831), mRNA.
Homo sapiens zinc finger protein 831 (ZNF831), mRNA.
Homo sapiens methionine sulfoxide reductase B2
Homo sapiens IKAROS family zinc finger 3 (Aiolos)
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens killer cell lectin-like receptor subfamily B,
Homo sapiens sphingosine-1-phosphate receptor 1
Homo sapiens FYN binding protein (FYB-120/130)
Homo sapiens CD79B antigen (immunoglobulin-
Homo sapiens pleiomorphic adenoma gene-like 1
Homo sapiens translocase of inner mitochondrial
Homo sapiens TNF receptor-associated factor 5 (TRAF5),
Homo sapiens transporter 1, ATP-binding cassette, sub-
Homo sapiens Fc receptor-like 2 (FCRL2), transcript
Homo sapiens Ral GTPase activating protein, alpha
Homo sapiens mitochondrial protein 18 kDa (MTP18),
Homo sapiens BTB and CNC homology 1, basic leucine
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens PAS domain containing serine/threonine
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens natural cytotoxicity triggering receptor 3
Homo sapiens CD8b molecule (CD8B), transcript variant
Homo sapiens heat shock 70 kDa protein 6 (HSP70B′)
Homo sapiens ubiquitin specific peptidase 32 (USP32),
Homo sapiens formyl peptide receptor 2 (FPR2), transcript
Homo sapiens histone cluster 2, H2ab (HIST2H2AB),
Homo sapiens CKLF-like MARVEL transmembrane
Homo sapiens vaccinia related kinase 1 (VRK1), mRNA.
Homo sapiens cAMP responsive element binding protein 5
Homo sapiens Fas (TNF receptor superfamily, member 6)
Homo sapiens metal-regulatory transcription factor 1
Homo sapiens quaking homolog, KH domain RNA
Homo sapiens chromosome 20 open reading frame 196
Homo sapiens caspase 1, apoptosis-related cysteine
Homo sapiens myosin, light chain 9, regulatory (MYL9),
Homo sapiens myosin, light chain 9, regulatory (MYL9),
Homo sapiens integrin, alpha 2b (platelet glycoprotein IIb
Homo sapiens interferon, alpha-inducible protein 6 (IFI6),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens lymphocyte-specific protein tyrosine kinase
Homo sapiens sterile alpha motif domain containing 9-like
Homo sapiens nerve growth factor receptor (TNFRSF16)
Homo sapiens nerve growth factor receptor (TNFRSF16)
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens chromosome 11 open reading frame 75
Homo sapiens WD repeat domain 54 (WDR54), mRNA.
Homo sapiens cornichon homolog 4 (Drosophila)
Homo sapiens lymphocyte antigen 9 (LY9), transcript
Homo sapiens RAB20, member RAS oncogene family
Homo sapiens suppressor of cytokine signaling 1
Homo sapiens procollagen-lysine, 2-oxoglutarate 5-
Homo sapiens BMP2 inducible kinase (BMP2K),
Homo sapiens integrin, beta 3 (platelet glycoprotein IIIa,
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens exportin 4 (XPO4), mRNA.
Homo sapiens Fc receptor-like 3 (FCRL3), mRNA.
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens histone cluster 2, H2aa4 (HIST2H2AA4),
Homo sapiens CD79a molecule, immunoglobulin-
Homo sapiens transmembrane protein 158 (TMEM158),
Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA.
Homo sapiens transforming growth factor beta regulator 4
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens sestrin 1 (SESN1), mRNA.
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens interferon-induced protein with
Homo sapiens interferon-induced protein with
Homo sapiens ropporin 1-like (ROPN1L), mRNA.
Homo sapiens tetratricopeptide repeat domain 27 (TTC27),
Homo sapiens phosphatidylglycerophosphate synthase 1
Homo sapiens protease, serine, 23 (PRSS23), mRNA.
Homo sapiens junctional adhesion molecule 3 (JAM3),
Homo sapiens D site of albumin promoter (albumin D-
Homo sapiens golgi associated, gamma adaptin ear
Homo sapiens alpha-kinase 1 (ALPK1), mRNA.
Homo sapiens COBL-like 1 (COBLL1), mRNA.
Homo sapiens ATP-grasp domain containing 1
Homo sapiens triggering receptor expressed on myeloid
Homo sapiens tRNA splicing endonuclease 54 homolog
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens protein S (alpha) (PROS1), mRNA.
Homo sapiens caldesmon 1 (CALD1), transcript variant 3,
Homo sapiens CD40 ligand (CD4OLG), mRNA.
Homo sapiens histone cluster 1, H3d (HIST1H3D),
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens solute carrier family 25 (mitochondrial
Homo sapiens deltex 3-like (Drosophila) (DTX3L),
Homo sapiens docking protein 3 (DOK3), mRNA.
Homo sapiens family with sequence similarity 160,
Homo sapiens sulfotransferase family, cytosolic, 1B,
Homo sapiens adrenomedullin (ADM), mRNA.
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens multimerin 1 (MMRN1), mRNA.
Homo sapiens glycogenin 1 (GYG1), mRNA.
Homo sapiens epoxide hydrolase 2, cytoplasmic (EPHX2),
Homo sapiens WAS protein family, member 3 (WASF3),
Homo sapiens actin binding LIM protein family, member 3
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens prepronociceptin (PNOC), mRNA.
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens epidermal growth factor (beta-urogastrone)
Homo sapiens pyrin and HIN domain family, member 1
Homo sapiens ST3 beta-galactoside alpha-2,3-
Homo sapiens transmembrane protein 19 (TMEM19),
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens family with sequence similarity 26, member
Homo sapiens Fc receptor-like A (FCRLA), mRNA.
Homo sapiens caspase 7, apoptosis-related cysteine
Homo sapiens coagulation factor XIII, A1 polypeptide
Homo sapiens DENN/MADD domain containing 1A
Homo sapiens Spi-B transcription factor (Spi-1/PU.1
Homo sapiens MAX interactor 1 (MXI1), transcript
Homo sapiens PDZ domain containing 4 (PDZD4),
Homo sapiens CD274 molecule (CD274), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 2,
Homo sapiens Janus kinase 2 (a protein tyrosine kinase)
Homo sapiens homer homolog 2 (Drosophila) (HOMER2),
Homo sapiens carbonic anhydrase IV (CA4), mRNA.
Homo sapiens interferon induced transmembrane protein 3
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens signal transducer and activator of
Homo sapiens signal transducer and activator of
Homo sapiens olfactory receptor, family 2, subfamily AG,
Homo sapiens cDNA: FLJ21199 fis, clone COL00235
Homo sapiens leucine-rich alpha-2-glycoprotein 1
Homo sapiens thymidine phosphorylase (TYMP),
Homo sapiens septin 5 (SEPT5), mRNA.
Homo sapiens histone cluster 1, H2be (HIST1H2BE),
Homo sapiens multiple C2 domains, transmembrane 2
Homo sapiens aquaporin 10 (AQP10), mRNA.
Homo sapiens WD repeat and SOCS box-containing 1
Homo sapiens cadherin 6, type 2, K-cadherin (fetal kidney)
Homo sapiens histone cluster 2, H2ac (HIST2H2AC),
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens Fas apoptotic inhibitory molecule 3
Homo sapiens transmembrane protein 194A
Homo sapiens SCO cytochrome oxidase deficient homolog
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens SLAM family member 6 (SLAMF6),
Homo sapiens outer dense fiber of sperm tails 3B
Homo sapiens CD151 molecule (Raph blood group)
Homo sapiens purinergic receptor P2Y, G-protein coupled,
Homo sapiens interleukin 18 receptor accessory protein
Homo sapiens BR serine/threonine kinase 1 (BRSK1),
Homo sapiens oxysterol binding protein-like 10
Homo sapiens sphingosine-1-phosphate receptor 5
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens Rho-related BTB domain containing 1
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens signal transducer and activator of
Homo sapiens WNK lysine deficient protein kinase 1
Homo sapiens CLR pseudogene (LOC374443), non-
Homo sapiens integrin, beta 5 (ITGB5), mRNA.
Homo sapiens integrin, beta 5 (ITGB5), mRNA.
Homo sapiens integrin, beta 5 (ITGB5), mRNA.
Homo sapiens Fc fragment of IgG, high affinity Ia,
Homo sapiens interferon-induced protein 44 (IFI44),
Homo sapiens lymphocyte-specific protein tyrosine kinase
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens methylenetetrahydrofolate dehydrogenase
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens microRNA 21 (MIR21), microRNA.
Homo sapiens HOP homeobox (HOPX), transcript variant
Homo sapiens C-type lectin domain family 1, member B
Homo sapiens praja ring finger 1 (PJA1), transcript variant
Homo sapiens caspase recruitment domain family, member
Homo sapiens SP140 nuclear body protein (SP140),
Homo sapiens F-box and leucine-rich repeat protein 16
Homo sapiens zeta-chain (TCR) associated protein kinase
Homo sapiens scavenger receptor class F, member 1
Homo sapiens fatty acid synthase (FASN), mRNA.
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens septin 4 (SEPT4), transcript variant 3,
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens matrix metallopeptidase 9 (gelatinase B,
Homo sapiens transporter 2, ATP-binding cassette, sub-
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens interferon-induced protein with
Homo sapiens galactose mutarotase (aldose 1-epimerase)
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens microtubule-associated protein 7 (MAP7),
Homo sapiens guanylate binding protein 4 (GBP4),
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha
Homo sapiens proteasomal ATPase-associated factor 1
Homo sapiens G protein-coupled receptor 68 (GPR68),
Homo sapiens interferon induced with helicase C domain 1
Homo sapiens proline rich Gla (G-carboxyglutamic acid) 4
Homo sapiens adaptor-related protein complex 3, mu 2
Homo sapiens BTB and CNC homology 1, basic leucine
Homo sapiens chromosome 9 open reading frame 123
Homo sapiens GRAM domain containing 1B
Homo sapiens chemokine (C-C motif) receptor 6 (CCR6),
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens phospholipase C, gamma 1 (PLCG1),
Homo sapiens endothelial cell adhesion molecule (ESAM),
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens carbonic anhydrase VB, mitochondrial
Homo sapiens ArfGAP with SH3 domain, ankyrin repeat
Homo sapiens complement component 1, q subcomponent,
Homo sapiens CD3e molecule, epsilon (CD3-TCR
Homo sapiens membrane-spanning 4-domains, subfamily
Homo sapiens solute carrier family 26, member 8
Homo sapiens nephroblastoma overexpressed gene
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
Homo sapiens KIAA0319-like (KIAA0319L), transcript
Homo sapiens tripartite motif-containing 22 (TRIM22),
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens neurocalcin delta (NCALD), mRNA.
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens guanylate binding protein 2, interferon-
Homo sapiens insulin-like growth factor 2 mRNA binding
Homo sapiens BEN domain containing 5 (BEND5),
Homo sapiens dysferlin, limb girdle muscular dystrophy
Homo sapiens family with sequence similarity 159,
Homo sapiens transforming growth factor beta 1 induced
Homo sapiens caldesmon 1 (CALD1), transcript variant 5,
Homo sapiens apolipoprotein L, 6 (APOL6), mRNA.
Homo sapiens interferon-induced protein with
Homo sapiens lysophosphatidylcholine acyltransferase 2
Homo sapiens zinc finger protein 654 (ZNF654), mRNA.
Homo sapiens zinc finger protein 17 (ZNF17), mRNA.
Homo sapiens ARP5 actin-related protein 5 homolog
Homo sapiens CTP synthase II (CTPS2), transcript variant
Homo sapiens S100 calcium binding protein A12
Homo sapiens chemokine (C—X—C motif) ligand 10
Homo sapiens sialic acid binding Ig-like lectin 9
Homo sapiens chromosome 22 open reading frame 32
Homo sapiens C-type lectin-like 1 (CLECL1), mRNA.
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens chromosome 20 open reading frame 100
Homo sapiens chromosome 6 open reading frame 190
Homo sapiens endothelial cell growth factor 1 (platelet-
Homo sapiens Fc receptor-like 3 (FCRL3), transcript
Homo sapiens chymotrypsin-like (CTRL), mRNA.
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger
Homo sapiens lysyl oxidase-like 3 (LOXL3), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 1,
Homo sapiens leukotriene B4 receptor (LTB4R), mRNA.
Homo sapiens CD79B antigen (immunoglobulin-
Homo sapiens E74-like factor 2 (ets domain transcription
Homo sapiens platelet endothelial aggregation receptor 1
Homo sapiens maltase-glucoamylase (alpha-glucosidase)
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens annexin A3 (ANXA3), mRNA.
Homo sapiens multiple EGF-like-domains 9 (MEGF9),
Homo sapiens G protein-coupled receptor 27 (GPR27),
Homo sapiens protein tyrosine phosphatase, receptor type,
Homo sapiens free fatty acid receptor 2 (FFAR2), mRNA.
Homo sapiens upstream transcription factor 1 (USF1),
Homo sapiens CD79a molecule, immunoglobulin-
Homo sapiens kelch-like 3 (Drosophila) (KLHL3),
Homo sapiens receptor (chemosensory) transporter protein
Homo sapiens plexin C1 (PLXNC1), mRNA.
Homo sapiens ras homolog gene family, member T1
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens RNA-binding protein (FLJ20273), mRNA.
Homo sapiens spastic ataxia of Charlevoix-Saguenay
Homo sapiens MYC-associated zinc finger protein
Homo sapiens zinc finger family member 783 (ZNF783),
Homo sapiens oncostatin M (OSM), mRNA.
Homo sapiens chromosome 9 open reading frame 66
Homo sapiens thymidine phosphorylase (TYMP),
Homo sapiens TCR gamma alternate reading frame protein
Homo sapiens FERM domain containing 3 (FRMD3),
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens histone cluster 1, H4h (HIST1H4H),
Homo sapiens kelch repeat and BTB (POZ) domain
Homo sapiens guanylate binding protein family, member 6
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens suppressor of cytokine signaling 3
Homo sapiens oligodendrocyte transcription factor 1
Homo sapiens LIM and senescent cell antigen-like
Homo sapiens AF4/FMR2 family, member 1 (AFF1),
Homo sapiens hypothetical protein LOC153561
Homo sapiens selectin P ligand (SELPLG), mRNA.
Homo sapiens complement component (3d/Epstein Barr
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens aspartate beta-hydroxylase domain
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens histone cluster 2, H3c (HIST2H3C),
Homo sapiens tumor necrosis factor, alpha-induced protein
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens glucuronidase, beta pseudogene
Homo sapiens CD177 molecule (CD177), mRNA.
Homo sapiens hypothetical gene supported by AK126539
Homo sapiens epithelial stromal interaction 1 (breast)
Homo sapiens WD repeat and FYVE domain containing
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens TBC1 domain family, member 24
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens cathelicidin antimicrobial peptide
Homo sapiens proline-serine-threonine phosphatase
Homo sapiens vesicle-associated membrane protein 5
Homo sapiens Fc fragment of IgG, high affinity Ic,
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens histone cluster 2, H2bf (HIST2H2BF),
Homo sapiens guanylate binding protein 5 (GBP5),
Homo sapiens bone marrow stromal cell antigen 1
Homo sapiens complement component 5 (C5), mRNA.
Homo sapiens ets variant 7 (ETV7), mRNA.
Homo sapiens pregnancy specific beta-1-glycoprotein 3
Homo sapiens chromosome 10 open reading frame 33
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens interleukin 15 (IL15), transcript variant 1,
Homo sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo sapiens vanin 2 (VNN2), transcript variant 1,
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens colony stimulating factor 2 receptor, beta,
Homo sapiens G protein-coupled receptor 109B
Homo sapiens prokineticin 2 (PROK2), mRNA.
Homo sapiens fucosyltransferase 7 (alpha (1,3)
Homo sapiens prostaglandin-endoperoxide synthase 1
Homo sapiens dual specificity phosphatase 3 (vaccinia
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens TAP binding protein (tapasin) (TAPBP),
Homo sapiens serpin peptidase inhibitor, clade G (C1
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens selectin P (granule membrane protein
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens multiple C2 domains, transmembrane 1
Homo sapiens acetyl-Coenzyme A carboxylase beta
Homo sapiens cholesteryl ester transfer protein, plasma
Homo sapiens G protein-coupled receptor 109A
Homo sapiens interferon-induced protein 35 (IFI35),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens formyl peptide receptor 2 (FPR2),
Homo sapiens kringle containing transmembrane protein
Homo sapiens kringle containing transmembrane protein
Homo sapiens vanin 1 (VNN1), mRNA.
Homo sapiens Kruppel-like factor 3 (basic) (KLF3),
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens F-box protein 6 (FBXO6), mRNA.
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens solute carrier family 6 (neurotransmitter
Homo sapiens calcium channel, voltage-dependent, L
Homo sapiens Src-like-adaptor (SLA), transcript variant
Homo sapiens dedicator of cytokinesis 5 (DOCK5),
Homo sapiens cAMP responsive element binding protein
Homo sapiens basic leucine zipper transcription factor,
Homo sapiens toll-like receptor 6 (TLR6), mRNA.
Homo sapiens solute carrier family 2 (facilitated glucose
Homo sapiens C-type lectin domain family 4, member D
Homo sapiens pre-B lymphocyte gene 3 (VPREB3),
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens signal-induced proliferation-associated 1
Homo sapiens transglutaminase 2 (C polypeptide,
Homo sapiens lamin B1 (LMNB1), mRNA.
Homo sapiens cytoplasmic polyadenylation element
sapiens cDNA clone IMAGE: 30405414 5, mRNA
Homo sapiens haptoglobin (HP), mRNA.
Homo sapiens zinc finger protein 438 (ZNF438), mRNA.
Homo sapiens G protein-coupled receptor 177 (GPR177),
Homo sapiens chromosome 6 open reading frame 25
Homo sapiens caspase 4, apoptosis-related cysteine
Homo sapiens solute carrier family 22 (organic
Homo sapiens toll-like receptor 2 (TLR2), mRNA.
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens arginase, liver (ARG1), mRNA.
Homo sapiens sulfotransferase family, cytosolic, 1A,
Homo sapiens STEAP family member 4 (STEAP4),
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens MANSC domain containing 1 (MANSC1),
Homo sapiens lin-7 homolog A (C. elegans) (LIN7A),
Homo sapiens sterile alpha motif and leucine zipper
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens Rho GTPase activating protein 25
Homo sapiens serpin peptidase inhibitor, clade A (alpha-1
Homo sapiens similar to Interferon-induced guanylate-
Homo sapiens caveolin 2 (CAV2), transcript variant 1,
Homo sapiens caveolin 2 (CAV2), transcript variant 1,
Homo sapiens GPRIN family member 3 (GPRIN3),
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens RAP1 GTPase activating protein
Homo sapiens NLR family, CARD domain containing 4
Homo sapiens caspase 5, apoptosis-related cysteine
Homo sapiens chemokine (C-C motif) receptor 2 (CCR2),
Homo sapiens chemokine (C-C motif) receptor 2 (CCR2),
Homo sapiens chromosome 16 open reading frame 7
Homo sapiens fasciculation and elongation protein zeta 1
Homo sapiens cystathionine-beta-synthase (CBS),
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens interleukin 1, beta (IL1B), mRNA.
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens platelet-derived growth factor alpha
Homo sapiens netrin 3 (NTN3), mRNA.
Homo sapiens complement component 1, q
Homo sapiens X-linked Kx blood group (McLeod
Homo sapiens poliovirus receptor-related 2 (herpesvirus
Homo sapiens CD36 molecule (thrombospondin receptor)
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens spectrin, beta, erythrocytic (SPTB),
Homo sapiens androgen-induced 1 (AIG1), mRNA.
Homo sapiens hypothetical protein LOC152195
Homo sapiens adenylate cyclase 3 (ADCY3), mRNA.
Homo sapiens toll-like receptor 5 (TLR5), mRNA.
Homo sapiens nuclear factor of activated T-cells,
Homo sapiens nicotinamide phosphoribosyltransferase
Homo sapiens nicotinamide phosphoribosyltransferase
Homo sapiens tetratricopeptide repeat domain 35
Homo sapiens caspase recruitment domain family,
Homo sapiens caspase recruitment domain family,
Homo sapiens male-specific lethal 3-like 1 (Drosophila)
Homo sapiens lipoma HMGIC fusion partner-like 2
Homo sapiens cell division cycle 42 (GTP binding
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens TRAF-interacting protein with forkhead-
Homo sapiens cytochrome P450, family 4, subfamily F,
Homo sapiens chromosome 19 open reading frame 59
Homo sapiens CDK5 regulatory subunit associated
Homo sapiens phospholipid scramblase 1 (PLSCR1),
Homo sapiens DKFZp761E198 protein
Homo sapiens sterile alpha motif domain containing 14
Homo sapiens ankyrin 1, erythrocytic (ANK1), transcript
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens CD151 molecule (Raph blood group)
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens acyl-CoA synthetase long-chain family
Homo sapiens sorting nexin 20 (SNX20), mRNA.
Homo sapiens coagulation factor II (thrombin) receptor-
Homo sapiens interleukin 1 receptor antagonist (IL1RN),
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens XIAP associated factor 1 (XAF1),
Homo sapiens methionine sulfoxide reductase B2
Homo sapiens FYN binding protein (FYB-120/130)
Homo sapiens translocase of inner mitochondrial
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens sialic acid binding Ig-like lectin 14
Homo sapiens natural cytotoxicity triggering receptor 3
Homo sapiens interferon-induced protein with
Homo sapiens heat shock 70 kDa protein 6 (HSP70B′)
Homo sapiens histone cluster 2, H2ab (HIST2H2AB),
Homo sapiens phosphoinositide-3-kinase, regulatory
Homo sapiens cAMP responsive element binding protein
Homo sapiens C-type lectin domain family 7, member A
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens chromosome 20 open reading frame 196
Homo sapiens myosin, light chain 9, regulatory (MYL9),
Homo sapiens interferon, alpha-inducible protein 6
Homo sapiens 2′,5′-oligoadenylate synthetase 1,
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens 5-oxoprolinase (ATP-hydrolysing)
Homo sapiens brain expressed, X-linked 1 (BEX1),
Homo sapiens chromosome 11 open reading frame 75
Homo sapiens RAB20, member RAS oncogene family
Homo sapiens procollagen-lysine, 2-oxoglutarate 5-
Homo sapiens BMP2 inducible kinase (BMP2K),
Homo sapiens integrin, beta 3 (platelet glycoprotein IIIa,
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens Rho guanine nucleotide exchange factor
Homo sapiens transmembrane protein 158 (TMEM158),
Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA.
Homo sapiens glycophorin B (MNS blood group)
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens interferon-induced protein with
Homo sapiens interferon-induced protein with
Homo sapiens ropporin 1-like (ROPN1L), mRNA.
Homo sapiens G protein-coupled receptor 141 (GPR141),
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens caldesmon 1 (CALD1), transcript variant
Homo sapiens AF4/FMR2 family, member 1 (AFF1),
Homo sapiens histone cluster 1, H3d (HIST1H3D),
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens deltex 3-like (Drosophila) (DTX3L),
Homo sapiens docking protein 3 (DOK3), mRNA.
Homo sapiens sulfotransferase family, cytosolic, 1B,
Homo sapiens adrenomedullin (ADM), mRNA.
Homo sapiens benzodiazapine receptor (peripheral)
sapiens cDNA clone IMAGE: 3082558 3, mRNA
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens peptidyl arginine deiminase, type II
Homo sapiens WAS protein family, member 3 (WASF3),
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens ring finger protein 149 (RNF149), mRNA.
Homo sapiens spermatid perinuclear RNA binding
Homo sapiens ST3 beta-galactoside alpha-2,3-
Homo sapiens family with sequence similarity 26,
Homo sapiens chromosome 9 open reading frame 40
Homo sapiens eyes shut homolog (Drosophila) (EYS),
Homo sapiens chromosome 3 open reading frame 23
Homo sapiens CD274 molecule (CD274), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 2,
Homo sapiens carbonic anhydrase IV (CA4), mRNA.
Homo sapiens interferon induced transmembrane protein
Homo sapiens membrane metallo-endopeptidase (MME),
Homo sapiens signal transducer and activator of
Homo sapiens cDNA: FLJ21199 fis, clone COL00235
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens protein phosphatase 1, regulatory
Homo sapiens interferon-induced protein 44-like
Homo sapiens leucine-rich alpha-2-glycoprotein 1
Homo sapiens multiple C2 domains, transmembrane 2
Homo sapiens WD repeat and SOCS box-containing 1
Homo sapiens cadherin 6, type 2, K-cadherin (fetal
Homo sapiens chromosome 4 open reading frame 23
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens Fc fragment of IgE, low affinity II,
Homo sapiens SCO cytochrome oxidase deficient
Homo sapiens G protein-coupled receptor 44 (GPR44),
Homo sapiens tudor domain containing 9 (TDRD9),
Homo sapiens tudor domain containing 9 (TDRD9),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens interleukin 18 receptor accessory protein
Homo sapiens BR serine/threonine kinase 1 (BRSK1),
Homo sapiens oxysterol binding protein-like 10
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens Fc fragment of IgG, high affinity Ia,
Homo sapiens interferon-induced protein 44 (IFI44),
Homo sapiens toll-like receptor 4 (TLR4), mRNA.
Homo sapiens desmocollin 2 (DSC2), transcript variant
Homo sapiens phosphatidylinositol binding clathrin
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens microRNA 21 (MIR21), microRNA.
Homo sapiens caspase recruitment domain family,
Homo sapiens caspase recruitment domain family,
Homo sapiens SP140 nuclear body protein (SP140),
Homo sapiens chemokine (C-C motif) receptor-like 2
Homo sapiens interferon, alpha-inducible protein 27
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens septin 4 (SEPT4), transcript variant 3,
Homo sapiens matrix metallopeptidase 9 (gelatinase B,
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens huntingtin interacting protein 1 related
Homo sapiens B-cell CLL/lymphoma 10 (BCL10),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens transmembrane protein 150B
Homo sapiens G protein-coupled receptor 68 (GPR68),
Homo sapiens proline rich Gla (G-carboxyglutamic acid)
Homo sapiens GRAM domain containing 1B
Homo sapiens phospholipase C, gamma 1 (PLCG1),
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens CD84 molecule (CD84), mRNA.
Homo sapiens complement component 1, q
Homo sapiens solute carrier family 26, member 8
Homo sapiens elongation factor, RNA polymerase II, 2
Homo sapiens polyhomeotic-like 2 (Drosophila) (PHC2),
Homo sapiens insulin-like growth factor 2 mRNA
Homo sapiens dysferlin, limb girdle muscular dystrophy
Homo sapiens G0/G1switch 2 (G0S2), mRNA.
Homo sapiens transforming growth factor beta 1 induced
Homo sapiens caldesmon 1 (CALD1), transcript variant
Homo sapiens DNAJC25-GNG10 readthrough
Homo sapiens desmocollin 2 (DSC2), transcript variant
Homo sapiens apolipoprotein L, 6 (APOL6), mRNA.
Homo sapiens interferon-induced protein with
Homo sapiens lysophosphatidylcholine acyltransferase 2
Homo sapiens S100 calcium binding protein A12
Homo sapiens chemokine (C—X—C motif) ligand 10
Homo sapiens C-type lectin-like 1 (CLECL1), mRNA.
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger
Homo sapiens glycerol kinase (GK), transcript variant 1,
Homo sapiens retbindin (RTBDN), transcript variant 2,
Homo sapiens solute carrier family 22 (organic
Homo sapiens insulin-like 3 (Leydig cell) (INSL3),
Homo sapiens E74-like factor 2 (ets domain transcription
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens annexin A3 (ANXA3), mRNA.
Homo sapiens multiple EGF-like-domains 9 (MEGF9),
Homo sapiens G protein-coupled receptor 27 (GPR27),
Homo sapiens free fatty acid receptor 2 (FFAR2),
Homo sapiens upstream transcription factor 1 (USF1),
Homo sapiens extracellular matrix protein 1 (ECM1),
Homo sapiens receptor (chemosensory) transporter
Homo sapiens ras homolog gene family, member T1
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens SUMO1 pseudogene 1 (SUMO1P1) on
Homo sapiens spastic ataxia of Charlevoix-Saguenay
Homo sapiens chromosome 9 open reading frame 72
Homo sapiens MYC-associated zinc finger protein
Homo sapiens calpain 12 (CAPN12), mRNA.
Homo sapiens radial spoke head 9 homolog
Homo sapiens oncostatin M (OSM), mRNA.
Homo sapiens coagulation factor V (proaccelerin, labile
Homo sapiens histone cluster 1, H4h (HIST1H4H),
Homo sapiens guanylate binding protein family, member
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens suppressor of cytokine signaling 3
Homo sapiens chromosome 11 open reading frame 80
Homo sapiens hypothetical protein LOC153561
Homo sapiens cDNA FLJ12777 fis, clone
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens aspartate beta-hydroxylase domain
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens tumor necrosis factor, alpha-induced
Homo sapiens seryl-tRNA synthetase 2, mitochondrial
Homo sapiens ectonucleoside triphosphate
Homo sapiens exoribonuclease 1 (ERI1), mRNA.
Homo sapiens chemokine (C—X—C motif) receptor 3
Homo sapiens kelch domain containing 8B (KLHDC8B),
Homo sapiens monoglyceride lipase (MGLL), transcript
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens pregnancy specific beta-1-glycoprotein 9
Homo sapiens cDNA: FLJ22140 fis, clone HEP20977
Homo sapiens glucuronidase, beta pseudogene
Homo sapiens hypothetical gene supported by AK126539
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens suppressor of cytokine signaling 3
Homo sapiens transmembrane protein 88 (TMEM88),
Homo sapiens epithelial stromal interaction 1 (breast)
Homo sapiens chemokine (C—X—C motif) receptor 6
Homo sapiens complement component 2 (C2), mRNA.
Homo sapiens serologically defined colon cancer antigen
Homo sapiens alkaline phosphatase, liver/bone/kidney
Homo sapiens WD repeat and FYVE domain containing
Homo sapiens tissue factor pathway inhibitor
Homo sapiens tissue factor pathway inhibitor
Homo sapiens G protein-coupled receptor 84 (GPR84),
Homo sapiens interleukin 28 receptor, alpha (interferon,
Homo sapiens tRNA methyltransferase 11 homolog (S. cerevisiae)
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens Fc fragment of IgE, high affinity I,
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens NOP2 nucleolar protein homolog (yeast)
Homo sapiens NOP2 nucleolar protein homolog (yeast)
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens cathelicidin antimicrobial peptide
Homo sapiens proline-serine-threonine phosphatase
Homo sapiens cytidine monophosphate (UMP-CMP)
Homo sapiens chromosome 19 open reading frame 48
Homo sapiens vesicle-associated membrane protein 5
Homo sapiens engulfment and cell motility 2 (ELMO2),
Homo sapiens SMAD family member 7 (SMAD7),
Homo sapiens Fc fragment of IgG, high affinity Ic,
Homo sapiens CD79b molecule, immunoglobulin-
Homo sapiens coiled-coil domain containing 65
Homo sapiens reversion-inducing-cysteine-rich protein
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens MOB1, Mps One Binder kinase activator-
Homo sapiens nucleolar complex associated 3 homolog
Homo sapiens Fc fragment of IgG binding protein
Homo sapiens histone cluster 2, H2bf (HIST2H2BF),
Homo sapiens melanoma antigen family D, 1
Homo sapiens guanylate binding protein 5 (GBP5),
Homo sapiens complement component 5 (C5), mRNA.
Homo sapiens SEC14 and spectrin domains 1 (SESTD1),
Homo sapiens ets variant 7 (ETV7), mRNA.
Homo sapiens pregnancy specific beta-1-glycoprotein 3
Homo sapiens ilvB (bacterial acetolactate synthase)-like
Homo sapiens granulysin (GNLY), transcript variant
Homo sapiens chromosome 10 open reading frame 33
Homo sapiens selenoprotein M (SELM), mRNA.
Homo sapiens interferon regulatory factor 1 (IRF1),
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens Fc fragment of IgG, low affinity IIIa,
Homo sapiens ecotropic viral integration site 2A
Homo sapiens abhydrolase domain containing 14B
Homo sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo sapiens RAB6B, member RAS oncogene family
Homo sapiens dual adaptor of phosphotyrosine and 3-
Homo sapiens mitogen-activated protein kinase kinase 5
sapiens cDNA clone IMAGE: 1387877 3, mRNA
Homo sapiens cell division cycle associated 7-like
Homo sapiens interleukin 15 (IL15), transcript variant 1,
Homo sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo sapiens immediate early response 3 (IER3),
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens mitochondrial ribosomal protein L2
Homo sapiens colony stimulating factor 2 receptor, beta,
Homo sapiens G protein-coupled receptor 109B
Homo sapiens aspartic peptidase, retroviral-like 1
Homo sapiens histone cluster 2, H4b (HIST2H4B),
Homo sapiens DnaJ (Hsp40) homolog, subfamily C,
Homo sapiens abhydrolase domain containing 2
Homo sapiens nth endonuclease III-like 1 (E. coli)
Homo sapiens zinc finger protein 82 homolog (mouse)
Homo sapiens fucosyltransferase 7 (alpha (1,3)
Homo sapiens dual specificity phosphatase 3 (vaccinia
Homo sapiens 5′-nucleotidase, ecto (CD73) (NT5E),
Homo sapiens SLAM family member 8 (SLAMF8),
Homo sapiens endothelin converting enzyme 1 (ECE1),
Homo sapiens inhibitor of DNA binding 3, dominant
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens TAP binding protein (tapasin) (TAPBP),
Homo sapiens WD repeat domain 5 (WDR5), transcript
Homo sapiens potassium voltage-gated channel, Shal-
Homo sapiens serpin peptidase inhibitor, clade G (C1
Homo sapiens hypothetical LOC100129637
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens small Cajal body-specific RNA 3
Homo sapiens tetraspanin 9 (TSPAN9), mRNA.
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens paroxysmal nonkinesiogenic dyskinesia
Homo sapiens chromosome 15 open reading frame 54
Homo sapiens zinc finger protein 540 (ZNF540), mRNA.
Homo sapiens opiate receptor-like 1 (OPRL1), transcript
Homo sapiens granulysin (GNLY), transcript variant 519,
Homo sapiens GRIP1 associated protein 1 (GRIPAP1),
Homo sapiens WD repeat domain 36 (WDR36), mRNA.
Homo sapiens 3-oxoacyl-ACP synthase, mitochondrial
Homo sapiens selectin P (granule membrane protein
Homo sapiens mediator complex subunit 24 (MED24),
Homo sapiens chitinase 3-like 2 (CHI3L2), transcript
Homo sapiens EPH receptor A1 (EPHA1), mRNA.
Homo sapiens chromodomain helicase DNA binding
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens cDNA FLJ41846 fis, clone
Homo sapiens ankyrin repeat domain 9 (ANKRD9),
Homo sapiens nucleotide-binding oligomerization
Homo sapiens multiple C2 domains, transmembrane 1
Homo sapiens B-cell scaffold protein with ankyrin
Homo sapiens acetyl-Coenzyme A carboxylase beta
Homo sapiens zinc finger protein 30 (ZNF30), transcript
Homo sapiens son of sevenless homolog 1 (Drosophila)
Homo sapiens YTH domain containing 2 (YTHDC2),
Homo sapiens synaptotagmin-like 4 (granuphilin-a)
Homo sapiens sterile alpha motif domain containing 3
Homo sapiens sterile alpha motif domain containing 3
Homo sapiens myoferlin (MYOF), transcript variant 1,
Homo sapiens nuclear factor of activated T-cells 5,
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens Fc fragment of IgG, low affinity IIIb,
Homo sapiens zinc finger protein 329 (ZNF329), mRNA.
Homo sapiens calcium/calmodulin-dependent protein
Homo sapiens cholesteryl ester transfer protein, plasma
Homo sapiens chemokine (C—X—C motif) receptor 7
Homo sapiens ubiquitin associated and SH3 domain
Homo sapiens tropomyosin 1 (alpha) (TPM1), transcript
Homo sapiens transcriptional adaptor 1 (HFI1 homolog,
Homo sapiens interferon induced transmembrane protein
Homo sapiens G protein-coupled receptor 109A
Homo sapiens CD244 molecule, natural killer cell
Homo sapiens programmed cell death 2-like (PDCD2L),
Homo sapiens interferon-induced protein 35 (IFI35),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens interferon regulatory factor 7 (IRF7),
Homo sapiens formyl peptide receptor 2 (FPR2),
Homo sapiens kringle containing transmembrane protein
Homo sapiens kringle containing transmembrane protein
Homo sapiens vanin 1 (VNN1), mRNA.
Homo sapiens SWI/SNF-related, matrix-associated actin-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens guanylate binding protein 1, interferon-
Homo sapiens ubiquitin-conjugating enzyme E2C
Homo sapiens defensin, alpha 4, corticostatin (DEFA4),
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens germinal center expressed transcript 2
Homo sapiens hypothetical LOC644873 (FLJ33630),
Homo sapiens F-box protein 6 (FBXO6), mRNA.
Homo sapiens lactamase, beta (LACTB), nuclear gene
Homo sapiens interleukin 18 receptor 1 (IL18R1),
sapiens cDNA clone IMAGE: 2726592 3, mRNA
Homo sapiens RNA binding motif protein 15B
Homo sapiens zinc finger protein 337 (ZNF337), mRNA.
Homo sapiens AF4/FMR2 family, member 3 (AFF3),
Homo sapiens CTP synthase (CTPS), mRNA.
Homo sapiens Kruppel-like factor 12 (KLF12), mRNA.
Homo sapiens cDNA FLJ31407 fis, clone
Homo sapiens neurocalcin delta (NCALD), transcript
Homo sapiens Src-like-adaptor (SLA), transcript variant
Homo sapiens dedicator of cytokinesis 5 (DOCK5),
Homo sapiens TRAF-type zinc finger domain containing
Homo sapiens HCC-related HCC-C11_v3
Homo sapiens hypothetical protein MGC52282
Homo sapiens C-type lectin domain family 5, member A
Homo sapiens BCR downstream signaling 1 (BRDG1),
Homo sapiens polycomb group ring finger 5 (PCGF5),
Homo sapiens WD repeat domain 92 (WDR92), mRNA.
Homo sapiens cAMP responsive element binding protein
Homo sapiens activating transcription factor 7 interacting
Homo sapiens lectin, galactoside-binding, soluble, 9
Homo sapiens basic leucine zipper transcription factor,
Homo sapiens chibby homolog 1 (Drosophila) (CBY1),
Homo sapiens solute carrier family 2 (facilitated glucose
Homo sapiens C-type lectin domain family 4, member D
Homo sapiens calcium channel, voltage-dependent, R
Homo sapiens tribbles homolog 2 (Drosophila) (TRIB2),
Homo sapiens pre-B lymphocyte gene 3 (VPREB3),
Homo sapiens septin 1 (SEPT1), mRNA. XM_944608
Homo sapiens multiple EGF-like-domains 6 (MEGF6),
Homo sapiens phosphoribosylformylglycinamidine
Homo sapiens CD320 molecule (CD320), mRNA.
Homo sapiens RIO kinase 1 (yeast) (RIOK1), transcript
Homo sapiens axin 2 (conductin, axil) (AXIN2), mRNA.
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
Homo sapiens caspase recruitment domain family,
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens secreted protein, acidic, cysteine-rich
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens seven in absentia homolog 2 (Drosophila)
Homo sapiens dimethylarginine dimethylaminohydrolase
Homo sapiens peroxisomal proliferator-activated receptor
Homo sapiens Rh blood group, CcEe antigens (RHCE),
Homo sapiens protein phosphatase 2 (formerly 2A),
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo sapiens lipocalin 2 (LCN2), mRNA.
Homo sapiens bromodomain adjacent to zinc finger
Homo sapiens nuclear receptor subfamily 1, group I,
Homo sapiens up-regulated gene 4 (URG4), nuclear gene
Homo sapiens coiled-coil domain containing 132
Homo sapiens methionyl-tRNA synthetase 2,
Homo sapiens (human)
Homo sapiens signal-induced proliferation-associated 1
Homo sapiens lemur tyrosine kinase 2 (LMTK2), mRNA.
Homo sapiens histone cluster 1, H4e (HIST1H4E),
Homo sapiens protein tyrosine phosphatase, receptor
Homo sapiens elastase, neutrophil expressed (ELANE),
Homo sapiens cathepsin A (CTSA), transcript variant 1,
Homo sapiens transglutaminase 2 (C polypeptide,
Homo sapiens chemokine (C-C motif) ligand 4-like 2
Homo sapiens coiled-coil domain containing 58
Homo sapiens feline leukemia virus subgroup C cellular
Homo sapiens EPH receptor B6 (EPHB6), mRNA.
Homo sapiens lamin B1 (LMNB1), mRNA.
Homo sapiens mitogen-activated protein kinase kinase
Homo sapiens proteasome (prosome, macropain) subunit,
Homo sapiens activating transcription factor 3 (ATF3),
Homo sapiens CD5 molecule (CD5), mRNA.
Homo sapiens synaptotagmin-like 2 (SYTL2), transcript
Homo sapiens H2A histone family, member J (H2AFJ),
Homo sapiens haptoglobin (HP), mRNA.
Homo sapiens protein phosphatase 1, regulatory
Homo sapiens histone cluster 1, H2bk (HIST1H2BK),
Homo sapiens histone cluster 1, H2bk (HIST1H2BK),
Homo sapiens transmembrane protein 140 (TMEM140),
Homo sapiens sorbin and SH3 domain containing 3
Homo sapiens RAB13, member RAS oncogene family
Homo sapiens B lymphoid tyrosine kinase (BLK),
Homo sapiens CD160 molecule (CD160), mRNA.
Homo sapiens plexin A4 (PLXNA4), transcript variant 2,
Homo sapiens CD19 molecule (CD19), mRNA.
Homo sapiens zinc finger protein 438 (ZNF438), mRNA.
Homo sapiens G protein-coupled receptor 177 (GPR177),
Homo sapiens chromosome 3 open reading frame 17
Homo sapiens chromosome 6 open reading frame 25
Homo sapiens solute carrier family 22 (organic
Homo sapiens polyhomeotic homolog 1 (Drosophila)
Homo sapiens actin, alpha 2, smooth muscle, aorta
Homo sapiens KIAA1632 (KIAA1632), mRNA.
Homo sapiens caspase 4, apoptosis-related cysteine
Homo sapiens solute carrier family 22 (organic
Homo sapiens glyoxalase domain containing 4 (GLOD4),
Homo sapiens POU class 2 associating factor 1
Homo sapiens toll-like receptor 2 (TLR2), mRNA.
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens arginase, liver (ARG1), mRNA.
Homo sapiens vanin 3 (VNN3), transcript variant 2,
Homo sapiens ST8 alpha-N-acetyl-neuraminide alpha-
Homo sapiens melanoma antigen family E, 1 (MAGEE1),
Homo sapiens TSPY-like 2 (TSPYL2), mRNA.
Homo sapiens WD repeat and FYVE domain containing
Homo sapiens methionine sulfoxide reductase B3
Homo sapiens centrosomal protein 57 kDa (CEP57),
Homo sapiens guanylate binding protein 3 (GBP3),
Homo sapiens STEAP family member 4 (STEAP4),
Homo sapiens tectonic family member 3 (TCTN3),
Homo sapiens F-box protein 4 (FBXO4), transcript
Homo sapiens GATA binding protein 3 (GATA3),
Homo sapiens superoxide dismutase 2, mitochondrial
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger
Homo sapiens myeloproliferative leukemia virus
Homo sapiens reticulon 2 (RTN2), transcript variant 3,
Homo sapiens adenosine A2b receptor (ADORA2B),
Homo sapiens coiled-coil domain containing 102A
Homo sapiens platelet factor 4 variant 1 (PF4V1),
Homo sapiens killer cell lectin-like receptor subfamily F,
Homo sapiens thrombospondin 1 (THBS1), mRNA.
Homo sapiens phosphorylated adaptor for RNA export
Homo sapiens lin-7 homolog A (C. elegans) (LIN7A),
Homo sapiens sterile alpha motif and leucine zipper
Homo sapiens hypothetical LOC283663 (LOC283663),
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens Rho GTPase activating protein 25
Homo sapiens neighbor of BRCA1 gene 1 (NBR1),
Homo sapiens microtubule associated serine/threonine
Homo sapiens Sfi1 homolog, spindle assembly associated
Homo sapiens serpin peptidase inhibitor, clade A (alpha-1
Homo sapiens immunoglobulin superfamily, member 6
Homo sapiens similar to Interferon-induced guanylate-
Homo sapiens plasminogen-like B1 (PLGLB1), mRNA.
Homo sapiens caveolin 2 (CAV2), transcript variant 1,
Homo sapiens caveolin 2 (CAV2), transcript variant 1,
Homo sapiens GPRIN family member 3 (GPRIN3),
Homo sapiens chromosome 16 open reading frame 30
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens RAP1 GTPase activating protein
Homo sapiens Fc fragment of IgG, low affinity IIc,
Homo sapiens centrosomal protein 78 kDa (CEP78),
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens ubiquinol-cytochrome c reductase complex
Homo sapiens T-cell acute lymphocytic leukemia 1
Homo sapiens kinesin family member 1B (KIF1B),
Homo sapiens ER lipid raft associated 1 (ERLIN1),
Homo sapiens polymerase (DNA directed), alpha 1,
Homo sapiens BMP and activin membrane-bound
Homo sapiens TAR (HIV-1) RNA binding protein 1
Homo sapiens interleukin-1 receptor-associated kinase 3
Homo sapiens LIM domain and actin binding 1 (LIMA1),
Homo sapiens NLR family, CARD domain containing 4
Homo sapiens histone cluster 1, H2bc (HIST1H2BC),
Homo sapiens src kinase associated phosphoprotein 1
Homo sapiens caspase 5, apoptosis-related cysteine
Homo sapiens chemokine (C-C motif) receptor 2 (CCR2),
Homo sapiens GAR1 ribonucleoprotein homolog (yeast)
Homo sapiens UDP-Gal:betaGlcNAc beta 1,4-
Homo sapiens chromosome 16 open reading frame 7
Homo sapiens aldehyde dehydrogenase 18 family,
Homo sapiens cDNA FLJ20182 fis, clone COLF0190
Homo sapiens protein kinase C and casein kinase
Homo sapiens CD28 molecule (CD28), mRNA.
Homo sapiens macrophage receptor with collagenous
Homo sapiens cortactin (CTTN), transcript variant 1,
Homo sapiens cystathionine-beta-synthase (CBS),
Homo sapiens lysosomal protein transmembrane 4 beta
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens potassium large conductance calcium-
Homo sapiens purinergic receptor P2X, ligand-gated ion
Homo sapiens homogentisate 1,2-dioxygenase
Homo sapiens interleukin 1, beta (IL1B), mRNA.
Homo sapiens CTAGE family, member 5 (CTAGE5),
Homo sapiens cyclin B1 interacting protein 1
Homo sapiens neuropilin (NRP) and tolloid (TLL)-like 2
Homo sapiens IQ motif containing B1 (IQCB1),
Homo sapiens complement component 4 binding protein,
Homo sapiens histone cluster 2, H2be (HIST2H2BE),
Homo sapiens absent in melanoma 2 (AIM2), mRNA.
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens methyl CpG binding protein 2 (Rett
Homo sapiens glycerol kinase 5 (putative) (GK5),
Homo sapiens guanylate cyclase 1, soluble, alpha 3
Homo sapiens zinc finger protein 1 homolog (mouse)
Homo sapiens C-type lectin domain family 2, member D
Homo sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NLR family, apoptosis inhibitory protein
Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA.
Homo sapiens SID1 transmembrane family, member 1
Homo sapiens signaling lymphocytic activation molecule
Homo sapiens mitogen-activated protein kinase 14
Homo sapiens cut-like 1, CCAAT displacement protein
Homo sapiens chemokine (C-C motif) receptor 3 (CCR3),
Homo sapiens DNA segment on chromosome 4 (unique)
Homo sapiens glutamate-cysteine ligase, modifier subunit
Homo sapiens nibrin (NBN), transcript variant 2, mRNA.
Homo sapiens B and T lymphocyte associated (BTLA),
Homo sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo sapiens hypothetical LOC25845 (LOC25845),
Homo sapiens CD83 molecule (CD83), transcript variant
Homo sapiens platelet-derived growth factor alpha
Homo sapiens leucine rich repeat neuronal 3 (LRRN3),
Homo sapiens cDNA clone MGC: 13035
Homo sapiens netrin 3 (NTN3), mRNA.
Homo sapiens Z-DNA binding protein 1 (ZBP1), mRNA.
Homo sapiens syntaxin 11 (STX11), mRNA.
Homo sapiens complement component 1, q
Homo sapiens X-linked Kx blood group (McLeod
Homo sapiens zinc finger, MYND-type containing 15
Homo sapiens secreted and transmembrane 1 (SECTM1),
Homo sapiens chemokine (C—X—C motif) receptor 5
Homo sapiens chemokine (C—X—C motif) receptor 5
Homo sapiens Fas (TNF receptor superfamily, member 6)
Homo sapiens transmembrane protein 156 (TMEM156),
Homo sapiens Fc fragment of IgG, high affinity Ib,
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens Epstein-Barr virus induced gene 2
Homo sapiens spectrin, beta, erythrocytic (SPTB),
Homo sapiens androgen-induced 1 (AIG1), mRNA.
Homo sapiens hypothetical protein LOC152195
Homo sapiens adenylate cyclase 3 (ADCY3), mRNA.
Homo sapiens lanosterol synthase (2,3-oxidosqualene-
Homo sapiens toll-like receptor 5 (TLR5), mRNA.
Homo sapiens nuclear factor of activated T-cells,
Homo sapiens nicotinamide phosphoribosyltransferase
Homo sapiens tetratricopeptide repeat domain 35
Homo sapiens granzyme K (granzyme 3; tryptase II)
Homo sapiens caspase recruitment domain family,
Homo sapiens caspase recruitment domain family,
Homo sapiens mitogen-activated protein kinase kinase
Homo sapiens family with sequence similarity 129,
Homo sapiens CD8a molecule (CD8A), transcript variant
sapiens cDNA clone oj15g10 5, mRNA sequence
Homo sapiens acyl-Coenzyme A binding domain
Homo sapiens migration and invasion inhibitory protein
Homo sapiens polymerase (RNA) I polypeptide E, 53 kDa
Homo sapiens chromosome 10 open reading frame 119
Homo sapiens chromosome 17 open reading frame 60
Homo sapiens lipoma HMGIC fusion partner-like 2
Homo sapiens complement component (3b/4b) receptor 1
Homo sapiens kazrin (KIAA1026), transcript variant B,
Homo sapiens family with sequence similarity 102,
Homo sapiens family with sequence similarity 102,
Homo sapiens SET and MYND domain containing 4
Homo sapiens elaC homolog 2 (E. coli) (ELAC2),
Homo sapiens zinc finger protein 680 (ZNF680), mRNA.
Homo sapiens calcium channel, voltage-dependent, alpha
Homo sapiens cell division cycle associated 4 (CDCA4),
Homo sapiens tyrosyl-DNA phosphodiesterase 1 (TDP1),
Homo sapiens chromosome 7 open reading frame 53
Homo sapiens chromodomain helicase DNA binding
Homo sapiens SPOC domain containing 1 (SPOCD1),
Homo sapiens chromatin modifying protein 5 (CHMP5),
Homo sapiens protein phosphatase 1B (formerly 2C),
Homo sapiens hippocampus abundant transcript-like 1
Homo sapiens TRAF-interacting protein with forkhead-
Homo sapiens ADP-ribosylation factor-like 4C (ARL4C),
Homo sapiens T-cell leukemia/lymphoma 1A (TCL1A),
Homo sapiens filamin B, beta (actin binding protein 278)
Homo sapiens EPH receptor A4 (EPHA4), mRNA.
Homo sapiens eukaryotic translation initiation factor 1A,
Homo sapiens killer cell immunoglobulin-like receptor,
Homo sapiens chromosome 19 open reading frame 59
Homo sapiens protein phosphatase 2 (formerly 2A),
Homo sapiens protein phosphatase 2 (formerly 2A),
Homo sapiens CDK5 regulatory subunit associated
Homo sapiens phospholipid scramblase 1 (PLSCR1),
Homo sapiens glycoprotein IX (platelet) (GP9), mRNA.
Homo sapiens ATPase, class II, type 9A (ATP9A),
Homo sapiens survival of motor neuron protein
Homo sapiens zinc finger protein 256 (ZNF256), mRNA.
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens DKFZp761E198 protein
Homo sapiens sterile alpha motif domain containing 14
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens enoyl Coenzyme A hydratase domain
Homo sapiens OCIA domain containing 2 (OCIAD2),
Homo sapiens hypothetical protein LOC90925
Homo sapiens ankyrin 1, erythrocytic (ANK1), transcript
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens poly (ADP-ribose) polymerase family,
Homo sapiens CD151 molecule (Raph blood group)
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens sialic acid binding Ig-like lectin 5
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens leucine-rich repeats and immunoglobulin-
Homo sapiens potassium voltage-gated channel, Isk-
Homo sapiens crystallin, gamma S (CRYGS), mRNA.
Homo sapiens prostaglandin D2 receptor (DP) (PTGDR),
Homo sapiens prostaglandin D2 receptor (DP) (PTGDR),
Homo sapiens acyl-CoA synthetase long-chain family
Homo sapiens sorting nexin 20 (SNX20), mRNA.
Homo sapiens coagulation factor II (thrombin) receptor-
Homo sapiens coagulation factor II (thrombin) receptor-
Homo sapiens milk fat globule-EGF factor 8 protein
Homo sapiens interleukin 4 receptor (IL4R), transcript
Homo sapiens hypothetical protein FLJ33590
Homo sapiens interleukin 1 receptor antagonist (IL1RN),
Homo sapiens 2′-5′-oligoadenylate synthetase 3, 100 kDa
Homo sapiens chromosome 2 open reading frame 18
Homo sapiens putative homeodomain transcription factor
Homo sapiens membrane-spanning 4-domains, subfamily
Homo sapiens potassium inwardly-rectifying channel,
Homo sapiens iduronidase, alpha-L-(IDUA), mRNA.
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens killer cell immunoglobulin-like receptor,
Homo sapiens amyloid beta (A4) precursor protein
Homo sapiens amyloid beta (A4) precursor protein
Homo sapiens ZFP-36 for a zinc finger protein
Homo sapiens cathepsin F (CTSF), mRNA.
Homo sapiens XIAP associated factor 1 (XAF1),
Homo sapiens XIAP associated factor 1 (XAF1),
Homo sapiens zinc finger protein 831 (ZNF831), mRNA.
Homo sapiens zinc finger protein 831 (ZNF831), mRNA.
Homo sapiens methionine sulfoxide reductase B2
Homo sapiens cystatin A (stefin A) (CSTA), mRNA.
Homo sapiens ferrochelatase (protoporphyria) (FECH),
Homo sapiens IKAROS family zinc finger 3 (Aiolos)
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens killer cell lectin-like receptor subfamily B,
Homo sapiens spinster homolog 3 (Drosophila) (SPNS3),
Homo sapiens sphingosine-1-phosphate receptor 1
Homo sapiens FYN binding protein (FYB-120/130)
Homo sapiens crystallin, beta B2 (CRYBB2), mRNA.
Homo sapiens cDNA FLJ34018 fis, clone
Homo sapiens CD79B antigen (immunoglobulin-
Homo sapiens transmembrane protein 14A (TMEM14A),
Homo sapiens family with sequence similarity 84,
Homo sapiens pleiomorphic adenoma gene-like 1
Homo sapiens translocase of inner mitochondrial
Homo sapiens TNF receptor-associated factor 5
Homo sapiens transporter 1, ATP-binding cassette, sub-
Homo sapiens Fc receptor-like 2 (FCRL2), transcript
Homo sapiens Ral GTPase activating protein, alpha
Homo sapiens mitochondrial protein 18 kDa (MTP18),
Homo sapiens chromosome 22 open reading frame 34
Homo sapiens transducin-like enhancer of split 1 (E(sp1)
Homo sapiens BTB and CNC homology 1, basic leucine
Homo sapiens chromosome 7 open reading frame 36
Homo sapiens RALBP1 associated Eps domain
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens apolipoprotein L, 2 (APOL2), transcript
Homo sapiens PAS domain containing serine/threonine
Homo sapiens serine peptidase inhibitor, Kunitz type, 3
Homo sapiens fer-1-like 3, myoferlin (C. elegans)
Homo sapiens heterogeneous nuclear ribonucleoprotein
Homo sapiens natural cytotoxicity triggering receptor 3
Homo sapiens CD8b molecule (CD8B), transcript variant
Homo sapiens heat shock 70 kDa protein 6 (HSP70B′)
Homo sapiens complement component 1, q
Homo sapiens ubiquitin specific peptidase 32 (USP32),
Homo sapiens ubiquitin specific peptidase 32 (USP32),
Homo sapiens formyl peptide receptor 2 (FPR2),
Homo sapiens zinc finger protein 239 (ZNF239),
Homo sapiens apolipoprotein B mRNA editing enzyme,
Homo sapiens acyl-CoA thioesterase 7 (ACOT7),
Homo sapiens histone cluster 2, H2ab (HIST2H2AB),
Homo sapiens secretoglobin, family 3A, member 1
Homo sapiens lymphocyte-activation gene 3 (LAG3),
Homo sapiens CKLF-like MARVEL transmembrane
Homo sapiens chromosome 21 open reading frame 2
Homo sapiens 5′,3′-nucleotidase, mitochondrial (NT5M),
Homo sapiens vaccinia related kinase 1 (VRK1), mRNA.
Homo sapiens cAMP responsive element binding protein
Homo sapiens C-type lectin domain family 7, member A
Homo sapiens Fas (TNF receptor superfamily, member 6)
Homo sapiens metal-regulatory transcription factor 1
Homo sapiens quaking homolog, KH domain RNA
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens chromosome 20 open reading frame 196
Homo sapiens TAF1 RNA polymerase II, TATA box
Homo sapiens caspase 1, apoptosis-related cysteine
Homo sapiens integrin, alpha 6 (ITGA6), transcript
Homo sapiens myosin, light chain 9, regulatory (MYL9),
Homo sapiens myosin, light chain 9, regulatory (MYL9),
Homo sapiens integrin, alpha 2b (platelet glycoprotein IIb
Homo sapiens interferon, alpha-inducible protein 6
Homo sapiens 2′,5′-oligoadenylate synthetase 1,
Homo sapiens 2′,5′-oligoadenylate synthetase 1,
Homo sapiens WD repeat domain 21A (WDR21A),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens sorting nexin 6 (SNX6), transcript variant
Homo sapiens lymphocyte-specific protein tyrosine
Homo sapiens sterile alpha motif domain containing 9-
Homo sapiens nerve growth factor receptor (TNFRSF16)
Homo sapiens nerve growth factor receptor (TNFRSF16)
Homo sapiens GRINL1A complex locus (GCOM1),
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens MIR155 host gene (non-protein coding)
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens 5-oxoprolinase (ATP-hydrolysing)
Homo sapiens ferritin, heavy polypeptide-like 2 (FTHL2)
Homo sapiens chromosome 11 open reading frame 75
Homo sapiens WD repeat domain 54 (WDR54), mRNA.
Homo sapiens cornichon homolog 4 (Drosophila)
Homo sapiens lymphocyte antigen 9 (LY9), transcript
Homo sapiens RAB20, member RAS oncogene family
Homo sapiens suppressor of cytokine signaling 1
Homo sapiens zinc finger protein 571 (ZNF571), mRNA.
Homo sapiens diacylglycerol kinase, alpha 80 kDa
Homo sapiens procollagen-lysine, 2-oxoglutarate 5-
Homo sapiens BMP2 inducible kinase (BMP2K),
Homo sapiens integrin, beta 3 (platelet glycoprotein IIIa,
Homo sapiens v-erb-b2 erythroblastic leukemia viral
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens KIAA0125 (KIAA0125), mRNA.
Homo sapiens ASAP1 intronic transcript 1 (non-protein
Homo sapiens RNA, U4atac small nuclear (U12-
Homo sapiens exportin 4 (XPO4), mRNA.
Homo sapiens protein phosphatase 2, regulatory subunit
Homo sapiens Fc receptor-like 3 (FCRL3), mRNA.
Homo sapiens fucosyltransferase 6 (alpha (1,3)
Homo sapiens radical S-adenosyl methionine domain
Homo sapiens ISG15 ubiquitin-like modifier (ISG15),
Homo sapiens histone cluster 2, H2aa4 (HIST2H2AA4),
Homo sapiens CD79a molecule, immunoglobulin-
Homo sapiens transmembrane protein 158 (TMEM158),
Homo sapiens Fanconi anemia, complementation group
Homo sapiens dual specificity phosphatase 14 (DUSP14),
Homo sapiens family with sequence similarity 3, member
Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA.
Homo sapiens transforming growth factor beta regulator 4
Homo sapiens solute carrier family 6 (neurotransmitter
Homo sapiens tumor necrosis factor (ligand) superfamily,
Homo sapiens sestrin 1 (SESN1), mRNA.
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens signal-regulatory protein gamma (SIRPG),
Homo sapiens interferon-induced protein with
Homo sapiens interferon-induced protein with
Homo sapiens ropporin 1-like (ROPN1L), mRNA.
Homo sapiens tetratricopeptide repeat domain 27
Homo sapiens G protein-coupled receptor 141 (GPR141),
Homo sapiens phosphatidylglycerophosphate synthase 1
Homo sapiens protease, serine, 23 (PRSS23), mRNA.
Homo sapiens junctional adhesion molecule 3 (JAM3),
Homo sapiens D site of albumin promoter (albumin D-
Homo sapiens golgi associated, gamma adaptin ear
Homo sapiens killer cell lectin-like receptor subfamily C,
Homo sapiens alpha-kinase 1 (ALPK1), mRNA.
Homo sapiens branched chain aminotransferase 1,
Homo sapiens myosin light chain kinase (MYLK),
Homo sapiens COBL-like 1 (COBLL1), mRNA.
Homo sapiens ATP-grasp domain containing 1
Homo sapiens triggering receptor expressed on myeloid
Homo sapiens mannosidase, alpha, class 1C, member 1
Homo sapiens tRNA splicing endonuclease 54 homolog
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens ankyrin repeat domain 22 (ANKRD22),
Homo sapiens protein S (alpha) (PROS1), mRNA.
Homo sapiens caldesmon 1 (CALD1), transcript variant
Homo sapiens CD40 ligand (CD40LG), mRNA.
Homo sapiens polymerase (RNA) III (DNA directed)
Homo sapiens AF4/FMR2 family, member 1 (AFF1),
Homo sapiens histone cluster 1, H3d (HIST1H3D),
Homo sapiens solute carrier family 26, member 8
Homo sapiens solute carrier family 26, member 8
Homo sapiens prostate transmembrane protein, androgen
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens ubiquitin-conjugating enzyme E2L 6
Homo sapiens slingshot homolog 1 (Drosophila) (SSH1),
Homo sapiens solute carrier family 25 (mitochondrial
Homo sapiens deltex 3-like (Drosophila) (DTX3L),
Homo sapiens docking protein 3 (DOK3), mRNA.
Homo sapiens family with sequence similarity 160,
Homo sapiens sulfotransferase family, cytosolic, 1B,
Homo sapiens adrenomedullin (ADM), mRNA.
Homo sapiens benzodiazapine receptor (peripheral)
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo sapiens LIM domain kinase 2 (LIMK2), transcript
Homo sapiens multimerin 1 (MMRN1), mRNA.
Homo sapiens glycogenin 1 (GYG1), mRNA.
Homo sapiens spindlin family, member 4 (SPIN4),
Homo sapiens defensin, alpha 1 (DEFA1), mRNA.
Homo sapiens epoxide hydrolase 2, cytoplasmic
Homo sapiens ribosomal RNA processing 1 homolog B
Homo sapiens WAS protein family, member 3 (WASF3),
Homo sapiens actin binding LIM protein family, member
Homo sapiens helicase (DNA) B (HELB), mRNA.
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens prepronociceptin (PNOC), mRNA.
Homo sapiens rhomboid 5 homolog 2 (Drosophila)
Homo sapiens epidermal growth factor (beta-urogastrone)
Homo sapiens microtubule-associated protein 1A
Homo sapiens zinc finger protein 789 (ZNF789),
Homo sapiens solute carrier family 38, member 9
Homo sapiens musashi homolog 2 (Drosophila) (MSI2),
Homo sapiens pyrin and HIN domain family, member 1
Homo sapiens transmembrane protein 180 (TMEM180),
Homo sapiens ST3 beta-galactoside alpha-2,3-
Homo sapiens Fas ligand (TNF superfamily, member 6)
Homo sapiens transmembrane protein 19 (TMEM19),
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens centromere protein K (CENPK), mRNA.
Homo sapiens family with sequence similarity 26,
Homo sapiens Fc receptor-like A (FCRLA), mRNA.
Homo sapiens v-maf musculoaponeurotic fibrosarcoma
Homo sapiens v-maf musculoaponeurotic fibrosarcoma
Homo sapiens caspase 7, apoptosis-related cysteine
Homo sapiens coagulation factor XIII, A1 polypeptide
Homo sapiens protein tyrosine phosphatase type IVA,
Homo sapiens DENN/MADD domain containing 1A
Homo sapiens Spi-B transcription factor (Spi-1/PU.1
Homo sapiens MAX interactor 1 (MXI1), transcript
Homo sapiens cytochrome P450, family 2, subfamily R,
Homo sapiens ras homolog gene family, member T1
Homo sapiens oligodendrocyte lineage transcription
Homo sapiens PDZ domain containing 4 (PDZD4),
Homo sapiens THO complex 3 (THOC3), mRNA.
Homo sapiens CD274 molecule (CD274), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 2,
Homo sapiens Janus kinase 2 (a protein tyrosine kinase)
Homo sapiens homer homolog 2 (Drosophila)
Homo sapiens carbonic anhydrase IV (CA4), mRNA.
Homo sapiens interferon induced transmembrane protein
Homo sapiens citrate lyase beta like (CLYBL), mRNA.
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens RAB, member of RAS oncogene family-
Homo sapiens signal transducer and activator of
Homo sapiens signal transducer and activator of
Homo sapiens olfactory receptor, family 2, subfamily
Homo sapiens cDNA: FLJ21199 fis, clone COL00235
Homo sapiens interferon-induced protein 44-like
Homo sapiens BCL2/adenovirus E1B 19 kDa interacting
Homo sapiens family with sequence similarity 125,
Homo sapiens leucine-rich alpha-2-glycoprotein 1
Homo sapiens LIM domain kinase 1 (LIMK1), transcript
Homo sapiens thymidine phosphorylase (TYMP),
Homo sapiens fragile histidine triad gene (FHIT), mRNA.
Homo sapiens defensin, alpha 1B (DEFA1B), mRNA.
Homo sapiens defensin, alpha 1B (DEFA1B), mRNA.
Homo sapiens defensin, alpha 1B (DEFA1B), mRNA.
Homo sapiens RALBP1 associated Eps domain
Homo sapiens septin 5 (SEPT5), mRNA.
Homo sapiens zinc finger protein 550 (ZNF550), mRNA.
Homo sapiens histone cluster 1, H2be (HIST1H2BE),
Homo sapiens multiple C2 domains, transmembrane 2
Homo sapiens aquaporin 10 (AQP10), mRNA.
Homo sapiens WD repeat and SOCS box-containing 1
Homo sapiens Fc receptor-like 6 (FCRL6), mRNA.
Homo sapiens cadherin 6, type 2, K-cadherin (fetal
Homo sapiens mitochondrial ribosomal protein L52
Homo sapiens arrestin domain containing 2 (ARRDC2),
Homo sapiens cytokine induced apoptosis inhibitor 1
Homo sapiens histone cluster 2, H2ac (HIST2H2AC),
Homo sapiens RAB24, member RAS oncogene family
Homo sapiens solute carrier family 7 (cationic amino acid
Homo sapiens Fas apoptotic inhibitory molecule 3
Homo sapiens Fc fragment of IgE, low affinity II,
Homo sapiens transmembrane protein 194A
Homo sapiens cytotoxic T-lymphocyte-associated protein
Homo sapiens SCO cytochrome oxidase deficient
Homo sapiens G protein-coupled receptor 44 (GPR44),
Homo sapiens tudor domain containing 9 (TDRD9),
Homo sapiens tudor domain containing 9 (TDRD9),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens G protein-coupled receptor 97 (GPR97),
Homo sapiens SLAM family member 6 (SLAMF6),
Homo sapiens outer dense fiber of sperm tails 3B
Homo sapiens SH3 and PX domains 2A (SH3PXD2A),
Homo sapiens CD151 molecule (Rapp blood group)
Homo sapiens chloride intracellular channel 3 (CLIC3),
Homo sapiens purinergic receptor P2Y, G-protein
Homo sapiens interleukin 18 receptor accessory protein
Homo sapiens defensin, alpha 3, neutrophil-specific
Homo sapiens BR serine/threonine kinase 1 (BRSK1),
Homo sapiens oxysterol binding protein-like 10
Homo sapiens sphingosine-1-phosphate receptor 5
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens vascular endothelial growth factor B
Homo sapiens Rho-related BTB domain containing 1
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens beta-1,3-glucuronyltransferase 1
Homo sapiens GRAM domain containing 3 (GRAMD3),
Homo sapiens signal transducer and activator of
Homo sapiens signal transducing adaptor family member
Homo sapiens WNK lysine deficient protein kinase 1
Homo sapiens CLR pseudogene (LOC374443), non-
Homo sapiens integrin, beta 5 (ITGB5), mRNA.
Homo sapiens integrin, beta 5 (ITGB5), mRNA.
Homo sapiens integrin, beta 5 (ITGB5), mRNA.
Homo sapiens ribosomal RNA processing 15 homolog (S. cerevisiae)
Homo sapiens hypothetical gene supported by AK127131
Homo sapiens Rho GTPase activating protein 26
Homo sapiens Fc fragment of IgG, high affinity Ia,
Homo sapiens interferon-induced protein 44 (IFI44),
Homo sapiens lymphocyte-specific protein tyrosine
Homo sapiens polymerase (RNA) II (DNA directed)
Homo sapiens desmocollin 2 (DSC2), transcript variant
Homo sapiens ectonucleotide
Homo sapiens heparanase (HPSE), mRNA.
Homo sapiens methylenetetrahydrofolate dehydrogenase
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens microRNA 21 (MIR21), microRNA.
Homo sapiens HOP homeobox (HOPX), transcript
Homo sapiens NOL1/NOP2/Sun domain family, member
Homo sapiens C-type lectin domain family 1, member B
Homo sapiens CDK5 regulatory subunit associated
Homo sapiens histone cluster 1, H2bg (HIST1H2BG),
Homo sapiens chromosome 14 open reading frame 80
Homo sapiens praja ring finger 1 (PJA1), transcript
Homo sapiens F-box and leucine-rich repeat protein 13
Homo sapiens tRNA splicing endonuclease 15 homolog
Homo sapiens caspase recruitment domain family,
Homo sapiens caspase recruitment domain family,
Homo sapiens SP140 nuclear body protein (SP140),
Homo sapiens F-box and leucine-rich repeat protein 16
Homo sapiens zinc finger protein 260 (ZNF260), mRNA.
Homo sapiens protease, serine, 33 (PRSS33), mRNA.
Homo sapiens frizzled homolog 2 (Drosophila) (FZD2),
Homo sapiens zeta-chain (TCR) associated protein kinase
Homo sapiens chemokine (C-C motif) receptor-like 2
Homo sapiens scavenger receptor class F, member 1
Homo sapiens interferon, alpha-inducible protein 27
Homo sapiens microtubule-associated protein 7 (MAP7),
Homo sapiens fatty acid synthase (FASN), mRNA.
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo sapiens von Willebrand factor (VWF), mRNA.
Homo sapiens septin 4 (SEPT4), transcript variant 3,
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens matrix metallopeptidase 9 (gelatinase B,
Homo sapiens discs, large homolog 4 (Drosophila)
Homo sapiens transporter 2, ATP-binding cassette, sub-
Homo sapiens coagulation factor III (thromboplastin,
Homo sapiens glycoprotein VI (platelet) (GP6), mRNA.
Homo sapiens guanylate cyclase 1, soluble, beta 3
Homo sapiens SWI/SNF related, matrix associated, actin
Homo sapiens enolase superfamily member 1 (ENOSF1),
Homo sapiens cat eye syndrome chromosome region,
Homo sapiens B-cell CLL/lymphoma 10 (BCL10),
Homo sapiens leucine rich repeat neuronal 3 (LRRN3),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo sapiens phenylalanyl-tRNA synthetase, alpha
Homo sapiens exosome component 5 (EXOSC5), mRNA.
Homo sapiens interferon-induced protein with
Homo sapiens galactose mutarotase (aldose 1-epimerase)
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens microtubule-associated protein 7 (MAP7),
Homo sapiens guanylate binding protein 4 (GBP4),
Homo sapiens NADH dehydrogenase (ubiquinone) 1
Homo sapiens proteasomal ATPase-associated factor 1
Homo sapiens zinc finger protein 789 (ZNF789),
Homo sapiens zinc fingers and homeoboxes 3 (ZHX3),
Homo sapiens G protein-coupled receptor 68 (GPR68),
Homo sapiens interferon induced with helicase C domain
Homo sapiens proline rich Gla (G-carboxyglutamic acid)
Homo sapiens dolichyl pyrophosphate phosphatase 1
Homo sapiens adaptor-related protein complex 3, mu 2
Homo sapiens CD69 molecule (CD69), mRNA.
Homo sapiens BTB and CNC homology 1, basic leucine
Homo sapiens chromosome 9 open reading frame 123
Homo sapiens chromosome 10 open reading frame 2
Homo sapiens GRAM domain containing 1B
Homo sapiens harakiri, BCL2 interacting protein
Homo sapiens chemokine (C-C motif) receptor 6 (CCR6),
Homo sapiens growth arrest and DNA-damage-inducible,
Homo sapiens phospholipase C, gamma 1 (PLCG1),
Homo sapiens endothelial cell adhesion molecule
Homo sapiens Fc fragment of IgA, receptor for (FCAR),
Homo sapiens CD84 molecule (CD84), mRNA.
Homo sapiens carbonic anhydrase VB, mitochondrial
Homo sapiens WW domain binding protein 5 (WBP5),
Homo sapiens ArfGAP with SH3 domain, ankyrin repeat
Homo sapiens ArfGAP with SH3 domain, ankyrin repeat
Homo sapiens complement component 1, q
Homo sapiens CD3e molecule, epsilon (CD3-TCR
Homo sapiens mitochondrial ribosomal protein L12
Homo sapiens G protein-coupled receptor 183 (GPR183),
Homo sapiens coiled-coil domain containing 76
Homo sapiens membrane-spanning 4-domains, subfamily
Homo sapiens nuclear factor I/X (CCAAT-binding
Homo sapiens solute carrier family 26, member 8
Homo sapiens nephroblastoma overexpressed gene
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
Homo sapiens chromosome 16 open reading frame 35
Homo sapiens KIAA0319-like (KIAA0319L), transcript
Homo sapiens tripartite motif-containing 22 (TRIM22),
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens Tctex1 domain containing 2 (TCTEX1D2),
Homo sapiens small cell adhesion glycoprotein
Homo sapiens neurocalcin delta (NCALD), mRNA.
Homo sapiens tryptophanyl-tRNA synthetase (WARS),
Homo sapiens guanylate binding protein 2, interferon-
Homo sapiens insulin-like growth factor 2 mRNA
Homo sapiens BEN domain containing 5 (BEND5),
Homo sapiens dysferlin, limb girdle muscular dystrophy
Homo sapiens family with sequence similarity 159,
Homo sapiens G0/G1switch 2 (G0S2), mRNA.
Homo sapiens transforming growth factor beta 1 induced
Homo sapiens nicotinamide nucleotide
Homo sapiens caldesmon 1 (CALD1), transcript variant
Homo sapiens mucin 1, cell surface associated (MUC1),
Homo sapiens chromosome 14 open reading frame 124
Homo sapiens desmocollin 2 (DSC2), transcript variant
Homo sapiens apolipoprotein L, 6 (APOL6), mRNA.
Homo sapiens suppressor of Ty 3 homolog (S. cerevisiae)
Homo sapiens interferon-induced protein with
Homo sapiens lysophosphatidylcholine acyltransferase 2
Homo sapiens zinc finger protein 654 (ZNF654), mRNA.
Homo sapiens zinc finger protein 17 (ZNF17), mRNA.
Homo sapiens ARP5 actin-related protein 5 homolog
Homo sapiens CTP synthase II (CTPS2), transcript
Homo sapiens S100 calcium binding protein A12
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens chemokine (C—X—C motif) ligand 10
Homo sapiens urotensin 2 (UTS2), transcript variant 1,
Homo sapiens sialic acid binding Ig-like lectin 9
Homo sapiens chromosome 22 open reading frame 32
Homo sapiens C-type lectin-like 1 (CLECL1), mRNA.
Homo sapiens leukocyte immunoglobulin-like receptor,
Homo sapiens chromosome 20 open reading frame 100
Homo sapiens chromosome 6 open reading frame 190
Homo sapiens endothelial cell growth factor 1 (platelet-
Homo sapiens growth factor receptor-bound protein 10
Homo sapiens Fc receptor-like 3 (FCRL3), transcript
Homo sapiens C-type lectin domain family 1, member A
Homo sapiens zinc finger protein 91 homolog (mouse)
Homo sapiens inturned planar cell polarity effector
Homo sapiens chymotrypsin-like (CTRL), mRNA.
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger
Homo sapiens sterile alpha motif domain containing 3
Homo sapiens EP300 interacting inhibitor of
Homo sapiens lysyl oxidase-like 3 (LOXL3), mRNA.
Homo sapiens glycerol kinase (GK), transcript variant 1,
Homo sapiens retbindin (RTBDN), transcript variant 2,
Homo sapiens 2′-5′-oligoadenylate synthetase 2,
Homo sapiens leukotriene B4 receptor (LTB4R), mRNA.
Homo sapiens malignant fibrous histiocytoma amplified
Homo sapiens histone cluster 1, H3e (HIST1H3E),
Homo sapiens intraflagellar transport 74 homolog
Homo sapiens CD79B antigen (immunoglobulin-
Homo sapiens small Cajal body-specific RNA 22
Homo sapiens E74-like factor 2 (ets domain transcription
Homo sapiens similar to 2010300C02Rik protein
Homo sapiens protein kinase C substrate 80K-H
Homo sapiens latrophilin 1 (LPHN1), transcript variant 2,
Homo sapiens platelet endothelial aggregation receptor 1
Homo sapiens transmembrane protein 107 (TMEM107),
Homo sapiens maltase-glucoamylase (alpha-glucosidase)
Homo sapiens septin 4 (SEPT4), transcript variant 2,
Homo sapiens annexin A3 (ANXA3), mRNA.
Homo sapiens multiple EGF-like-domains 9 (MEGF9),
Homo sapiens G protein-coupled receptor 27 (GPR27),
Homo sapiens protein tyrosine phosphatase, receptor
Homo sapiens GTPase activating protein (SH3 domain)
Homo sapiens free fatty acid receptor 2 (FFAR2),
Homo sapiens LYR motif containing 4 (LYRM4),
Homo sapiens carcinoembryonic antigen-related cell
Homo sapiens transcription factor 7 (T-cell specific,
Homo sapiens transient receptor potential cation channel,
Homo sapiens phospholipase C, delta 1 (PLCD1),
Homo sapiens upstream transcription factor 1 (USF1),
Homo sapiens eukaryotic translation initiation factor 1A,
Homo sapiens guanine nucleotide binding protein (G
Homo sapiens CD79a molecule, immunoglobulin-
Homo sapiens chromosome 9 open reading frame 84
Homo sapiens divergent-paired related homeobox
Homo sapiens extracellular matrix protein 1 (ECM1),
Homo sapiens ST6 beta-galactosamide alpha-2,6-
Homo sapiens kelch-like 3 (Drosophila) (KLHL3),
Homo sapiens receptor (chemosensory) transporter
Homo sapiens plexin C1 (PLXNC1), mRNA.
Homo sapiens ras homolog gene family, member T1
Homo sapiens BMX non-receptor tyrosine kinase (BMX),
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens RNA-binding protein (FLJ20273), mRNA.
Homo sapiens spastic ataxia of Charlevoix-Saguenay
Homo sapiens MYC-associated zinc finger protein
Homo sapiens sphingosine-1-phosphate receptor 3
Homo sapiens zinc finger family member 783 (ZNF783),
Homo sapiens asparagine-linked glycosylation 10, alpha-
Homo sapiens ATPase, Ca++ transporting, plasma
Homo sapiens oncostatin M (OSM), mRNA.
Homo sapiens zinc finger protein 589 (ZNF589), mRNA.
Homo sapiens chromosome 9 open reading frame 66
Homo sapiens family with sequence similarity 195,
Homo sapiens chloride intracellular channel 4 (CLIC4),
Homo sapiens B melanoma antigen family, member 3
Homo sapiens thymidine phosphorylase (TYMP),
Homo sapiens POM121 membrane glycoprotein-like 4
Homo sapiens tumor necrosis factor receptor superfamily,
Homo sapiens VENT homeobox homolog (Xenopus
laevis) (VENTX), mRNA.
Homo sapiens TCR gamma alternate reading frame
Homo sapiens HECT domain containing 2 (HECTD2),
Homo sapiens FERM domain containing 3 (FRMD3),
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens plasminogen activator, urokinase receptor
Homo sapiens histone cluster 1, H4h (HIST1H4H),
Homo sapiens kelch repeat and BTB (POZ) domain
Homo sapiens interferon, gamma (IFNG), mRNA.
Homo sapiens CD72 molecule (CD72), mRNA.
Homo sapiens guanylate binding protein family, member
Homo sapiens galectin-related protein (HSPC159),
Homo sapiens tripartite motif-containing 5 (TRIM5),
Homo sapiens myosin light chain kinase (MYLK),
Homo sapiens suppressor of cytokine signaling 3
Homo sapiens oligodendrocyte transcription factor 1
Homo sapiens LIM and senescent cell antigen-like
Homo sapiens AF4/FMR2 family, member 1 (AFF1),
Homo sapiens hypothetical protein LOC153561
Homo sapiens proteasome (prosome, macropain)
Homo sapiens selectin P ligand (SELPLG), mRNA.
Homo sapiens complement component (3d/Epstein Barr
Homo sapiens abhydrolase domain containing 14A
Homo sapiens chromosome 4 open reading frame 18
Homo sapiens kinesin family member C3 (KIFC3),
Homo sapiens laminin, alpha 5 (LAMA5), mRNA.
Homo sapiens aspartate beta-hydroxylase domain
Homo sapiens dehydrogenase/reductase (SDR family)
Homo sapiens BEN domain containing 7 (BEND7),
Homo sapiens histone cluster 2, H3c (HIST2H3C),
Homo sapiens tumor necrosis factor, alpha-induced
Homo sapiens fibulin 1 (FBLN1), transcript variant C,
sapiens cDNA clone IMAGp998A124183;
Homo
sapiens chemokine (C-X-C motif) receptor 3
Homo
sapiens kelch domain containing 8B
Homo
sapiens monoglyceride lipase (MGLL), transcript
Homo
sapiens potassium inwardly-rectifying channel,
Homo
sapiens pregnancy specific beta-1-glycoprotein 9
Homo
sapiens suppressor of cytokine signaling 3
Homo
sapiens epithelial stromal interaction 1 (breast)
Homo
sapiens complement component 2 (C2), mRNA.
Homo
sapiens alkaline phosphatase, liver/bone/kidney
Homo
sapiens tissue factor pathway inhibitor
Homo
sapiens tissue factor pathway inhibitor
Homo
sapiens G protein-coupled receptor 84 (GPR84),
Homo
sapiens interleukin 28 receptor, alpha (interferon,
Homo
sapiens Fc fragment of IgE, high affinity I,
Homo
sapiens ankyrin repeat domain 22 (ANKRD22),
Homo
sapiens kelch-like 14 (Drosophila) (KLHL14),
Homo
sapiens leukocyte immunoglobulin-like receptor,
Homo
sapiens phosphotriesterase related (PTER),
Homo
sapiens cathelicidin antimicrobial peptide
Homo
sapiens Abelson helper integration site 1 (AHI1),
Homo
sapiens proline-serine-threonine phosphatase
Homo
sapiens calmodulin binding transcription activator
Homo
sapiens cytidine monophosphate (UMP-CMP)
Homo
sapiens vesicle-associated membrane protein 5
Homo
sapiens cytohesin 3 (CYTH3), mRNA.
Homo
sapiens coiled-coil domain containing 65
Homo
sapiens kringle containing transmembrane protein
Homo
sapiens ankyrin repeat domain 20 family, member
Homo
sapiens Fc fragment of IgG, high affinity Ib,
Homo
sapiens dynein, cytoplasmic 2, light intermediate
Homo
sapiens Fc fragment of IgG binding protein
Homo
sapiens guanylate binding protein 5 (GBP5),
Homo
sapiens TAF9 RNA polymerase II, TATA box
Homo
sapiens ets variant 7 (ETV7), mRNA.
Homo
sapiens cadherin-like 23 (CDH23), transcript
Homo
sapiens T-cell receptor alpha chain-like protein
Homo
sapiens growth arrest-specific 6 (GAS6), mRNA.
Homo
sapiens transmembrane protein 50B
sapiens cDNA clone DKFZp434O1935 5, mRNA
Homo
sapiens interleukin 15 (ILI5), transcript variant 1,
Homo
sapiens cDNA: FLJ23098 fis, clone LNG07440
Homo
sapiens mitogen-activated protein kinase 14
Homo
sapiens histone cluster 1, H2ae (HIST1H2AE),
Homo
sapiens G protein-coupled receptor 109B
Homo
sapiens metallothionein 1G (MT1G), mRNA.
Homo
sapiens abhydrolase domain containing 2
Homo
sapiens dual specificity phosphatase 3 (vaccinia
virus phosphatase VH1-related) (DUSP3), mRNA.
Homo
sapiens SLAM family member 8 (SLAMF8),
Homo
sapiens inhibitor of DNA binding 3, dominant
Homo
sapiens complement component (3b/4b) receptor
Homo
sapiens complement component (3b/4b) receptor
Homo
sapiens TAP binding protein (tapasin) (TAPBP),
Homo
sapiens serpin peptidase inhibitor, clade G (C1
Homo
sapiens sulfide quinone reductase-like (yeast)
Homo
sapiens superoxide dismutase 2, mitochondrial
Homo
sapiens amyotrophic lateral sclerosis 2 (juvenile)
Homo
sapiens tetraspanin 9 (TSPAN9), mRNA.
Homo
sapiens growth arrest-specific 8 (GAS8), mRNA.
Homo
sapiens fer-1-like 3, myoferlin (C.elegans)
Homo
sapiens chromosome 10 open reading frame 132
Homo
sapiens paroxysmal nonkinesiogenic dyskinesia
Homo
sapiens chromosome 15 open reading frame 54
sapiens cDNA clone IMAGE:30386692 5, mRNA
Homo
sapiens zinc finger protein 540 (ZNF540),
Homo
sapiens folate receptor 3 (gamma) (FOLR3),
Homo
sapiens tubulin polymerization-promoting protein
Homo
sapiens selectin P (granule membrane protein
Homo
sapiens chitinase 3-like 2 (CHI3L2), transcript
Homo
sapiens 5-hydroxytryptamine (serotonin) receptor
Homo
sapiens coagulation factor II (thrombin) receptor-
Homo
sapiens EPH receptor A1 (EPHA1), mRNA.
Homo
sapiens LIM domain kinase 2 (LIMK2), transcript
Homo
sapiens ankyrin repeat domain 9 (ANKRD9),
Homo
sapiens multiple C2 domains, transmembrane 1
Homo
sapiens sterile alpha motif domain containing 8
Homo
sapiens kinesin family member 1B (KIF1B),
Homo
sapiens B-cell scaffold protein with ankyrin
Homo
sapiens cerebellar degeneration-related protein 2-
Homo
sapiens lysosomal-associated membrane protein 3
Homo
sapiens RRN3 RNA polymerase I transcription
Homo
sapiens ferredoxin 1 (FDX1), nuclear gene
Homo
sapiens tissue specific transplantation antigen
Homo
sapiens cholesteryl ester transfer protein, plasma
Homo
sapiens sarcoglycan, epsilon (SGCE), transcript
Homo
sapiens netrin G2 (NTNG2), mRNA.
Homo
sapiens tropomyosin 1 (alpha) (TPM1), transcript
Homo
sapiens cDNA FLJ20012 fis, clone ADKA03438
Homo
sapiens G protein-coupled receptor 109A
Homo
sapiens interferon-induced protein 35 (IEI35),
Homo
sapiens interferon regulatory factor 7 (IRF7),
Homo
sapiens megakaryocyte-associated tyrosine kinase
Homo
sapiens kringle containing transmembrane protein
Homo
sapiens kringle containing transmembrane protein
Homo
sapiens vanin 1 (VNN1), mRNA.
Homo
sapiens guanylate binding protein 1, interferon-
Homo
sapiens protein tyrosine phosphatase, receptor
Homo
sapiens defensin, alpha 4, corticostatin (DEFA4),
Homo
sapiens germinal center expressed transcript 2
Homo
sapiens ADAM metallopeptidase domain 7
Homo
sapiens F-box protein 6 (FBXO6), mRNA.
Homo
sapiens N-myristoyltransferase 2 (NMT2),
Homo
sapiens AF4/FMR2 family, member 3 (AFF3),
Homo
sapiens solute carrier family 6 (neurotransmitter
Homo
sapiens acyl-CoA synthetase long-chain family
Homo
sapiens histone cluster 1, H3h (HIST1H3H),
Homo
sapiens hypothetical protein MGC52282
Homo
sapiens interleukin 23, alpha subunit p19
Homo
sapiens BCR downstream signaling 1 (BRDG1),
Homo
sapiens cAMP responsive element binding protein
Homo
sapiens thymosin-like 8 (TMSL8), mRNA.
Homo
sapiens basic leucine zipper transcription factor,
Homo
sapiens deltex 3 homolog (Drosophila) (DTX3),
Homo
sapiens KIAA1407 (KIAA1407), mRNA.
Homo
sapiens solute carrier family 2 (facilitated glucose
Homo
sapiens C-type lectin domain family 4, member D
Homo
sapiens calcium channel, voltage-dependent, R
Homo
sapiens pre-B lymphocyte gene 3 (VPREB3),
Homo
sapiens NLR family, pyrin domain containing 2
Homo
sapiens, clone IMAGE: 4655360, mRNA
Homo
sapiens nucleoporin 35 kDa (NUP35), mRNA.
Homo
sapiens ATP binding domain 4 (ATPBD4),
Homo
sapiens transmembrane 4 L six family member 19
Homo
sapiens CAST domain containing 1 (CASD1),
Homo
sapiens plasminogen activator, urokinase receptor
Homo
sapiens LON peptidase N-terminal domain and
Homo
sapiens chromosome 6 open reading frame 151
Homo
sapiens carcinoembryonic antigen-related cell
Homo
sapiens carcinoembryonic antigen-related cell
Homo
sapiens seven in absentia homolog 2 (Drosophila)
Homo
sapiens chromosome 19 open reading frame 29
Homo
sapiens leucine-rich repeat kinase 2 (LRRK2),
Homo
sapiens lipocalin 2 (LCN2), mRNA.
Homo
sapiens pleckstrin homology-like domain, family
Homo
sapiens signal-induced proliferation-associated 1
Homo
sapiens lemur tyrosine kinase 2 (LMTK2),
Homo
sapiens histone cluster 1, H4e (HIST1H4E),
Homo
sapiens elastase 2, neutrophil (ELA2), mRNA.
Homo
sapiens cathepsin A (CTSA), transcript variant 1,
Homo
sapiens transglutaminase 2 (C polypeptide,
Homo
sapiens chromosome 1 open reading frame 198
Homo
sapiens
feline leukemia virus subgroup C cellular
Homo
sapiens lamin B1 (LMNB1), mRNA.
Homo
sapiens proteasome (prosome, macropain)
Homo
sapiens proteasome (prosome, macropain)
Homo
sapiens activating transcription factor 3 (ATF3),
Homo
sapiens H2A histone family, member J (H2AFJ),
Homo
sapiens haptoglobin (HP), mRNA.
Homo
sapiens sortilin 1 (SORT1), mRNA.
Homo
sapiens histone cluster 1, H2bk (HIST1H2BK),
Homo
sapiens synaptogyrin 1 (SYNGRI), transcript
Homo
sapiens KIAA1324-like (KIAA1324L), mRNA.
Homo
sapiens B lymphoid tyrosine kinase (BLK),
Homo
sapiens CD160 molecule (CD160), mRNA.
Homo
sapiens similar to CGI-96 (dJ222E13.2) on
Homo
sapiens CD19 molecule (CD19), mRNA.
Homo
sapiens zinc finger protein 438 (ZNF438),
Homo
sapiens zinc finger CCCH-type containing 12B
Homo
sapiens leucine rich repeat containing 56
Homo
sapiens solute carrier family 35, member D3
Homo
sapiens chromosome 6 open reading frame 25
Homo
sapiens actin, alpha 2, smooth muscle, aorta
Homo
sapiens syntaxin 16 (STX16), transcript variant 1,
Homo
sapiens tripartite motif-containing 6 (TRIM6),
Homo
sapiens caspase 4, apoptosis-related cysteine
Homo
sapiens uronyl-2-sulfotransferase (UST), mRNA.
Homo
sapiens phosphatase, orphan 2 (PHOSPHO2),
Homo
sapiens lymphocyte-specific protein tyrosine
Homo
sapiens superoxide dismutase 2, mitochondrial
Homo
sapiens myeloproliferative leukemia virus
Homo
sapiens like-glycosyltransferase (LARGE),
Homo
sapiens sirtuin (silent mating type information
Homo
sapiens CD22 molecule (CD22), mRNA.
Homo
sapiens ectodysplasin A receptor (EDAR),
Homo
sapiens proline rich 11 (PRR11), mRNA.
Homo
sapiens SEC14-like 5 (S.cerevisiae) (SEC14L5),
Homo
sapiens hypothetical gene LOC401431
Homo
sapiens sterile alpha motif and leucine zipper
Homo
sapiens killer cell lectin-like receptor subfamily
Homo
sapiens anoctamin 9 (ANO9), mRNA.
Homo
sapiens potassium inwardly-rectifying channel,
Homo
sapiens potassium inwardly-rectifying channel,
Homo
sapiens chromosome 21 open reading frame 81
Homo
sapiens microtubule associated serine/threonine
Homo
sapiens O-sialoglycoprotein endopeptidase-like 1
Homo
sapiens serpin peptidase inhibitor, clade A (alpha-
Homo
sapiens zinc finger protein 37 homolog (mouse)
Homo
sapiens DKFZP564O0823 protein
Homo
sapiens similar to Interferon-induced guanylate-
Homo
sapiens interleukin 27 (IL27), mRNA.
Homo
sapiens caveolin 2 (CAV2), transcript variant 1,
Homo
sapiens succinate receptor 1 (SUCNR1), mRNA.
Homo
sapiens growth arrest and DNA-damage-
Homo
sapiens guanine nucleotide binding protein (G
Homo
sapiens RAP1 GTPase activating protein
Homo
sapiens tumor necrosis factor (ligand)
Homo
sapiens 2′,5′-oligoadenylate synthetase 1,
Homo
sapiens kinesin family member 1B (KIF1B),
Homo
sapiens ER lipid raft associated 1 (ERLIN1),
Homo
sapiens BMP and activin membrane-bound
Homo
sapiens interleukin-1 receptor-associated kinase 3
Homo
sapiens AE binding protein 1 (AEBP1), mRNA.
Homo
sapiens NLR family, CARD domain containing 4
Homo
sapiens dynein, axonemal, heavy chain 5
Homo
sapiens caspase 5, apoptosis-related cysteine
Homo
sapiens neurogranin (protein kinase C substrate,
Homo
sapiens leucine rich repeat containing 26
Homo
sapiens chromosome 16 open reading frame 7
Homo
sapiens early B-cell factor 1 (EBF1), mRNA.
Homo
sapiens fasciculation and elongation protein zeta 1
Homo
sapiens E2F transcription factor 5, p130-binding
Homo
sapiens RGD motif, leucine rich repeats,
Homo
sapiens macrophage receptor with collagenous
Homo
sapiens MKL/myocardin-like 2 (MKL2), mRNA.
Homo
sapiens G protein-coupled receptor 174
Homo
sapiens cytotoxic T-lymphocyte-associated
Homo
sapiens mitogen-activated protein kinase 14
Homo
sapiens interleukin 1, beta (IL1B), mRNA.
Homo
sapiens complement component 4 binding
Homo
sapiens histone cluster 2, H2be (HIST2H2BE),
Homo
sapiens serine incorporator 5 (SERINC5), mRNA.
Homo
sapiens absent in melanoma 2 (AIM2), mRNA.
Homo
sapiens absent in melanoma 2 (AIM2), mRNA.
Homo
sapiens GRAM domain containing IC
Homo
sapiens purinergic receptor P2Y, G-protein
Homo
sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo
sapiens histone cluster 1, H2bd (HIST1H2BD),
Homo
sapiens NLR family, apoptosis inhibitory protein
Homo
sapiens NLR family, apoptosis inhibitory protein
Homo
sapiens NEL-like 2 (chicken) (NELL2), mRNA.
Homo
sapiens mitogen-activated protein kinase 14
Homo
sapiens G patch domain containing 4
Homo
sapiens collagen, type IV, alpha 3 (Goodpasture
Homo
sapiens GTP cyclohydrolase 1 (GCH1), transcript
Homo
sapiens heat shock transcription factor family
Homo
sapiens platelet-derived growth factor alpha
Homo
sapiens tubulin, alpha 8 (TUBA8), mRNA.
Homo
sapiens leucine rich repeat neuronal 3 (LRRN3),
Homo
sapiens syntaxin 11 (STX11), mRNA.
Homo
sapiens complement component 1, q
Homo
sapiens X-linked Kx blood group (McLeod
Homo
sapiens secreted and transmembrane 1
Homo
sapiens chemokine (C-X-C motif) receptor 5
Homo
sapiens Fas (TNF receptor superfamily, member
Homo
sapiens Fc fragment of IgG, high affinity Ib,
Homo
sapiens chromosome 4 open reading frame 32
Homo
sapiens Epstein-Barr virus induced gene 2
Homo
sapiens Epstein-Barr virus induced gene 2
Homo
sapiens spectrin, beta, erythrocytic (SPTB),
Homo
sapiens plexin A3 (PLXNA3), mRNA.
Homo
sapiens chromosome 19 open reading frame 35
Homo
sapiens hypothetical protein LOC152195
Homo
sapiens adenylate cyclase 3 (ADCY3), mRNA.
Homo
sapiens toll-like receptor 5 (TLR5), mRNA.
Homo
sapiens granzyme K (granzyme 3; tryptase II)
Homo
sapiens inhibitory caspase recruitment domain
Homo
sapiens invasion inhibitory protein 45 (IIP45),
Homo
sapiens PR domain containing 1, with ZNF
Homo
sapiens G protein-coupled estrogen receptor 1
Homo
sapiens lipoma HMGIC fusion partner-like 2
Homo
sapiens complement component (3b/4b) receptor
Homo
sapiens NAD(P)H dehydrogenase, quinone 1
Homo
sapiens kazrin (KIAA1026), transcript variant B,
Homo
sapiens family with sequence similarity 102,
Homo
sapiens calcium channel, voltage-dependent,
Homo
sapiens zinc finger protein 567 (ZNF567),
Homo
sapiens SPOC domain containing 1 (SPOCD1),
Homo
sapiens TRAF-interacting protein with forkhead-
Homo
sapiens SLAIN motif family, member 1
Homo
sapiens EPH receptor A4 (EPHA4), mRNA.
Homo
sapiens eukaryotic translation initiation factor 1A,
Homo
sapiens natriuretic peptide receptor B/guanylate
Homo
sapiens chromosome 19 open reading frame 59
Homo
sapiens CDK5 regulatory subunit associated
Homo
sapiens phospholipid scramblase 1 (PLSCR1),
Homo
sapiens purinergic receptor P2Y, G-protein
Homo
sapiens glycoprotein IX (platelet) (GP9), mRNA.
Homo
sapiens lipoma HMGIC fusion partner (LHFP),
Homo
sapiens tumor necrosis factor (ligand)
Homo
sapiens DKFZp761E198 protein
Homo
sapiens sterile alpha motif domain containing 14
Homo
sapiens poly (ADP-ribose) polymerase family,
Homo
sapiens ankyrin 1, erythrocytic (ANK1),
Homo
sapiens poly (ADP-ribose) polymerase family,
Homo
sapiens poly (ADP-ribose) polymerase family,
Homo
sapiens CD151 molecule (Raph blood group)
Homo
sapiens synaptotagmin-like 2 (SYTL2), transcript
Homo
sapiens nucleoporin like 1 (NUPL1), transcript
Homo
sapiens prostaglandin D2 receptor (DP)
Homo
sapiens prostaglandin D2 receptor (DP)
Homo
sapiens acyl-CoA synthetase long-chain family
Homo
sapiens sorting nexin 20 (SNX20), mRNA.
Homo
sapiens tripartite motif-containing 9 (TRIM9),
Homo
sapiens interleukin 4 receptor (IL4R), transcript
Homo
sapiens 2′-5′-oligoadenylate synthetase 3, 100 kDa
Homo
sapiens 2′-5′-oligoadenylate synthetase 3, 100 kDa
Homo
sapiens membrane-spanning 4-domains,
Homo
sapiens potassium inwardly-rectifying channel,
Homo
sapiens carcinoembryonic antigen-related cell
Homo
sapiens zinc finger protein interacting with K
Homo
sapiens formin-like 3 (FMNL3), transcript variant
Homo
sapiens XIAP associated factor 1 (XAF1),
Homo
sapiens XIAP associated factor 1 (XAF1),
Homo
sapiens zinc finger protein 831 (ZNF831),
Homo
sapiens methionine sulfoxide reductase B2
Homo
sapiens IKAROS family zinc finger 3 (Aiolos)
Homo
sapiens tripartite motif-containing 5 (TRIM5),
Homo
sapiens apolipoprotein L, 1 (APOL1), transcript
Homo
sapiens rhomboid 5 homolog 2 (Drosophila)
Homo
sapiens kinesin family member 5C (KIF5C),
Homo
sapiens FYN binding protein (FYB-120/130)
Homo
sapiens ATP-binding cassette, sub-family A
Homo
sapiens DENN/MADD domain containing lA
Homo
sapiens required for meiotic nuclear division 5
Homo
sapiens TNF receptor-associated factor 5
Homo
sapiens transporter 1, ATP-binding cassette, sub-
Homo
sapiens Fc receptor-like 2 (FCRL2), transcript
Homo
sapiens Fc receptor-like 2 (FCRL2), transcript
Homo
sapiens V-set and immunoglobulin domain
Homo
sapiens serpin peptidase inhibitor, clade F (alpha-
sapiens cDNA clone IMAGE: 1387462 3, mRNA
Homo
sapiens chromosome 17 open reading frame 69
Homo
sapiens TBC1 domain family, member 19
Homo
sapiens viral DNA polymerase-transactivated
Homo
sapiens apolipoprotein L, 2 (APOL2), transcript
Homo
sapiens apolipoprotein L, 2 (APOL2), transcript
Homo
sapiens killer cell lectin-like receptor subfamily
Homo
sapiens fer-1-like 3, myoferlin (C.elegans)
Homo
sapiens CD8b molecule (CD8B), transcript
Homo
sapiens leukocyte immunoglobulin-like receptor,
Homo
sapiens cDNA clone IMAGE: 4811759
Homo
sapiens centrosomal protein 120 kDa (CEP120),
Homo
sapiens histone cluster 2, H2ab (HIST2H2AB),
Homo
sapiens secretoglobin, family 3A, member 1
Homo
sapiens CKLF-like MARVEL transmembrane
Homo
sapiens 5′,3′-nucleotidase, mitochondrial (NT5M),
Homo
sapiens cAMP responsive element binding protein
Homo
sapiens sprouty homolog 2 (Drosophila)
Homo
sapiens radical S-adenosyl methionine domain
Homo
sapiens caspase 1, apoptosis-related cysteine
Homo
sapiens general transcription factor IIA, 1,
Homo
sapiens chromosome 20 open reading frame 74
Homo
sapiens myosin, light chain 9, regulatory (MYL9),
Homo
sapiens myosin, light chain 9, regulatory (MYL9),
Homo
sapiens integrin, alpha 2b (platelet glycoprotein
Homo
sapiens COX11 homolog, cytochrome c oxidase
Homo
sapiens similar to fidgetin (LOC401720), mRNA.
Homo
sapiens Ral GEF with PH domain and SH3
Homo
sapiens interferon, alpha-inducible protein 6
Homo
sapiens 2′,5′-oligoadenylate synthetase 1,
Homo
sapiens 2′,5′-oligoadenylate synthetase 1,
Homo
sapiens WD repeat domain 21A (WDR21A),
Homo
sapiens LIM domain kinase 2 (LIMK2), transcript
Homo
sapiens LIM domain kinase 2 (LIMK2), transcript
Homo
sapiens SWI/SNF related, matrix associated, actin
Homo
sapiens troponin I type 2 (skeletal, fast) (TNNI2),
Homo
sapiens sterile alpha motif domain containing 9-
Homo
sapiens nerve growth factor receptor
Homo
sapiens nerve growth factor receptor
Homo
sapiens oxytocin receptor (OXTR), mRNA.
Homo
sapiens similar to metallo-beta-lactamase
Homo
sapiens transmembrane protein 56 (TMEM56),
Homo
sapiens carcinoembryonic antigen-related cell
Homo
sapiens X (inactive)-specific transcript (non-
Homo
sapiens 5-oxoprolinase (ATP-hydrolysing)
Homo
sapiens ADP-ribosylation factor-like 11 (ARL11),
Homo
sapiens brain expressed, X-linked 1 (BEX1),
Homo
sapiens chromosome 11 open reading frame 75
Homo
sapiens cornichon homolog 4 (Drosophila)
Homo
sapiens RAB20, member RAS oncogene family
Homo
sapiens suppressor of cytokine signaling 1
Homo
sapiens zinc finger protein 571 (ZNF571),
Homo
sapiens procollagen-lysine, 2-oxoglutarate 5-
Homo
sapiens ADAM metallopeptidase domain 28
Homo
sapiens integrin, beta 3 (platelet glycoprotein IIIa,
Homo
sapiens branched chain keto acid dehydrogenase
Homo
sapiens leucine rich repeat containing 1 (LRRC1),
Homo
sapiens dehydrogenase/reductase (SDR family)
Homo
sapiens solute carrier family 24
Homo
sapiens Fc receptor-like 3 (FCRL3), mRNA.
Homo
sapiens Fc receptor-like 3 (FCRL3), mRNA.
Homo
sapiens chromosome 1 open reading frame 138
Homo
sapiens purinergic receptor P2X, ligand-gated ion
Homo
sapiens ISG15 ubiquitin-like modifier (ISG15),
Homo
sapiens CD79a molecule, immunoglobulin-
Homo
sapiens transmembrane protein 158 (TMEM158),
Homo
sapiens family with sequence similarity 3,
Homo
sapiens leucine aminopeptidase 3 (LAP3),
Homo
sapiens Fc receptor-like 5 (FCRL5), mRNA.
Homo
sapiens solute carrier family 6 (neurotransmitter
Homo
sapiens tumor necrosis factor (ligand)
Homo
sapiens purinergic receptor P2Y, G-protein
Homo
sapiens purinergic receptor P2Y, G-protein
Homo
sapiens signal-regulatory protein gamma
Homo
sapiens zinc finger protein 181 (ZNF181),
Homo
sapiens interferon-induced protein with
Homo
sapiens interferon-induced protein with
Homo
sapiens G protein-coupled receptor 141
Homo
sapiens phosphatidylglycerophosphate synthase 1
Homo
sapiens protease, serine, 23 (PRSS23), mRNA.
Homo
sapiens junctional adhesion molecule 3 (JAM3),
Homo
sapiens alpha-kinase 1 (ALPK1), mRNA.
Homo
sapiens triggering receptor expressed on myeloid
Homo
sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo
sapiens ankyrin repeat domain 22 (ANKRD22),
Homo
sapiens protein S (alpha) (PROS1), mRNA.
Homo
sapiens T cell receptor alpha locus, mRNA
Homo
sapiens caldesmon 1 (CALD1), transcript variant
Homo
sapiens zinc finger protein 416 (ZNF416),
Homo
sapiens histone cluster 1, H3d (HIST1H3D),
Homo
sapiens solute carrier family 26, member 8
Homo
sapiens solute carrier family 26, member 8
Homo
sapiens prostate transmembrane protein, androgen
Homo
sapiens ubiquitin-conjugating enzyme E2L 6
Homo
sapiens ubiquitin-conjugating enzyme E2L 6
Homo
sapiens deltex 3-like (Drosophila) (DTX3L),
Homo
sapiens methyltransferase like 7B (METTL7B),
Homo
sapiens adrenomedullin (ADM), mRNA.
Homo
sapiens tumor necrosis factor receptor
Homo
sapiens calpastatin (CAST), transcript variant 9,
Homo
sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo
sapiens histone cluster 2, H2aa3 (HIST2H2AA3),
Homo
sapiens LIM domain kinase 2 (LIMK2), transcript
Homo
sapiens multimerin 1 (MMRN1), mRNA.
Homo
sapiens glycogenin 1 (GYG1), mRNA.
Homo
sapiens tripartite motif-containing 61 (TRIM61),
Homo
sapiens glycoprotein VI (platelet) (GP6),
Homo
sapiens defensin, alpha 1 (DEFA1), mRNA.
Homo
sapiens cytokeratin associated protein
Homo
sapiens actin binding LIM protein family,
Homo
sapiens prepronociceptin (PNOC), mRNA.
Homo
sapiens deoxyribonuclease I-like 3 (DNASE1L3),
Homo
sapiens rhomboid 5 homolog 2 (Drosophila)
Homo
sapiens rhomboid 5 homolog 2 (Drosophila)
Homo
sapiens musashi homolog 2 (Drosophila) (MSI2),
Homo
sapiens limb bud and heart development homolog
Homo
sapiens spermatid perinuclear RNA binding
Homo
sapiens ST3 beta-galactoside alpha-2,3-
Homo
sapiens dehydrogenase/reductase (SDR family)
sapiens cDNA 3, mRNA sequence
Homo
sapiens IQ motif containing K (IQCK), mRNA.
Homo
sapiens family with sequence similarity 26,
Homo
sapiens Fc receptor-like A (FCRLA), mRNA.
Homo
sapiens podocan (PODN), mRNA.
Homo
sapiens proprotein convertase subtilisin/kexin
Homo
sapiens zinc finger, DHHC-type containing 19
Homo
sapiens promyelocytic leukemia (PML), transcript
Homo
sapiens caspase 4, apoptosis-related cysteine
Homo
sapiens Spi-B transcription factor (Spi-1/PU.1
Homo
sapiens CD59 molecule, complement regulatory
Homo
sapiens CD274 molecule (CD274), mRNA.
Homo
sapiens glycerol kinase (GK), transcript variant 2,
Homo
sapiens homer homolog 2 (Drosophila)
Homo
sapiens interferon induced transmembrane protein
Homo
sapiens kelch repeat and BTB (POZ) domain
Homo
sapiens signal transducer and activator of
Homo
sapiens signal transducer and activator of
Homo
sapiens indoleamine-pyrrole 2,3 dioxygenase
Homo
sapiens cDNA: FLJ21199 fis, clone COL00235
Homo
sapiens interferon-induced protein 44-like
Homo
sapiens BCL2/adenovirus E1B 19 kDa interacting
Homo
sapiens leucine-rich alpha-2-glycoprotein 1
Homo
sapiens LIM domain kinase 1 (LIMK1), transcript
Homo
sapiens defensin, alpha 1 (LOC728358), mRNA.
Homo
sapiens defensin, alpha 1 (LOC728358), mRNA.
Homo
sapiens defensin, alpha 1 (LOC728358), mRNA.
Homo
sapiens platelet derived growth factor D
Homo
sapiens septin 5 (SEPT5), mRNA.
Homo
sapiens CTF18, chromosome transmission fidelity
Homo
sapiens chromosome 2 open reading frame 15
Homo
sapiens aquaporin 10 (AQP10), mRNA.
Homo
sapiens Fc receptor-like 6 (FCRL6), mRNA.
Homo
sapiens histone cluster 2, H2ac (HIST2H2AC),
Homo
sapiens Fas apoptotic inhibitory molecule 3
Homo
sapiens Fc fragment of IgE, low affinity II,
Homo
sapiens programmed cell death 1 (PDCD1),
Homo
sapiens SCO cytochrome oxidase deficient
Homo
sapiens tudor domain containing 9 (TDRD9),
Homo
sapiens tudor domain containing 9 (TDRD9),
sapiens cDNA clone IMAGE:6569320 5, mRNA
Homo
sapiens G protein-coupled receptor 97 (GPR97),
Homo
sapiens G protein-coupled receptor 97 (GPR97),
Homo
sapiens G protein-coupled receptor 97 (GPR97),
Homo
sapiens titin (TTN), transcript variant N2-A,
Homo
sapiens KIAA0329 (KIAA0329), mRNA.
Homo
sapiens interleukin 18 receptor accessory protein
Homo
sapiens defensin, alpha 3, neutrophil-specific
Homo
sapiens tetratricopeptide repeat domain 26
Homo
sapiens oxysterol binding protein-like 10
Homo
sapiens BMX non-receptor tyrosine kinase
Homo
sapiens hect domain and RLD 5 (HERC5),
Homo
sapiens signal transducer and activator of
Homo
sapiens clone DTIP1B6 mRNA, CAG repeat
Homo
sapiens integrin, beta 5 (ITGB5), mRNA.
Homo
sapiens integrin, beta 5 (ITGB5), mRNA.
Homo
sapiens family with sequence similarity 129,
Homo
sapiens Fc fragment of IgG, high affinity Ia,
Homo
sapiens interferon-induced protein 44 (IF144),
Homo
sapiens desmocollin 2 (DSC2), transcript variant
Homo
sapiens heparanase (HPSE), mRNA.
Homo
sapiens chromosome 14 open reading frame 45
Homo
sapiens cytochrome P450, family 26, subfamily
Homo
sapiens apolipoprotein L, 1 (APOL1), transcript
Homo
sapiens Fc fragment of IgA, receptor for (FCAR),
Homo
sapiens C-type lectin domain family 1, member B
Homo
sapiens RNA binding protein with multiple
Homo
sapiens clone 115D87 T cell receptor beta chain
Homo
sapiens caspase-1 dominant-negative inhibitor
Homo
sapiens caspase-1 dominant-negative inhibitor
Homo
sapiens sialic acid binding Ig-like lectin 16
Homo
sapiens microtubule-associated protein 7 (MAP7),
Homo
sapiens mucin 20, cell surface associated
Homo
sapiens 6-phosphofructo-2-kinase/fructose-2,6-
Homo
sapiens von Willebrand factor (VWF), mRNA.
Homo
sapiens septin 4 (SEPT4), transcript variant 3,
Homo
sapiens tryptophanyl-tRNA synthetase (WARS),
Homo
sapiens matrix metallopeptidase 9 (gelatinase B,
Homo
sapiens transporter 2, ATP-binding cassette, sub-
Homo
sapiens glycoprotein VI (platelet) (GP6), mRNA.
Homo
sapiens selectin ligand interactor cytoplasmic-1
Homo
sapiens nuclear factor I/B (NFIB), mRNA.
Homo
sapiens paraneoplastic antigen MA3 (PNMA3),
Homo
sapiens SWI/SNF related, matrix associated, actin
Homo
sapiens thromboxane A2 receptor (TBXA2R),
Homo
sapiens CD151 molecule (Raph blood group)
Homo
sapiens synapsin II (SYN2), transcript variant IIa,
Homo
sapiens major facilitator superfamily domain
Homo
sapiens RAD17 homolog (S. pombe) (RAD17),
Homo
sapiens leucine rich repeat neuronal 3 (LRRN3),
Homo
sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo
sapiens asialoglycoprotein receptor 2 (ASGR2),
Homo
sapiens interferon-induced protein with
Homo
sapiens GM2 ganglioside activator (GM2A),
Homo
sapiens microtubule-associated protein 7 (MAP7),
Homo
sapiens guanylate binding protein 4 (GBP4),
Homo
sapiens chromosome 3 open reading frame 60
Homo
sapiens G protein-coupled receptor 68 (GPR68),
Homo
sapiens proline rich Gla (G-carboxyglutamic acid)
Homo
sapiens guanine nucleotide binding protein (G
Homo
sapiens BTB and CNC homology 1, basic leucine
Homo
sapiens zinc finger protein 30 homolog (mouse)
Homo
sapiens Fas apoptotic inhibitory molecule
Homo
sapiens gastrin (GAST), mRNA.
Homo
sapiens GRINL1A combined protein (Gcom1),
Homo
sapiens plexin A1 (PLXNA1), mRNA.
Homo
sapiens chromosome 10 open reading frame 2
Homo
sapiens harakiri, BCL2 interacting protein
Homo
sapiens chemokine (C-C motif) receptor 6
Homo
sapiens growth arrest and DNA-damage-
Homo
sapiens phospholipase C, gamma 1 (PLCG1),
Homo
sapiens transcobalamin II; macrocytic anemia
Homo
sapiens fibroblast growth factor 9 (glia-activating
Homo
sapiens complement component 1, q
Homo
sapiens membrane-spanning 4-domains,
Homo
sapiens interferon-induced protein with
Homo
sapiens solute carrier family 26, member 8
Homo
sapiens solute carrier family 26, member 8
Homo
sapiens nephroblastoma overexpressed gene
Homo
sapiens homeobox A9 (HOXA9), mRNA.
Homo
sapiens tripartite motif-containing 22 (TRIM22),
sapiens cDNA clone IMAGE: 2722975 3, mRNA
Homo
sapiens fibulin 2 (FBLN2), transcript variant 2,
Homo
sapiens fibulin 2 (FBLN2), transcript variant 2,
Homo
sapiens tryptophanyl-tRNA synthetase (WARS),
Homo
sapiens guanylate binding protein 2, interferon-
Homo
sapiens zinc finger protein 331 (ZNF331),
Homo
sapiens insulin-like growth factor 2 mRNA
Homo
sapiens dysferlin, limb girdle muscular dystrophy
Homo
sapiens transforming growth factor beta 1 induced
Homo
sapiens caldesmon 1 (CALD1), transcript variant
Homo
sapiens desmocollin 2 (DSC2), transcript variant
Homo
sapiens apolipoprotein L, 6 (APOL6), mRNA.
Homo
sapiens suppressor of Ty 3 homolog (S.
cerevisiae) (SUPT3H), transcript variant 2, mRNA.
Homo
sapiens interferon-induced protein with
Homo
sapiens lysophosphatidylcholine acyltransferase 2
Homo
sapiens tropomyosin 1 (alpha) (TPM1), transcript
Homo
sapiens SH2 domain containing 1B (SH2D1B),
Homo
sapiens non-SMC condensin II complex, subunit
Homo
sapiens interleukin 28 receptor, alpha (interferon,
Homo
sapiens Ras association (RalGDS/AF-6) domain
Homo
sapiens S100 calcium binding protein A12
Homo
sapiens tumor necrosis factor receptor
Homo
sapiens chemokine (C-C motif) receptor 2
Homo
sapiens chemokine (C-X-C motif) ligand 10
Homo
sapiens C-type lectin-like 1 (CLECL1), mRNA.
Homo
sapiens leukocyte immunoglobulin-like receptor,
Homo
sapiens phosphodiesterase 9A (PDE9A),
Homo
sapiens coagulation factor C homolog, cochlin
Homo
sapiens endothelial cell growth factor 1 (platelet-
Homo
sapiens endothelial cell growth factor 1 (platelet-
Homo
sapiens arachidonate 12-lipoxygenase (ALOX12),
Homo
sapiens Fc receptor-like 3 (FCRL3), transcript
Homo
sapiens glycerol kinase (GK), transcript variant 1,
Homo
sapiens zinc finger, CCHC domain containing 6
Homo
sapiens insulin-like 3 (Leydig cell) (INSL3),
Homo
sapiens CD79B antigen (immunoglobulin-
Homo
sapiens E74-like factor 2 (ets domain
Homo
sapiens calpain 11 (CAPN11), mRNA.
Homo
sapiens cellular repressor of E1A-stimulated
Homo
sapiens lin-9 homolog (C.elegans) (LIN9),
Homo
sapiens septin 4 (SEPT4), transcript variant 2,
Homo
sapiens annexin A3 (ANXA3), mRNA.
Homo
sapiens RCAN family member 3 (RCAN3),
Homo
sapiens carcinoembryonic antigen-related cell
Homo
sapiens eukaryotic translation initiation factor 1A,
Homo
sapiens CD79a molecule, immunoglobulin-
Homo
sapiens receptor (chemosensory) transporter
Homo
sapiens mitochondrial intermediate peptidase
Homo
sapiens BMX non-receptor tyrosine kinase
Homo
sapiens tudor and KH domain containing
Homo
sapiens cDNA clone IMAGE: 5277162
Homo
sapiens sodium channel, voltage-gated, type IX,
Homo
sapiens oncostatin M (OSM), mRNA.
Homo
sapiens MYC associated factor X (MAX),
Homo
sapiens sterile alpha motif domain containing 4A
Homo
sapiens poly (ADP-ribose) polymerase family,
Homo
sapiens FERM domain containing 3 (FRMD3),
Homo
sapiens plasminogen activator, urokinase receptor
Homo
sapiens phosphate cytidylyltransferase 2,
Homo
sapiens histone cluster 1, H3f (HIST1H3F),
Homo
sapiens centromere protein Q (CENPQ), mRNA.
Homo
sapiens histone cluster 1, H4h (HIST1H4H),
Homo
sapiens thymocyte selection-associated high
Homo
sapiens guanylate binding protein family, member
Homo
sapiens guanylate binding protein family, member
Homo
sapiens galectin-related protein (HSPC159),
Homo
sapiens suppressor of cytokine signaling 3
Homo
sapiens sorting nexin 25 (SNX25), mRNA.
Homo
sapiens chromosome 11 open reading frame 80
Homo
sapiens hypothetical protein LOC153561
Homo
sapiens exostoses (multiple)-like 2 (EXTL2),
Homo
sapiens laminin, alpha 5 (LAMA5), mRNA.
Homo
sapiens calcium/calmodulin-dependent protein
Homo
sapiens aspartate beta-hydroxylase domain
Homo
sapiens dehydrogenase/reductase (SDR family)
Homo
sapiens dehydrogenase/reductase (SDR family)
Homo
sapiens C-type lectin domain family 4, member F
Homo
sapiens histone cluster 1, H1c (HIST1H1C),
Homo
sapiens ephrin-A1 (EFNA1), transcript variant 1,
Homo
sapiens histone cluster 2, H3c (HIST2H3C),
Homo
sapiens chromosome 14 open reading frame 149
Homo
sapiens tumor necrosis factor, alpha-induced
Homo
sapiens serine peptidase inhibitor, Kazal type 2
Of the 29 untreated active TB patients, 16 were also included in the previous Berry et al study, and of the 38 untreated latent TB patients, 17 were also included in the previous Berry et al study [11]. For study reported in Example 2 herein, all untreated samples were processed again alongside all the other samples.
This application claims priority to, and incorporates by reference in its entirety, provisional patent application Ser. No. 61/610,121 filed Mar. 13, 2012, and which is also titled “Early Detection of Tuberculosis Treatment Response.”
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2013/030986 | 3/13/2013 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61610121 | Mar 2012 | US |
